GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: September 30, 2004, 16:30:56 ; Search time 1 Seconds
(without alignments)
1.712 Million cell updates/sec

Title: US-09-503-596-2
Perfect score: 634
Sequence: 1 ggaattccaggagggtgcag.....ataacttttttagatttag 634

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 57 seqs, 1350 residues

Total number of hits satisfying chosen parameters: 114

Minimum DB seq length: 10
Maximum DB seq length: 100

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 57 summaries

Database : rng2.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	65	10.3	65	1	AAD48759	Human fatty acid b
	2	60	9.5	60	1	ABN39828	Human spliced tran
c	3	51	8.0	60	1	AAD03972	Probe related to t
	4	50	7.9	50	1	ABZ08011	Human leukocyte ge
c	5	33	5.2	33	1	AAD25480	Probe #17 used in
c	6	33	5.2	33	1	AAI68020	ap2 mRNA specific
c	7	33	5.2	33	1	AAD24704	Probe #17, used in
c	8	29	4.6	29	1	AAD25479	Probe #16 used in
c	9	29	4.6	29	1	AAI68019	ap2 mRNA specific
c	10	29	4.6	29	1	AAD24703	Probe #16, used in
c	11	26	4.1	26	1	AAD25478	Probe #15 used in
c	12	26	4.1	26	1	AAI68018	ap2 mRNA specific
c	13	26	4.1	26	1	AAD24702	Probe #15, used in
c	14	26	4.1	26	1	ACC44484	Primer aP2 antisen
	15	24.2	3.8	30	1	AAA72371	Mouse aP2 hybridis
c	16	24	3.8	24	1	AAD25482	Probe #19 used in
c	17	24	3.8	24	1	AAI68022	ap2 mRNA specific
c	18	24	3.8	24	1	AAD24706	Probe #19, used in
c	19	23	3.6	23	1	AAD25481	Probe #18 used in
c	20	23	3.6	23	1	AAI68021	ap2 mRNA specific
c	21	23	3.6	23	1	AAD24705	Probe #18, used in
	22	20	3.2	20	1	AAI66788	aP2 mRNA amplifyin
c	23	20	3.2	20	1	ABK87128	Human fatty acid b
	24	20	3.2	20	1	ABK87127	Human fatty acid b
	25	20	3.2	20	1	AAD29732	aFABP cDNA amplify
c	26	20	3.2	20	1	AAD29733	aFABP cDNA amplify
c	27	20	3.2	20	1	AAD55891	Human aP2 gene amp
c	28	19	3.0	19	1	AAI66789	aP2 mRNA amplifyin
c	29	19	3.0	19	1	AAD25483	Probe #20 used in
c	30	19	3.0	19	1	AAI68023	ap2 mRNA specific
c	31	19	3.0	19	1	AAD24707	Probe #20, used in
	32	19	3.0	20	1	AAD55892	Human aP2 gene amp
c	33	18.8	3.0	22	1	AAX32484	Forward primer fla
	34	18	2.8	18	1	AAD48760	Human fatty acid b
	35	16.8	2.6	20	1	ABZ85335	Human oligonucleot
	36	16.8	2.6	21	1	ABK92082	Novel fatty acid-b
c	37	15.4	2.4	17	1	ABZ61709	Human H-Ras DNAzym
	38	15.4	2.4	18	1	AAZ77088	Human biallelic ma
	39	14.8	2.3	18	1	AAZ73388	Human biallelic ma
	40	14.8	2.3	18	1	AAD33908	Human carboxypepti
	41	14.4	2.3	17	1	AAQ11390	Probe COD 957 spec
	42	14.4	2.3	17	1	ABV80082	Human HTPL scannin
	43	14.4	2.3	17	1	ABV80083	Human HTPL scannin
c	44	14.4	2.3	17	1	ABK17807	Human ERG hammerhe
c	45	14.4	2.3	17	1	ADB45486	Tumour suppression
	46	14.4	2.3	18	1	AAS95047	Human otoferlin ex
c	47	14	2.2	17	1	ADB42764	Tumour suppression
	48	13.8	2.2	17	1	AAA21306	Integrin alpha 6 s
	49	13.8	2.2	17	1	AAA21305	Integrin alpha 6 s
c	50	13.8	2.2	17	1	AAS05096	Neurofibromatosis
c	51	13.8	2.2	17	1	ABV85336	Human pp-GaNTase 1
	52	13.8	2.2	17	1	ABT36459	Tumour suppression
	53	13.8	2.2	17	1	ABZ60950	Human K-Ras DNAzym
c	54	13.8	2.2	17	1	ADB40481	Tumour suppression
c	55	13.4	2.1	15	1	AAV93839	Target sequence wi
	56	13.4	2.1	16	1	AAQ28744	Probe for anti-CEA
	57	13.4	2.1	16	1	AAV48633	junB gene antisens

ALIGNMENTS

RESULT 1
AAD48759
ID AAD48759 standard; RNA; 65 BP.
XX
AC AAD48759;
XX
DT 07-MAR-2003 (first entry)
XX
DE Human fatty acid binding protein 2 (FABP-2) RNA fragment #1.
XX
KW Human; RNA binding molecule; fatty acid binding protein 2; FABP-2; ss.
XX
OS Homo sapiens.
XX
PN WO200281748-A1.
XX
PD 17-OCT-2002.
XX
PF 04-APR-2002; 2002WO-SE000677.
XX
PR 05-APR-2001; 2001SE-00001218.
PR 05-APR-2001; 2001US-0281384P.
XX
PA (BIOV-) BIOVITRUM AB.
XX
PI Ekblom J;
XX
DR WPI; 2003-058568/05.
XX
PT Identifying RNA-binding molecule by predicting structure of RNA fragment,
PT synthesizing DNA fragment corresponding to predicted RNA structure,
PT performing reporter gene assay after placing the DNA upstream of reporter
PT gene.
XX
PS Claim 12; Page 28; 35pp; English.
XX
CC The present invention relates to a method of identifying RNA-binding
CC molecule comprising predicting the structure of RNA-fragment, selecting
CC suitable predicted RNA fragment with an individual stem, synthesising a
CC DNA-fragment corresponding to the RNA fragment, inserting the DNA
CC fragment in upstream proximity of reporter assay gene to form reporter
CC construct and performing a reporter gene assay which detects interaction
CC between a molecule to be tested for RNA-binding and RNA fragment of the
CC reporter construct. The method is useful for identifying an RNA binding

CC molecule. The present sequence is human fatty acid binding protein 2
CC (FABP-2) RNA fragment. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 65 BP; 22 A; 15 C; 13 G; 0 T; 15 U; 0 Other;

Query Match 10.3%; Score 65; DB 1; Length 65;
Best Local Similarity 76.9%; Pred. No. 0.12;
Matches 50; Conservative 15; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 GGAATTCCAGGAGGGTGCAGCTTCCTTCTCACCTTGAAGAATAATCCTAGAAAACTCACA 60
              ||||::|||||||||:|||||::||::|:||||::||||||:||:||:|||||||:||||
Db          1 GGAAUUCCAGGAGGGUGCAGCUUCCUUCUCACCUUGAAGAAUAAUCCUAGAAAACUCACA 60

Qy         61 AAATG 65
              |||:|
Db         61 AAAUG 65
```

RESULT 2
ABN39828
ID ABN39828 standard; DNA; 60 BP.
XX
AC ABN39828;
XX
DT 15-JUL-2002 (first entry)
XX
DE Human spliced transcript detection oligonucleotide SEQ ID NO:12576.
XX
KW Human; mouse; rat; splice transcript; detection; RNA transcript;
KW splice variant; transcriptome; oligonucleotide library; ss.
XX
OS Homo sapiens.
XX
PN WO200210449-A2.
XX
PD 07-FEB-2002.
XX
PF 20-JUL-2001; 2001WO-IB001903.
XX
PR 28-JUL-2000; 2000US-0221607P.
PR 02-MAY-2001; 2001US-0287724P.
XX
PA (COMP-) COMPUGEN INC.
XX
PI Shoshan A, Wasserman A, Mintz E, Mintz L, Faigler S;
XX
DR WPI; 2002-257383/30.
XX
PT New oligonucleotide libraries comprising oligonucleotides which
PT selectively hybridize to mRNAs transcribed from a transcription unit of a
PT genome, useful for detecting tissue-, pathology-, and developmental-
PT specific genes.
XX
PS Example 1; SEQ ID NO 12576; 47pp; English.
XX
CC The present invention describes oligonucleotide libraries for detecting
CC messenger RNAs that populate a (sub-)transcriptome, where the (sub-
CC)transcriptome comprises messenger RNAs transcribed from multiple
CC transcription units that populate a genome. The library comprises several
CC oligonucleotides, each capable of hybridising selectively to a set of
CC messenger RNAs transcribed from a given transcription unit of the genome,
CC which encodes one or more messenger RNA splice variants. The
CC oligonucleotide libraries are useful for detecting mRNAs from a
CC biological sample, in expression profiling studies, in qualitatively or
CC quantitatively characterising the corresponding transcriptome, and in
CC detecting RNA transcripts and splice variants of human or animal
CC transcriptomes. The libraries may also be used as specialised mini
CC libraries to detect transcripts of a sub-transcriptome under a particular
CC biological or pathological state, and so allowing the detection of tissue
CC - and pathology-specific genes such as those genes only expressed in
CC specific tissue under a specific pathological condition; to detect
CC developmental specific genes; and to detect RNA transcripts and splice
CC variants of a transcriptome of a patient suffering from a particular
CC disorder. ABN27253 to ABN59589 represent oligonucleotide sequences from
CC rats, humans and mice, which are used in the exemplification of the
CC present invention. N.B. The sequence data for this patent did not form
CC part of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 60 BP; 18 A; 12 C; 16 G; 14 T; 0 U; 0 Other;

Query Match 9.5%; Score 60; DB 1; Length 60;
Best Local Similarity 100.0%; Pred. No. 0.23;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        446 TTATGAGAGAGCATAAGCCAAGGGACGTTGACCTGGACTGAAGTTCGCATTGAACTCTAC 505
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 TTATGAGAGAGCATAAGCCAAGGGACGTTGACCTGGACTGAAGTTCGCATTGAACTCTAC 60
```

RESULT 3
AAD03972/c
ID AAD03972 standard; DNA; 60 BP.
XX
AC AAD03972;
XX
DT 02-JUL-2001 (first entry)
XX
DE Probe related to the invention.
XX
KW Human; cyclic adenosine mono phosphate; cell phenotype modulator; CREB;
KW cAMP responsive element binding protein; antidiabetic; cytostatic;
KW neuroprotective; nootropic; osteopathic; antiarthritic; antianginal;
KW antiatherosclerotic; vasotropic; cerebroprotective; antidepressant;
KW cardiant; hypotensive; obesity; cardiovascular disease; cardiomyopathy;
KW congestive heart failure; macrovascular disease; pulmonary hypertension;
KW acute myocardial infarction; stroke; peripheral vascular disease;
KW post-angioplasty restenosis; heart failure; neurodegenerative disease;
KW Alzheimer's disease; Parkinson's disease; spinal transection;
KW acute neuronal ischaemia; tumour neovascularisation; probe; ss.
XX
OS Unidentified.
XX
PN WO200129062-A2.
XX
PD 26-APR-2001.
XX
PF 12-OCT-2000; 2000WO-US028316.
XX
PR 18-OCT-1999; 99US-00420060.
XX
PA (UYTE-) UNIV TECHNOLOGY CORP.
PA (NAJE-) NAT JEWISH MEDICAL & RES CENT.
PA (USGO) US DEPT VETERANS AFFAIRS.
XX
PI Reusch JE, Klemm DJ;
XX
DR WPI; 2001-290891/30.
XX
PT Modulating cell phenotype in a patient having or risk of developing a
PT disease/condition linked with disregulation of cellular phenotype,
PT comprises administering nucleic acid encoding cyclic-AMP responsive
PT element binding protein.
XX
PS Disclosure; Page 141; 156pp; English.
XX
CC The patent discloses a method for modulating the phenotype of a target
CC cell population in a patient who has or is at risk of developing a
CC disease or condition associated with dysregulation of cellular phenotype.
CC The method involves the administration of a composition containing a
CC recombinant nucleic acid molecule (rNA) encoding a cyclic- AMP responsive
CC element binding (CREB) protein having CREB biological activity to a
CC patient, such that the CREB protein is expressed in target cells, and is
CC sufficient to modulate the phenotype of the target cells. CREB protein is
CC a transcription factor necessary and sufficient to induce a modulation in

CC cell phenotype and to induce cell differentiation in many cells. This
CC method is useful for modulating the phenotype of target cell population
CC such as adipocytes, vascular smooth muscle cells, cardiomyocytes,
CC hepatocytes, skeletal muscle, beta-cells, pituitary, synovial lining,
CC ovarian, testicular, fibroblasts, endothelial, neural cells (dopaminergic
CC neural transplant cells), hippocampal neurons, cells of cortex and basal
CC ganglia in a patient having or risk of developing obesity, diabetes,
CC cardiovascular disease (congestive heart failure, cardiomyopathy),
CC macrovascular disease (atherosclerosis, angina, acute myocardial
CC infarction, stroke, pulmonary hypertension and amputation from peripheral
CC vascular disease), post- angioplasty restenosis, osteoarthritis, heart
CC failure, and neuro- degenerative diseases (Alzheimer's disease,
CC Parkinson's disease, spinal transection, acute neuronal ischaemia and
CC depression). This method is also used to inhibit tumour
CC neovascularisation. The present sequence is a human DNA related to the
CC invention. The present DNA sequence is a probe related to the invention
XX
SQ Sequence 60 BP; 19 A; 16 C; 11 G; 14 T; 0 U; 0 Other;

Query Match 8.0%; Score 51; DB 1; Length 60;
Best Local Similarity 91.5%; Pred. No. 0.88;
Matches 54; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 63 ATGTGTGATGCTTTTGTAGGTACCTGGAAACTTGTCTCCAGTGAAAACTTTGATGATTA 121
||||||||||| ||||| || |||||||| |||||||||||||||||||| ||||||||
Db 60 ATGTGTGATGCCTTTGTGGGAACCTGGAAGCTTGTCTCCAGTGAAAACTTCGATGATTA 2

RESULT 4
ABZ08011
ID ABZ08011 standard; DNA; 50 BP.
XX
AC ABZ08011;
XX
DT 09-JAN-2003 (first entry)
XX
DE Human leukocyte gene expression profiling probe SEQ ID NO 8002.
XX
KW T7; leukocyte; gene expression profiling; allograft rejection;
KW atherosclerosis; congestive heart failure; systemic lupus erythematosus;
KW rheumatoid arthritis; osteoarthritis; cytomegalovirus; infection; probe;
KW ss.
XX
OS Homo sapiens.
XX
PN WO200257414-A2.
XX
PD 25-JUL-2002.
XX
PF 22-OCT-2001; 2001WO-US047856.
XX
PR 20-OCT-2000; 2000US-0241994P.
PR 08-JUN-2001; 2001US-0296764P.
XX
PA (BIOC-) BIOCARDIA INC.
XX
PI Wohlgemuth J, Fry K, Matcuk G, Altman P, Prentice J, Phillips J;
PI Ly N, Woodward R, Quertermous T, Johnson F;
XX
DR WPI; 2002-636525/68.
XX
PT New system for leukocyte expression profiling, diagnosing a disease, or
PT monitoring (the rate of) progression of a disease, e.g. atherosclerosis
PT or congestive heart failure, comprises diagnostic oligonucleotides.
XX
PS Claim 1; Page 586; 0pp; English.
XX
CC The invention relates to a system for detecting gene expression, which
CC comprises one or two isolated DNA molecules that detect expression of a
CC gene, where the gene corresponds to any of 8143 oligonucleotides
CC (ABZ00010-ABZ08152) each having 50 base pairs (bp). The system is useful
CC for leukocyte expression profiling. It is particularly useful for
CC diagnosing a disease, monitoring (rate of) progression of a disease,
CC predicting therapeutic outcome, determining prognosis for a patient,
CC predicting disease complications in an individual or monitoring response
CC to treatment in an individual. The diseases include cardiac allograft
CC rejection, kidney allograft rejection, liver allograft rejection,
CC atherosclerosis, congestive heart failure, systemic lupus erythematosus,
CC rheumatoid arthritis, osteoarthritis or cytomegalovirus infection
XX
SQ Sequence 50 BP; 11 A; 10 C; 8 G; 21 T; 0 U; 0 Other;

Query Match 7.9%; Score 50; DB 1; Length 50;
Best Local Similarity 100.0%; Pred. No. 0.84;
Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 539 TTGTTGTTTTCCCTGATTTAGCAAGCAAGTAATTTTCTCCCAAGCTGATT 588
||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 TTGTTGTTTTCCCTGATTTAGCAAGCAAGTAATTTTCTCCCAAGCTGATT 50

RESULT 5
AAD25480/c
ID AAD25480 standard; DNA; 33 BP.
XX
AC AAD25480;
XX
DT 26-MAR-2002 (first entry)
XX
DE Probe #17 used in aP2 assay for antagonist.
XX
KW Benzoxazinone derivative; glucose metabolism; lipid metabolism; NIDDM;
KW PPAR gamma; peroxisome proliferator activated receptor gamma; therapy;
KW non-insulin dependant diabetes mellitus; nephropathy; neuropathy; PCOS;
KW atherosclerosis; retinopathy; polycystic ovary syndrome; hypertension;
KW ischaemia; obesity; heart disease; irritable bowel disorder; stroke;
KW reduced insulin sensitivity; inflammation; cataract; aP2 mRNA; probe; ss.
XX
OS Unidentified.
XX
PN WO200187860-A2.
XX
PD 22-NOV-2001.
XX
PF 11-MAY-2001; 2001WO-US015320.
XX
PR 12-MAY-2000; 2000US-0203859P.
PR 11-MAY-2001; 2001US-00853798.
XX
PA (ORTH) ORTHO-MCNEIL PHARM INC.
XX
PI Burris TP, Rybczynski PJ;
XX
DR WPI; 2002-082970/11.
XX
PT Use of benzoxazinone derivatives for treating a subject suffering from a
PT disorder in glucose and lipid metabolism such as non-insulin dependant
PT diabetes mellitus or obesity.
XX
PS Example 2; Page 34; 45pp; English.
XX
CC The invention relates to benzoxazinone derivatives useful as peroxisome
CC proliferator activated receptor (PPAR) gamma modulators. The invention
CC also relates to pharmaceutical compositions comprising benzoxazinone
CC derivatives and methods for treating the onset of a disorder in glucose
CC and lipid metabolism, preferably a condition of reduced insulin
CC sensitivity such as non-insulin dependant diabetes mellitus (NIDDM),
CC obesity, nephropathy, neuropathy, retinopathy, atherosclerosis,
CC polycystic ovary syndrome (PCOS), hypertension, ischaemia, stroke, heart
CC diseases, irritable bowel disorder, inflammation and cataract. The
CC present sequence is a probe designed to anneal to the aP2 mRNA and
CC function in the bDNA mRNA detection system. This probe used in the aP2
CC assay for antagonist which is used in the exemplification of the
CC invention
XX
SQ Sequence 33 BP; 9 A; 6 C; 7 G; 11 T; 0 U; 0 Other;

```
  Query Match             5.2%;  Score 33;  DB 1;  Length 33;
  Best Local Similarity   100.0%;  Pred. No. 6.6;
  Matches   33;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        237 AAAAATACTGAGATTTCCTTCATACTGGGCCAG 269
              |||||||||||||||||||||||||||||||||
Db         33 AAAAATACTGAGATTTCCTTCATACTGGGCCAG 1


RESULT 6
AAI68020/c
ID   AAI68020 standard; DNA; 33 BP.
XX
AC   AAI68020;
XX
DT   13-MAR-2002  (first entry)
XX
DE   ap2 mRNA specific oligonucleotide probe.
XX
KW   Peroxisome proliferator activated receptor gamma; benzoxazinone; NIDDM;
KW   non-insulin dependant diabetes mellitus; antidiabetic; anorectic;
KW   nephrotropic; ophthalmological; antiarteriosclerotic; cytostatic;
KW   hypotensive; vasotropic; cerebroprotective; cardiant; antiinflammatory;
KW   PPARgamma; probe; ap2; ss.
XX
OS   Synthetic.
XX
PN   WO200187861-A2.
XX
PD   22-NOV-2001.
XX
PF   11-MAY-2001; 2001WO-US015377.
XX
PR   12-MAY-2000; 2000US-0203861P.
PR   11-MAY-2001; 2001US-00854368.
XX
PA   (ORTH ) ORTHO-MCNEIL PHARM INC.
XX
PI   Burris TP,  Demarest KT,  Combs DW,  Rybczynski PJ,  Turchi IJ;
XX
DR   WPI; 2002-082971/11.
XX
PT   Use of benzoxazinone derivatives for treating a subject suffering from a
PT   condition associated with peroxisome proliferator activated receptor
PT   gamma activity e.g. non-insulin dependant diabetes mellitus and obesity.
XX
PS   Example 7; Page 29; 46pp; English.
XX
CC   The invention provides methods of treating a subject suffering from a
CC   condition associated with peroxisome proliferator activated receptor
CC   gamma (PPARgamma) activity that involves administering a benzoxazinone
CC   compound of a specified formula to the subject. The method is useful for
CC   treating and inhibiting in a subject the onset of a condition associated
CC   with PPARgamma activity such as a condition of reduced insulin
CC   sensitivity, non-insulin dependant diabetes mellitus, obesity,
CC   nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovary
CC   syndrome, hypertension, ischemia, stroke, heart diseases, irritable bowel
CC   disorder, inflammation and cataract. Sequences AAI68004-023 represent
CC   oligonucleotide probes specific for ap2 used in ap2 mRNA assay for
CC   antagonists
XX
SQ   Sequence 33 BP; 9 A; 6 C; 7 G; 11 T; 0 U; 0 Other;

  Query Match             5.2%;  Score 33;  DB 1;  Length 33;
  Best Local Similarity   100.0%;  Pred. No. 6.6;
  Matches   33;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        237 AAAAATACTGAGATTTCCTTCATACTGGGCCAG 269
              |||||||||||||||||||||||||||||||||
Db         33 AAAAATACTGAGATTTCCTTCATACTGGGCCAG 1


RESULT 7
AAD24704/c
ID   AAD24704 standard; DNA; 33 BP.
XX
AC   AAD24704;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Probe #17, used in aP2 assay for antagonist.
XX
KW   4h-Benzo(1,4)oxazin-3-one compound; glucose metabolism; lipid metabolism;
KW   PPAR gamma; peroxisome proliferator activated receptor; therapy; NIDDM;
KW   non-insulin dependant diabetes mellitus; nephropathy; neuropathy; stroke;
KW   atherosclerosis; retinopathy; polycystic ovary syndrome; hypertension;
KW   ischaemia; obesity; heart disease; irritable bowel disorder; cataract;
KW   anorectic; nephrotropic; ophthalmological; cytostatic; hypotensive;
KW   vasotropic; cerebroprotective; cardiant; antiinflammatory; probe;
KW   aP2 mRNA; ss.
XX
OS   Unidentified.
XX
PN   WO200187862-A2.
XX
PD   22-NOV-2001.
XX
PF   11-MAY-2001; 2001WO-US015383.
XX
PR   12-MAY-2000; 2000US-0203860P.
PR   11-MAY-2001; 2001US-00854302.
XX
PA   (ORTH ) ORTHO-MCNEIL PHARM INC.
XX
PI   Burris TP,  Combs DW,  Rybczynski PJ;
XX
DR   WPI; 2002-055671/07.
XX
PT   Use of 4h-benzo(1,4)oxazin-3-one derivatives for treating a subject
PT   suffering from a disorder in glucose and lipid metabolism e.g. non-
PT   insulin dependant diabetes mellitus and obesity.
XX
PS   Example 38; Page 58; 76pp; English.
XX
CC   The patent discloses 4h-Benzo(1,4)oxazin-3-one compounds which are useful
CC   as peroxisome proliferator activated receptor (PPAR) gamma agonists and
CC   antagonists. The invention also relates to compositions comprising such
CC   compounds and methods for treating or inhibiting the onset of a disorder
CC   in glucose and lipid metabolism, preferably a condition of reduced
CC   insulin sensitivity, such as non-insulin dependent diabetes mellitus
CC   (NIDDM), obesity, atherosclerosis, nephropathy, neuropathy, retinopathy,
CC   polycystic ovary syndrome, hypertension, ischaemia, stroke, heart
CC   diseases, irritable bowel disorder, inflammation and cataract. The
CC   present DNA sequence is a probe which is designed to anneal to aP2 mRNA
CC   and function in the bDNA mRNA detection system. This probe is used in aP2
CC   assay for antagonist in the exemplification of the invention
XX
SQ   Sequence 33 BP; 9 A; 6 C; 7 G; 11 T; 0 U; 0 Other;

  Query Match             5.2%;  Score 33;  DB 1;  Length 33;
  Best Local Similarity   100.0%;  Pred. No. 6.6;
  Matches   33;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        237 AAAAATACTGAGATTTCCTTCATACTGGGCCAG 269
              |||||||||||||||||||||||||||||||||
Db         33 AAAAATACTGAGATTTCCTTCATACTGGGCCAG 1


RESULT 8
AAD25479/c
ID   AAD25479 standard; DNA; 29 BP.
XX
AC   AAD25479;
XX
DT   26-MAR-2002  (first entry)
```

XX
DE Probe #16 used in aP2 assay for antagonist.
XX
KW Benzoxazinone derivative; glucose metabolism; lipid metabolism; NIDDM;
KW PPAR gamma; peroxisome proliferator activated receptor gamma; therapy;
KW non-insulin dependant diabetes mellitus; nephropathy; neuropathy; PCOS;
KW atherosclerosis; retinopathy; polycystic ovary syndrome; hypertension;
KW ischaemia; obesity; heart disease; irritable bowel disorder; stroke;
KW reduced insulin sensitivity; inflammation; cataract; aP2 mRNA; probe; ss.
XX
OS Unidentified.
XX
PN WO200187860-A2.
XX
PD 22-NOV-2001.
XX
PF 11-MAY-2001; 2001WO-US015320.
XX
PR 12-MAY-2000; 2000US-0203859P.
PR 11-MAY-2001; 2001US-00853798.
XX
PA (ORTH) ORTHO-MCNEIL PHARM INC.
XX
PI Burris TP, Rybczynski PJ;
XX
DR WPI; 2002-082970/11.
XX
PT Use of benzoxazinone derivatives for treating a subject suffering from a
PT disorder in glucose and lipid metabolism such as non-insulin dependant
PT diabetes mellitus or obesity.
XX
PS Example 2; Page 34; 45pp; English.
XX
CC The invention relates to benzoxazinone derivatives useful as peroxisome
CC proliferator activated receptor (PPAR) gamma modulators. The invention
CC also relates to pharmaceutical compositions comprising benzoxazinone
CC derivatives and methods for treating the onset of a disorder in glucose
CC and lipid metabolism, preferably a condition of reduced insulin
CC sensitivity such as non-insulin dependant diabetes mellitus (NIDDM),
CC obesity, nephropathy, neuropathy, retinopathy, atherosclerosis,
CC polycystic ovary syndrome (PCOS), hypertension, ischaemia, stroke, heart
CC diseases, irritable bowel disorder, inflammation and cataract. The
CC present sequence is a probe designed to anneal to the aP2 mRNA and
CC function in the bDNA mRNA detection system. This probe used in the aP2
CC assay for antagonist which is used in the exemplification of the
CC invention
XX
SQ Sequence 29 BP; 10 A; 3 C; 6 G; 10 T; 0 U; 0 Other;

Query Match 4.6%; Score 29; DB 1; Length 29;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 208 TGATCACCATTAAATCTGAAAGTACCTTT 236
||||||||||||||||||||||||||||
Db 29 TGATCACCATTAAATCTGAAAGTACCTTT 1

RESULT 9
AAI68019/c
ID AAI68019 standard; DNA; 29 BP.
XX
AC AAI68019;
XX
DT 13-MAR-2002 (first entry)
XX
DE ap2 mRNA specific oligonucleotide probe.
XX
KW Peroxisome proliferator activated receptor gamma; benzoxazinone; NIDDM;
KW non-insulin dependant diabetes mellitus; antidiabetic; anorectic;
KW nephrotropic; ophthalmological; antiarteriosclerotic; cytostatic;
KW hypotensive; vasotropic; cerebroprotective; cardiant; antiinflammatory;
KW PPARgamma; probe; ap2; ss.
XX
OS Synthetic.
XX
PN WO200187861-A2.
XX
PD 22-NOV-2001.
XX
PF 11-MAY-2001; 2001WO-US015377.
XX
PR 12-MAY-2000; 2000US-0203861P.
PR 11-MAY-2001; 2001US-00854368.
XX
PA (ORTH) ORTHO-MCNEIL PHARM INC.
XX
PI Burris TP, Demarest KT, Combs DW, Rybczynski PJ, Turchi IJ;
XX
DR WPI; 2002-082971/11.
XX
PT Use of benzoxazinone derivatives for treating a subject suffering from a
PT condition associated with peroxisome proliferator activated receptor
PT gamma activity e.g. non-insulin dependant diabetes mellitus and obesity.
XX
PS Example 7; Page 29; 46pp; English.
XX
CC The invention provides methods of treating a subject suffering from a
CC condition associated with peroxisome proliferator activated receptor
CC gamma (PPARgamma) activity that involves administering a benzoxazinone
CC compound of a specified formula to the subject. The method is useful for
CC treating and inhibiting in a subject the onset of a condition associated
CC with PPARgamma activity such as a condition of reduced insulin
CC sensitivity, non-insulin dependant diabetes mellitus, obesity,
CC nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovary
CC syndrome, hypertension, ischemia, stroke, heart diseases, irritable bowel
CC disorder, inflammation and cataract. Sequences AAI68004-023 represent
CC oligonucleotide probes specific for ap2 used in ap2 mRNA assay for
CC antagonists
XX
SQ Sequence 29 BP; 10 A; 3 C; 6 G; 10 T; 0 U; 0 Other;

Query Match 4.6%; Score 29; DB 1; Length 29;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 208 TGATCACCATTAAATCTGAAAGTACCTTT 236
||||||||||||||||||||||||||||
Db 29 TGATCACCATTAAATCTGAAAGTACCTTT 1

RESULT 10
AAD24703/c
ID AAD24703 standard; DNA; 29 BP.
XX
AC AAD24703;
XX
DT 12-MAR-2002 (first entry)
XX
DE Probe #16, used in aP2 assay for antagonist.
XX
KW 4h-Benzo(1,4)oxazin-3-one compound; glucose metabolism; lipid metabolism;
KW PPAR gamma; peroxisome proliferator activated receptor; therapy; NIDDM;
KW non-insulin dependant diabetes mellitus; nephropathy; neuropathy; stroke;
KW atherosclerosis; retinopathy; polycystic ovary syndrome; hypertension;
KW ischaemia; obesity; heart disease; irritable bowel disorder; cataract;
KW anorectic; nephrotropic; ophthalmological; cytostatic; hypotensive;
KW vasotropic; cerebroprotective; cardiant; antiinflammatory; probe;
KW aP2 mRNA; ss.
XX
OS Unidentified.
XX
PN WO200187862-A2.
XX
PD 22-NOV-2001.
XX

PF 11-MAY-2001; 2001WO-US015383.
XX
PR 12-MAY-2000; 2000US-0203860P.
PR 11-MAY-2001; 2001US-00854302.
XX
PA (ORTH) ORTHO-MCNEIL PHARM INC.
XX
PI Burris TP, Combs DW, Rybczynski PJ;
XX
DR WPI; 2002-055671/07.
XX
PT Use of 4h-benzo(1,4)oxazin-3-one derivatives for treating a subject
PT suffering from a disorder in glucose and lipid metabolism e.g. non-
PT insulin dependant diabetes mellitus and obesity.
XX
PS Example 38; Page 58; 76pp; English.
XX
CC The patent discloses 4h-Benzo(1,4)oxazin-3-one compounds which are useful
CC as peroxisome proliferator activated receptor (PPAR) gamma agonists and
CC antagonists. The invention also relates to compositions comprising such
CC compounds and methods for treating or inhibiting the onset of a disorder
CC in glucose and lipid metabolism, preferably a condition of reduced
CC insulin sensitivity, such as non-insulin dependent diabetes mellitus
CC (NIDDM), obesity, atherosclerosis, nephropathy, neuropathy, retinopathy,
CC polycystic ovary syndrome, hypertension, ischaemia, stroke, heart
CC diseases, irritable bowel disorder, inflammation and cataract. The
CC present DNA sequence is a probe which is designed to anneal to aP2 mRNA
CC and function in the bDNA mRNA detection system. This probe is used in aP2
CC assay for antagonist in the exemplification of the invention
XX
SQ Sequence 29 BP; 10 A; 3 C; 6 G; 10 T; 0 U; 0 Other;

Query Match 4.6%; Score 29; DB 1; Length 29;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 208 TGATCACCATTAAATCTGAAAGTACCTTT 236
||||||||||||||||||||||||||||
Db 29 TGATCACCATTAAATCTGAAAGTACCTTT 1

RESULT 11
AAD25478/c
ID AAD25478 standard; DNA; 26 BP.
XX
AC AAD25478;
XX
DT 26-MAR-2002 (first entry)
XX
DE Probe #15 used in aP2 assay for antagonist.
XX
KW Benzoxazinone derivative; glucose metabolism; lipid metabolism; NIDDM;
KW PPAR gamma; peroxisome proliferator activated receptor gamma; therapy;
KW non-insulin dependant diabetes mellitus; nephropathy; neuropathy; PCOS;
KW atherosclerosis; retinopathy; polycystic ovary syndrome; hypertension;
KW ischaemia; obesity; heart disease; irritable bowel disorder; stroke;
KW reduced insulin sensitivity; inflammation; cataract; aP2 mRNA; probe; ss.
XX
OS Unidentified.
XX
PN WO200187860-A2.
XX
PD 22-NOV-2001.
XX
PF 11-MAY-2001; 2001WO-US015320.
XX
PR 12-MAY-2000; 2000US-0203859P.
PR 11-MAY-2001; 2001US-00853798.
XX
PA (ORTH) ORTHO-MCNEIL PHARM INC.
XX
PI Burris TP, Rybczynski PJ;
XX
DR WPI; 2002-082970/11.
XX
PT Use of benzoxazinone derivatives for treating a subject suffering from a
PT disorder in glucose and lipid metabolism such as non-insulin dependant
PT diabetes mellitus or obesity.
XX
PS Example 2; Page 34; 45pp; English.
XX
CC The invention relates to benzoxazinone derivatives useful as peroxisome
CC proliferator activated receptor (PPAR) gamma modulators. The invention
CC also relates to pharmaceutical compositions comprising benzoxazinone
CC derivatives and methods for treating the onset of a disorder in glucose
CC and lipid metabolism, preferably a condition of reduced insulin
CC sensitivity such as non-insulin dependant diabetes mellitus (NIDDM),
CC obesity, nephropathy, neuropathy, retinopathy, atherosclerosis,
CC polycystic ovary syndrome (PCOS), hypertension, ischaemia, stroke, heart
CC diseases, irritable bowel disorder, inflammation and cataract. The
CC present sequence is a probe designed to anneal to the aP2 mRNA and
CC function in the bDNA mRNA detection system. This probe used in the aP2
CC assay for antagonist which is used in the exemplification of the
CC invention
XX
SQ Sequence 26 BP; 8 A; 4 C; 5 G; 9 T; 0 U; 0 Other;

Query Match 4.1%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 14;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 90 AAACTTGTCTCCAGTGAAAACTTTGA 115
||||||||||||||||||||||||||
Db 26 AAACTTGTCTCCAGTGAAAACTTTGA 1

RESULT 12
AAI68018/c
ID AAI68018 standard; DNA; 26 BP.
XX
AC AAI68018;
XX
DT 13-MAR-2002 (first entry)
XX
DE ap2 mRNA specific oligonucleotide probe.
XX
KW Peroxisome proliferator activated receptor gamma; benzoxazinone; NIDDM;
KW non-insulin dependant diabetes mellitus; antidiabetic; anorectic;
KW nephrotropic; ophthalmological; antiarteriosclerotic; cytostatic;
KW hypotensive; vasotropic; cerebroprotective; cardiant; antiinflammatory;
KW PPARgamma; probe; ap2; ss.
XX
OS Synthetic.
XX
PN WO200187861-A2.
XX
PD 22-NOV-2001.
XX
PF 11-MAY-2001; 2001WO-US015377.
XX
PR 12-MAY-2000; 2000US-0203861P.
PR 11-MAY-2001; 2001US-00854368.
XX
PA (ORTH) ORTHO-MCNEIL PHARM INC.
XX
PI Burris TP, Demarest KT, Combs DW, Rybczynski PJ, Turchi IJ;
XX
DR WPI; 2002-082971/11.
XX
PT Use of benzoxazinone derivatives for treating a subject suffering from a
PT condition associated with peroxisome proliferator activated receptor
PT gamma activity e.g. non-insulin dependant diabetes mellitus and obesity.
XX
PS Example 7; Page 29; 46pp; English.
XX
CC The invention provides methods of treating a subject suffering from a

```
CC   condition associated with peroxisome proliferator activated receptor
CC   gamma (PPARgamma) activity that involves administering a benzoxazinone
CC   compound of a specified formula to the subject. The method is useful for
CC   treating and inhibiting in a subject the onset of a condition associated
CC   with PPARgamma activity such as a condition of reduced insulin
CC   sensitivity, non-insulin dependant diabetes mellitus, obesity,
CC   nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovary
CC   syndrome, hypertension, ischemia, stroke, heart diseases, irritable bowel
CC   disorder, inflammation and cataract. Sequences AAI68004-023 represent
CC   oligonucleotide probes specific for ap2 used in ap2 mRNA assay for
CC   antagonists
XX
SQ   Sequence 26 BP; 8 A; 4 C; 5 G; 9 T; 0 U; 0 Other;

  Query Match             4.1%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   100.0%;  Pred. No. 14;
  Matches   26;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         90 AAACTTGTCTCCAGTGAAAACTTTGA 115
              ||||||||||||||||||||||||||
Db         26 AAACTTGTCTCCAGTGAAAACTTTGA 1


RESULT 13
AAD24702/c
ID   AAD24702 standard; DNA; 26 BP.
XX
AC   AAD24702;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Probe #15, used in aP2 assay for antagonist.
XX
KW   4h-Benzo(1,4)oxazin-3-one compound; glucose metabolism; lipid metabolism;
KW   PPAR gamma; peroxisome proliferator activated receptor; therapy; NIDDM;
KW   non-insulin dependant diabetes mellitus; nephropathy; neuropathy; stroke;
KW   atherosclerosis; retinopathy; polycystic ovary syndrome; hypertension;
KW   ischaemia; obesity; heart disease; irritable bowel disorder; cataract;
KW   anorectic; nephrotropic; ophthalmological; cytostatic; hypotensive;
KW   vasotropic; cerebroprotective; cardiant; antiinflammatory; probe;
KW   aP2 mRNA; ss.
XX
OS   Unidentified.
XX
PN   WO200187862-A2.
XX
PD   22-NOV-2001.
XX
PF   11-MAY-2001; 2001WO-US015383.
XX
PR   12-MAY-2000; 2000US-0203860P.
PR   11-MAY-2001; 2001US-00854302.
XX
PA   (ORTH ) ORTHO-MCNEIL PHARM INC.
XX
PI   Burris TP,  Combs DW,  Rybczynski PJ;
XX
DR   WPI; 2002-055671/07.
XX
PT   Use of 4h-benzo(1,4)oxazin-3-one derivatives for treating a subject
PT   suffering from a disorder in glucose and lipid metabolism e.g. non-
PT   insulin dependant diabetes mellitus and obesity.
XX
PS   Example 38; Page 58; 76pp; English.
XX
CC   The patent discloses 4h-Benzo(1,4)oxazin-3-one compounds which are useful
CC   as peroxisome proliferator activated receptor (PPAR) gamma agonists and
CC   antagonists. The invention also relates to compositions comprising such
CC   compounds and methods for treating or inhibiting the onset of a disorder
CC   in glucose and lipid metabolism, preferably a condition of reduced
CC   insulin sensitivity, such as non-insulin dependent diabetes mellitus
CC   (NIDDM), obesity, atherosclerosis, nephropathy, neuropathy, retinopathy,
CC   polycystic ovary syndrome, hypertension, ischaemia, stroke, heart
CC   diseases, irritable bowel disorder, inflammation and cataract. The
CC   present DNA sequence is a probe which is designed to anneal to aP2 mRNA
CC   and function in the bDNA mRNA detection system. This probe is used in aP2
CC   assay for antagonist in the exemplification of the invention
XX
SQ   Sequence 26 BP; 8 A; 4 C; 5 G; 9 T; 0 U; 0 Other;

  Query Match             4.1%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   100.0%;  Pred. No. 14;
  Matches   26;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         90 AAACTTGTCTCCAGTGAAAACTTTGA 115
              ||||||||||||||||||||||||||
Db         26 AAACTTGTCTCCAGTGAAAACTTTGA 1


RESULT 14
ACC44484/c
ID   ACC44484 standard; DNA; 26 BP.
XX
AC   ACC44484;
XX
DT   29-AUG-2003  (first entry)
XX
DE   Primer aP2 antisense for RNA analysis in activated preadipocyte cells.
XX
KW   Primer; human; telomerase reverse transcriptase; adipogenic capacity;
KW   primary preadipocyte cell; adipogenesis; obesity; adipocytokine; ss; PCR;
KW   anorectic; adiponectin; insulin.
XX
OS   Homo sapiens.
XX
PN   WO2003031640-A2.
XX
PD   17-APR-2003.
XX
PF   07-OCT-2002; 2002WO-US031635.
XX
PR   06-OCT-2001; 2001US-0327650P.
PR   06-OCT-2001; 2001US-0327651P.
XX
PA   (BOST-) BOSTON MEDICAL CENT CORP.
XX
PI   Kirkland J,  Tchkonia T;
XX
DR   WPI; 2003-421278/39.
XX
PT   New primary preadipocyte strain expressing telomerase reverse
PT   transcriptase, useful in research applications, screening assays,
PT   clinical applications, and in the administration of therapeutic agents,
PT   particularly for obesity.
XX
PS   Disclosure; Page 21; 53pp; English.
XX
CC   The invention relates to the generation of primary preadipocyte cell
CC   strains that express telomerase reverse transcriptase (TERT- the
CC   catalytic subunit of telomerase), and maintain and/or enhance replicative
CC   potential and maintain adipogenic capacity of the cell. In order to
CC   detect adipocyte replication and adipogenicity, RNA analysis of a number
CC   of genes were carried out to detect cell proliferation. This sequence
CC   represents a primer used to detect RNA expression of the AP2 gene. The
CC   cell strain can be used in research to study all aspect of adipogenesis,
CC   especially in relation to researching treatments for e.g. obesity. The
CC   cell can also be used to identify adipogenesis modulators for use as
CC   therapeutic agents such as hormones, growth factors, cytokines, enzymes,
CC   cholesterol binding proteins, cholesterol removing proteins or their
CC   combinations. Alternatively, the therapeutic agent may be an
CC   adipocytokine, preferably adiponectin, or insulin
XX
SQ   Sequence 26 BP; 9 A; 3 C; 7 G; 7 T; 0 U; 0 Other;

  Query Match             4.1%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   100.0%;  Pred. No. 14;
```

```
  Matches   26;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        490 TCGCATTGAACTCTACAACATTCTGT 515
              ||||||||||||||||||||||||||
Db         26 TCGCATTGAACTCTACAACATTCTGT 1


RESULT 15
AAA72371
ID   AAA72371 standard; DNA; 30 BP.
XX
AC   AAA72371;
XX
DT   19-DEC-2000  (first entry)
XX
DE   Mouse aP2 hybridisation probe.
XX
KW   aP2; mouse; murine; prolactin induced adipocyte differentiation;
KW   multipotent mesenchymal stem cell; differentiation regulator;
KW   non insulin dependent diabetes; type II diabetes; obesity;
KW   hybridisation probe; ss.
XX
OS   Mus sp.
XX
PN   WO200046348-A1.
XX
PD   10-AUG-2000.
XX
PF   02-FEB-2000; 2000WO-JP000567.
XX
PR   02-FEB-1999;   99JP-00024625.
XX
PA   (HELI-) HELIX RES INST.
PA   (WAKA/) WAKAO H.
XX
PI   Wakao R;
XX
DR   WPI; 2000-543482/49.
XX
PT   Differentiation of stem cells into adipocytes by contact with prolactin
PT   or equivalent as a system for screening compounds for their effect on
PT   adipocyte differentiation.
XX
PS   Example; Page 19; 50pp; Japanese.
XX
CC   The invention relates to a method for inducing differentiation of
CC   multipotent mesenchymal stem cells into adipocytes by culturing the cells
CC   in the presence of prolactin or a substance with equivalent activity,
CC   such as methylisobutylxanthine, dexamethasone or insulin. The invention
CC   also encompasses a method for screening substances for their ability to
CC   promote or inhibit the differentiation of stem cells into adipocytes in
CC   the presence of prolactin or substances with equivalent activity, and the
CC   compounds identified using this method. Prolactin (or substances with
CC   equivalent activity) induce the differentiation of stem cells into
CC   adipocytes by inducing expression of the C/EBP-beta and PPAR-gamma genes.
CC   The methods may be used for the identification of substances which
CC   regulate adipocyte differentiation. These have potential for use in the
CC   treatment and prevention of diseases with which this differentiation is
CC   associated, such as non insulin-dependent (type II) diabetes and obesity.
CC   In the exemplifications of the invention, expression of the C/EPB-alpha,
CC   C/EBP-beta, C/EBP-gamma, C/EBP-delta, aP2 and GPD (glycerol-3-phosphate
CC   dehydrogenase) genes were examined in murine multipotent mesenchymal stem
CC   cells cultured according to the method of the invention. The present
CC   sequence represents a hybridisation probe used to detect mouse aP2 cDNA
XX
SQ   Sequence 30 BP; 6 A; 4 C; 11 G; 9 T; 0 U; 0 Other;

  Query Match             3.8%;  Score 24.2;  DB 1;  Length 30;
  Best Local Similarity   89.7%;  Pred. No. 20;
  Matches   26;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy         63 ATGTGTGATGCTTTTGTAGGTACCTGGAA 91
              |||||||||||| ||||| || ||||||||
Db          1 ATGTGTGATGCCTTTGTGGGAACCTGGAA 29


RESULT 16
AAD25482/c
ID   AAD25482 standard; DNA; 24 BP.
XX
AC   AAD25482;
XX
DT   26-MAR-2002  (first entry)
XX
DE   Probe #19 used in aP2 assay for antagonist.
XX
KW   Benzoxazinone derivative; glucose metabolism; lipid metabolism; NIDDM;
KW   PPAR gamma; peroxisome proliferator activated receptor gamma; therapy;
KW   non-insulin dependant diabetes mellitus; nephropathy; neuropathy; PCOS;
KW   atherosclerosis; retinopathy; polycystic ovary syndrome; hypertension;
KW   ischaemia; obesity; heart disease; irritable bowel disorder; stroke;
KW   reduced insulin sensitivity; inflammation; cataract; aP2 mRNA; probe; ss.
XX
OS   Unidentified.
XX
PN   WO200187860-A2.
XX
PD   22-NOV-2001.
XX
PF   11-MAY-2001; 2001WO-US015320.
XX
PR   12-MAY-2000; 2000US-0203859P.
PR   11-MAY-2001; 2001US-00853798.
XX
PA   (ORTH ) ORTHO-MCNEIL PHARM INC.
XX
PI   Burris TP,  Rybczynski PJ;
XX
DR   WPI; 2002-082970/11.
XX
PT   Use of benzoxazinone derivatives for treating a subject suffering from a
PT   disorder in glucose and lipid metabolism such as non-insulin dependant
PT   diabetes mellitus or obesity.
XX
PS   Example 2; Page 34; 45pp; English.
XX
CC   The invention relates to benzoxazinone derivatives useful as peroxisome
CC   proliferator activated receptor (PPAR) gamma modulators. The invention
CC   also relates to pharmaceutical compositions comprising benzoxazinone
CC   derivatives and methods for treating the onset of a disorder in glucose
CC   and lipid metabolism, preferably a condition of reduced insulin
CC   sensitivity such as non-insulin dependant diabetes mellitus (NIDDM),
CC   obesity, nephropathy, neuropathy, retinopathy, atherosclerosis,
CC   polycystic ovary syndrome (PCOS), hypertension, ischaemia, stroke, heart
CC   diseases, irritable bowel disorder, inflammation and cataract. The
CC   present sequence is a probe designed to anneal to the aP2 mRNA and
CC   function in the bDNA mRNA detection system. This probe used in the aP2
CC   assay for antagonist which is used in the exemplification of the
CC   invention
XX
SQ   Sequence 24 BP; 3 A; 6 C; 5 G; 10 T; 0 U; 0 Other;

  Query Match             3.8%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        293 TGACAGGAAAGTCAAGAGCACCAT 316
              ||||||||||||||||||||||||
Db         24 TGACAGGAAAGTCAAGAGCACCAT 1


RESULT 17
AAI68022/c
ID   AAI68022 standard; DNA; 24 BP.
XX
AC   AAI68022;
```

XX
DT 13-MAR-2002 (first entry)
XX
DE ap2 mRNA specific oligonucleotide probe.
XX
KW Peroxisome proliferator activated receptor gamma; benzoxazinone; NIDDM;
KW non-insulin dependant diabetes mellitus; antidiabetic; anorectic;
KW nephrotropic; ophthalmological; antiarteriosclerotic; cytostatic;
KW hypotensive; vasotropic; cerebroprotective; cardiant; antiinflammatory;
KW PPARgamma; probe; ap2; ss.
XX
OS Synthetic.
XX
PN WO200187861-A2.
XX
PD 22-NOV-2001.
XX
PF 11-MAY-2001; 2001WO-US015377.
XX
PR 12-MAY-2000; 2000US-0203861P.
PR 11-MAY-2001; 2001US-00854368.
XX
PA (ORTH) ORTHO-MCNEIL PHARM INC.
XX
PI Burris TP, Demarest KT, Combs DW, Rybczynski PJ, Turchi IJ;
XX
DR WPI; 2002-082971/11.
XX
PT Use of benzoxazinone derivatives for treating a subject suffering from a
PT condition associated with peroxisome proliferator activated receptor
PT gamma activity e.g. non-insulin dependant diabetes mellitus and obesity.
XX
PS Example 7; Page 29; 46pp; English.
XX
CC The invention provides methods of treating a subject suffering from a
CC condition associated with peroxisome proliferator activated receptor
CC gamma (PPARgamma) activity that involves administering a benzoxazinone
CC compound of a specified formula to the subject. The method is useful for
CC treating and inhibiting in a subject the onset of a condition associated
CC with PPARgamma activity such as a condition of reduced insulin
CC sensitivity, non-insulin dependant diabetes mellitus, obesity,
CC nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovary
CC syndrome, hypertension, ischemia, stroke, heart diseases, irritable bowel
CC disorder, inflammation and cataract. Sequences AAI68004-023 represent
CC oligonucleotide probes specific for ap2 used in ap2 mRNA assay for
CC antagonists
XX
SQ Sequence 24 BP; 3 A; 6 C; 5 G; 10 T; 0 U; 0 Other;

Query Match 3.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 293 TGACAGGAAAGTCAAGAGCACCAT 316
||||||||||||||||||||||||
Db 24 TGACAGGAAAGTCAAGAGCACCAT 1

RESULT 18
AAD24706/c
ID AAD24706 standard; DNA; 24 BP.
XX
AC AAD24706;
XX
DT 12-MAR-2002 (first entry)
XX
DE Probe #19, used in aP2 assay for antagonist.
XX
KW 4h-Benzo(1,4)oxazin-3-one compound; glucose metabolism; lipid metabolism;
KW PPAR gamma; peroxisome proliferator activated receptor; therapy; NIDDM;
KW non-insulin dependant diabetes mellitus; nephropathy; neuropathy; stroke;
KW atherosclerosis; retinopathy; polycystic ovary syndrome; hypertension;
KW ischaemia; obesity; heart disease; irritable bowel disorder; cataract;
KW anorectic; nephrotropic; ophthalmological; cytostatic; hypotensive;
KW vasotropic; cerebroprotective; cardiant; antiinflammatory; probe;
KW aP2 mRNA; ss.
XX
OS Unidentified.
XX
PN WO200187862-A2.
XX
PD 22-NOV-2001.
XX
PF 11-MAY-2001; 2001WO-US015383.
XX
PR 12-MAY-2000; 2000US-0203860P.
PR 11-MAY-2001; 2001US-00854302.
XX
PA (ORTH) ORTHO-MCNEIL PHARM INC.
XX
PI Burris TP, Combs DW, Rybczynski PJ;
XX
DR WPI; 2002-055671/07.
XX
PT Use of 4h-benzo(1,4)oxazin-3-one derivatives for treating a subject
PT suffering from a disorder in glucose and lipid metabolism e.g. non-
PT insulin dependant diabetes mellitus and obesity.
XX
PS Example 38; Page 58; 76pp; English.
XX
CC The patent discloses 4h-Benzo(1,4)oxazin-3-one compounds which are useful
CC as peroxisome proliferator activated receptor (PPAR) gamma agonists and
CC antagonists. The invention also relates to compositions comprising such
CC compounds and methods for treating or inhibiting the onset of a disorder
CC in glucose and lipid metabolism, preferably a condition of reduced
CC insulin sensitivity, such as non-insulin dependent diabetes mellitus
CC (NIDDM), obesity, atherosclerosis, nephropathy, neuropathy, retinopathy,
CC polycystic ovary syndrome, hypertension, ischaemia, stroke, heart
CC diseases, irritable bowel disorder, inflammation and cataract. The
CC present DNA sequence is a probe which is designed to anneal to aP2 mRNA
CC and function in the bDNA mRNA detection system. This probe is used in aP2
CC assay for antagonist in the exemplification of the invention
XX
SQ Sequence 24 BP; 3 A; 6 C; 5 G; 10 T; 0 U; 0 Other;

Query Match 3.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 293 TGACAGGAAAGTCAAGAGCACCAT 316
||||||||||||||||||||||||
Db 24 TGACAGGAAAGTCAAGAGCACCAT 1

RESULT 19
AAD25481/c
ID AAD25481 standard; DNA; 23 BP.
XX
AC AAD25481;
XX
DT 26-MAR-2002 (first entry)
XX
DE Probe #18 used in aP2 assay for antagonist.
XX
KW Benzoxazinone derivative; glucose metabolism; lipid metabolism; NIDDM;
KW PPAR gamma; peroxisome proliferator activated receptor gamma; therapy;
KW non-insulin dependant diabetes mellitus; nephropathy; neuropathy; PCOS;
KW atherosclerosis; retinopathy; polycystic ovary syndrome; hypertension;
KW ischaemia; obesity; heart disease; irritable bowel disorder; stroke;
KW reduced insulin sensitivity; inflammation; cataract; aP2 mRNA; probe; ss.
XX
OS Unidentified.
XX
PN WO200187860-A2.
XX
PD 22-NOV-2001.

XX
PF 11-MAY-2001; 2001WO-US015320.
XX
PR 12-MAY-2000; 2000US-0203859P.
PR 11-MAY-2001; 2001US-00853798.
XX
PA (ORTH) ORTHO-MCNEIL PHARM INC.
XX
PI Burris TP, Rybczynski PJ;
XX
DR WPI; 2002-082970/11.
XX
PT Use of benzoxazinone derivatives for treating a subject suffering from a
PT disorder in glucose and lipid metabolism such as non-insulin dependant
PT diabetes mellitus or obesity.
XX
PS Example 2; Page 34; 45pp; English.
XX
CC The invention relates to benzoxazinone derivatives useful as peroxisome
CC proliferator activated receptor (PPAR) gamma modulators. The invention
CC also relates to pharmaceutical compositions comprising benzoxazinone
CC derivatives and methods for treating the onset of a disorder in glucose
CC and lipid metabolism, preferably a condition of reduced insulin
CC sensitivity such as non-insulin dependant diabetes mellitus (NIDDM),
CC obesity, nephropathy, neuropathy, retinopathy, atherosclerosis,
CC polycystic ovary syndrome (PCOS), hypertension, ischaemia, stroke, heart
CC diseases, irritable bowel disorder, inflammation and cataract. The
CC present sequence is a probe designed to anneal to the aP2 mRNA and
CC function in the bDNA mRNA detection system. This probe used in the aP2
CC assay for antagonist which is used in the exemplification of the
CC invention
XX
SQ Sequence 23 BP; 5 A; 6 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 3.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 270 GAATTTGACGAAGTCACTGCAGA 292
||||||||||||||||||||||
Db 23 GAATTTGACGAAGTCACTGCAGA 1

RESULT 20
AAI68021/c
ID AAI68021 standard; DNA; 23 BP.
XX
AC AAI68021;
XX
DT 13-MAR-2002 (first entry)
XX
DE ap2 mRNA specific oligonucleotide probe.
XX
KW Peroxisome proliferator activated receptor gamma; benzoxazinone; NIDDM;
KW non-insulin dependant diabetes mellitus; antidiabetic; anorectic;
KW nephrotropic; ophthalmological; antiarteriosclerotic; cytostatic;
KW hypotensive; vasotropic; cerebroprotective; cardiant; antiinflammatory;
KW PPARgamma; probe; ap2; ss.
XX
OS Synthetic.
XX
PN WO200187861-A2.
XX
PD 22-NOV-2001.
XX
PF 11-MAY-2001; 2001WO-US015377.
XX
PR 12-MAY-2000; 2000US-0203861P.
PR 11-MAY-2001; 2001US-00854368.
XX
PA (ORTH) ORTHO-MCNEIL PHARM INC.
XX
PI Burris TP, Demarest KT, Combs DW, Rybczynski PJ, Turchi IJ;
XX
DR WPI; 2002-082971/11.
XX
PT Use of benzoxazinone derivatives for treating a subject suffering from a
PT condition associated with peroxisome proliferator activated receptor
PT gamma activity e.g. non-insulin dependant diabetes mellitus and obesity.
XX
PS Example 7; Page 29; 46pp; English.
XX
CC The invention provides methods of treating a subject suffering from a
CC condition associated with peroxisome proliferator activated receptor
CC gamma (PPARgamma) activity that involves administering a benzoxazinone
CC compound of a specified formula to the subject. The method is useful for
CC treating and inhibiting in a subject the onset of a condition associated
CC with PPARgamma activity such as a condition of reduced insulin
CC sensitivity, non-insulin dependant diabetes mellitus, obesity,
CC nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovary
CC syndrome, hypertension, ischemia, stroke, heart diseases, irritable bowel
CC disorder, inflammation and cataract. Sequences AAI68004-023 represent
CC oligonucleotide probes specific for ap2 used in ap2 mRNA assay for
CC antagonists
XX
SQ Sequence 23 BP; 5 A; 6 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 3.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 270 GAATTTGACGAAGTCACTGCAGA 292
||||||||||||||||||||||
Db 23 GAATTTGACGAAGTCACTGCAGA 1

RESULT 21
AAD24705/c
ID AAD24705 standard; DNA; 23 BP.
XX
AC AAD24705;
XX
DT 12-MAR-2002 (first entry)
XX
DE Probe #18, used in aP2 assay for antagonist.
XX
KW 4h-Benzo(1,4)oxazin-3-one compound; glucose metabolism; lipid metabolism;
KW PPAR gamma; peroxisome proliferator activated receptor; therapy; NIDDM;
KW non-insulin dependant diabetes mellitus; nephropathy; neuropathy; stroke;
KW atherosclerosis; retinopathy; polycystic ovary syndrome; hypertension;
KW ischaemia; obesity; heart disease; irritable bowel disorder; cataract;
KW anorectic; nephrotropic; ophthalmological; cytostatic; hypotensive;
KW vasotropic; cerebroprotective; cardiant; antiinflammatory; probe;
KW aP2 mRNA; ss.
XX
OS Unidentified.
XX
PN WO200187862-A2.
XX
PD 22-NOV-2001.
XX
PF 11-MAY-2001; 2001WO-US015383.
XX
PR 12-MAY-2000; 2000US-0203860P.
PR 11-MAY-2001; 2001US-00854302.
XX
PA (ORTH) ORTHO-MCNEIL PHARM INC.
XX
PI Burris TP, Combs DW, Rybczynski PJ;
XX
DR WPI; 2002-055671/07.
XX
PT Use of 4h-benzo(1,4)oxazin-3-one derivatives for treating a subject
PT suffering from a disorder in glucose and lipid metabolism e.g. non-
PT insulin dependant diabetes mellitus and obesity.
XX

PS Example 38; Page 58; 76pp; English.
XX
CC The patent discloses 4h-Benzo(1,4)oxazin-3-one compounds which are useful
CC as peroxisome proliferator activated receptor (PPAR) gamma agonists and
CC antagonists. The invention also relates to compositions comprising such
CC compounds and methods for treating or inhibiting the onset of a disorder
CC in glucose and lipid metabolism, preferably a condition of reduced
CC insulin sensitivity, such as non-insulin dependent diabetes mellitus
CC (NIDDM), obesity, atherosclerosis, nephropathy, neuropathy, retinopathy,
CC polycystic ovary syndrome, hypertension, ischaemia, stroke, heart
CC diseases, irritable bowel disorder, inflammation and cataract. The
CC present DNA sequence is a probe which is designed to anneal to aP2 mRNA
CC and function in the bDNA mRNA detection system. This probe is used in aP2
CC assay for antagonist in the exemplification of the invention
XX
SQ Sequence 23 BP; 5 A; 6 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 3.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 270 GAATTTGACGAAGTCACTGCAGA 292
||||||||||||||||||||||
Db 23 GAATTTGACGAAGTCACTGCAGA 1

RESULT 22
AAI66788
ID AAI66788 standard; DNA; 20 BP.
XX
AC AAI66788;
XX
DT 07-JAN-2002 (first entry)
XX
DE aP2 mRNA amplifying RT-PCR primer F.
XX
KW Adipocyte; hedgehog polypeptide; desert hedgehog; indian hedgehog; Dhh;
KW Ihh; sonic hedgehog; Shh; therapeutic; cytostatic; primer; RT-PCR; ss.
XX
OS Synthetic.
XX
PN WO200164238-A2.
XX
PD 07-SEP-2001.
XX
PF 28-FEB-2001; 2001WO-US006450.
XX
PR 29-FEB-2000; 2000US-0186058P.
XX
PA (CURI-) CURIS INC.
XX
PI Zehentner B, Leser-Reiff U, Burtscher H;
XX
DR WPI; 2001-607352/69.
XX
PT Method for regulating formation and/or maintenance of adipocyte tissue by
PT contacting pre-adipocyte or adipocyte cells with a hedgehog polypeptide
PT or ptc therapeutic.
XX
PS Example; Page 77; 132pp; English.
XX
CC The invention provides a method for regulating formation and/or
CC maintenance of adipocyte tissue that comprises contacting pre adipocyte
CC or adipocyte cells with a hedgehog polypeptide or ptc therapeutic. The
CC method is used for regulating the growth state of an adipocyte stem/
CC progenitor cell, and treating or preventing disorders of, or surgical or
CC cosmetic repair of, adipocyte tissues, e.g. for treating or preventing
CC hyperplastic or neoplastic conditions affecting adipocyte tissue, such as
CC soft tissue tumors, especially adipose cell tumors, e.g. lipomas,
CC fibrolipomas, lipoblastomas, lipomatosis, hibernomas, hemangiomas and/or
CC liposarcomas. Hedgehog polypeptides can be used in combination with other
CC therapeutic agents. Sequences AAI66784-793 represent primers used in
CC quantitative RT-PCR of PPARgamma, aP2, gli, ptc and actin mRNAs, during
CC the courrse of the invention
XX
SQ Sequence 20 BP; 3 A; 1 C; 7 G; 9 T; 0 U; 0 Other;

Query Match 3.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 63 ATGTGTGATGCTTTTGTAGG 82
||||||||||||||||||||
Db 1 ATGTGTGATGCTTTTGTAGG 20

RESULT 23
ABK87128/c
ID ABK87128 standard; DNA; 20 BP.
XX
AC ABK87128;
XX
DT 07-OCT-2002 (first entry)
XX
DE Human fatty acid binding protein 4, RT-PCR primer #2.
XX
KW Human; endothelial cell-specific molecule 4; ECSM4; neovasculature;
KW imaging vascular endothelium; proliferative disease; cancer; psoriasis;
KW diabetic retinopathy; atherosclerosis; menorrhagia; endothelial damage;
KW tumour neovasculature; cardiac disease; endometriosis; hypoxic condition;
KW angiogenesis; cytostatic; RT-PCR; fatty acid binding protein 4;
KW reverse transcription-PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200236771-A2.
XX
PD 10-MAY-2002.
XX
PF 06-NOV-2001; 2001WO-GB004906.
XX
PR 06-NOV-2000; 2000US-0245566P.
PR 07-MAR-2001; 2001US-0273662P.
XX
PA (IMCR) IMPERIAL CANCER RES TECHNOLOGY LTD.
XX
PI Bicknell R, Huminiecki L;
XX
DR WPI; 2002-508120/54.
XX
PT Novel endothelial cell-specific molecule polypeptide 1 or 4, useful for
PT imaging, diagnosing and treating a condition involving vascular
PT endothelium e.g. cancer, cardiac disease, endometriosis, diabetes.
XX
PS Example 1; Page 165; 248pp; English.
XX
CC The present invention relates to endothelial cell-specific molecule 4
CC (ECSM4), and the polynucleotide sequences encoding it. The ECSM4 proteins
CC are useful for imaging vascular endothelium in the body of an individual,
CC and for diagnosing and treating a proliferative disease or condition
CC involving the vascular endothelium (preferably, neovasculature) such as
CC cancer, psoriasis, diabetic retinopathy, atherosclerosis or menorrhagia.
CC The ECSM4 proteins are also useful in the manufacture of diagnostic or
CC prognostic agent for such conditions. The proteins are also useful for
CC detecting endothelial damage or activation, detecting a tumour or tumour
CC neovasculature, cardiac disease, or endometriosis by detecting the amount
CC of ECSM4 present in a sample. The polynucleotide sequences encoding ECSM4
CC are useful in gene therapy for treating a hypoxic condition such as
CC cancer, cardiac disease, endometriosis or atherosclerosis and in the
CC manufacture of medicaments for treating the above disease. The sequences
CC are useful for modulating angiogenesis in an individual. The present
CC sequence represents a RT-PCR primer for RNA encoding human fatty acid
CC binding protein 4
XX
SQ Sequence 20 BP; 5 A; 9 C; 1 G; 5 T; 0 U; 0 Other;

```
  Query Match             3.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 25;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        191 CAGTGTGAATGGGGATGTGA 210
              ||||||||||||||||||||
Db         20 CAGTGTGAATGGGGATGTGA 1
```

```
RESULT 24
ABK87127
ID   ABK87127 standard; DNA; 20 BP.
XX
AC   ABK87127;
XX
DT   07-OCT-2002  (first entry)
XX
DE   Human fatty acid binding protein 4, RT-PCR primer #1.
XX
KW   Human; endothelial cell-specific molecule 4; ECSM4; neovasculature;
KW   imaging vascular endothelium; proliferative disease; cancer; psoriasis;
KW   diabetic retinopathy; atherosclerosis; menorrhagia; endothelial damage;
KW   tumour neovasculature; cardiac disease; endometriosis; hypoxic condition;
KW   angiogenesis; cytostatic; RT-PCR; fatty acid binding protein 4;
KW   reverse transcription-PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200236771-A2.
XX
PD   10-MAY-2002.
XX
PF   06-NOV-2001; 2001WO-GB004906.
XX
PR   06-NOV-2000; 2000US-0245566P.
PR   07-MAR-2001; 2001US-0273662P.
XX
PA   (IMCR ) IMPERIAL CANCER RES TECHNOLOGY LTD.
XX
PI   Bicknell R,  Huminiecki L;
XX
DR   WPI; 2002-508120/54.
XX
PT   Novel endothelial cell-specific molecule polypeptide 1 or 4, useful for
PT   imaging, diagnosing and treating a condition involving vascular
PT   endothelium e.g. cancer, cardiac disease, endometriosis, diabetes.
XX
PS   Example 1; Page 165; 248pp; English.
XX
CC   The present invention relates to endothelial cell-specific molecule 4
CC   (ECSM4), and the polynucleotide sequences encoding it. The ECSM4 proteins
CC   are useful for imaging vascular endothelium in the body of an individual,
CC   and for diagnosing and treating a proliferative disease or condition
CC   involving the vascular endothelium (preferably, neovasculature) such as
CC   cancer, psoriasis, diabetic retinopathy, atherosclerosis or menorrhagia.
CC   The ECSM4 proteins are also useful in the manufacture of diagnostic or
CC   prognostic agent for such conditions. The proteins are also useful for
CC   detecting endothelial damage or activation, detecting a tumour or tumour
CC   neovasculature, cardiac disease, or endometriosis by detecting the amount
CC   of ECSM4 present in a sample. The polynucleotide sequences encoding ECSM4
CC   are useful in gene therapy for treating a hypoxic condition such as
CC   cancer, cardiac disease, endometriosis or atherosclerosis and in the
CC   manufacture of medicaments for treating the above disease. The sequences
CC   are useful for modulating angiogenesis in an individual. The present
CC   sequence represents a RT-PCR primer for RNA encoding human fatty acid
CC   binding protein 4
XX
SQ   Sequence 20 BP; 2 A; 8 C; 2 G; 8 T; 0 U; 0 Other;
```

```
  Query Match             3.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 25;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         16 TGCAGCTTCCTTCTCACCTT 35
              ||||||||||||||||||||
Db          1 TGCAGCTTCCTTCTCACCTT 20
```

```
RESULT 25
AAD29732
ID   AAD29732 standard; DNA; 20 BP.
XX
AC   AAD29732;
XX
DT   17-MAY-2002  (first entry)
XX
DE   aFABP cDNA amplifying forward PCR primer.
XX
KW   Pre-adipose cell line; white adipocyte; food ingredient; obesity; lipid;
KW   diabetes; cardiovascular disease; fatty acid binding protein; aFABP;
KW   PCR primer; ss.
XX
OS   Unidentified.
XX
PN   WO200206450-A1.
XX
PD   24-JAN-2002.
XX
PF   13-JUL-2001; 2001WO-EP008165.
XX
PR   18-JUL-2000; 2000EP-00115489.
XX
PA   (NEST ) SOC PROD NESTLE SA.
XX
PI   Darimont C,  Mace K,  Pfeifer A;
XX
DR   WPI; 2002-188539/24.
XX
PT   New human pre-adipose cell line capable of differentiating to adipose
PT   cells, useful in developing drug, food ingredients, and supplements
PT   against obesity, diabetes and cardiovascular diseases.
XX
PS   Example 5; Page 11; 30pp; English.
XX
CC   The present invention relates to new human pre-adipose cell lines capable
CC   to differentiate to white adipose cells, exhibiting essentially the same
CC   cellular properties of normal white adipose cells. The human pre-adipose
CC   cell lines are useful for the identification of substances controlling
CC   the regulation of lipid uptake and release by human white adipocytes, and
CC   substances controlling the differentiation of preadipocytes into mature
CC   adipocytes. They are useful for screening compounds capable to regulate
CC   the secretion of any metabolites or hormones from human white adipocytes.
CC   Sequences of the invention are useful for developing drugs, food
CC   ingredients and supplements against obesity, diabetes and cardio-
CC   vascular diseases. The present DNA sequence is a PCR primer which is used
CC   for amplifying fatty acid binding protein (aFABP) encoding cDNA. This
CC   primer is used in the exemplification of the invention for the expression
CC   of adipocytes in differentiated immortalised human preadipose cells
XX
SQ   Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;
```

```
  Query Match             3.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 25;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         81 GGTACCTGGAAACTTGTCTC 100
              ||||||||||||||||||||
Db          1 GGTACCTGGAAACTTGTCTC 20
```

```
RESULT 26
AAD29733/c
ID   AAD29733 standard; DNA; 20 BP.
XX
AC   AAD29733;
XX
```

```
DT   17-MAY-2002  (first entry)
XX
DE   aFABP cDNA amplifying reverse PCR primer.
XX
KW   Pre-adipose cell line; white adipocyte; food ingredient; obesity; lipid;
KW   diabetes; cardiovascular disease; fatty acid binding protein; aFABP;
KW   PCR primer; ss.
XX
OS   Unidentified.
XX
PN   WO200206450-A1.
XX
PD   24-JAN-2002.
XX
PF   13-JUL-2001; 2001WO-EP008165.
XX
PR   18-JUL-2000; 2000EP-00115489.
XX
PA   (NEST ) SOC PROD NESTLE SA.
XX
PI   Darimont C,  Mace K,  Pfeifer A;
XX
DR   WPI; 2002-188539/24.
XX
PT   New human pre-adipose cell line capable of differentiating to adipose
PT   cells, useful in developing drug, food ingredients, and supplements
PT   against obesity, diabetes and cardiovascular diseases.
XX
PS   Example 5; Page 11; 30pp; English.
XX
CC   The present invention relates to new human pre-adipose cell lines capable
CC   to differentiate to white adipose cells, exhibiting essentially the same
CC   cellular properties of normal white adipose cells. The human pre-adipose
CC   cell lines are useful for the identification of substances controlling
CC   the regulation of lipid uptake and release by human white adipocytes, and
CC   substances controlling the differentiation of preadipocytes into mature
CC   adipocytes. They are useful for screening compounds capable to regulate
CC   the secretion of any metabolites or hormones from human white adipocytes.
CC   Sequences of the invention are useful for developing drugs, food
CC   ingredients and supplements against obesity, diabetes and cardio-
CC   vascular diseases. The present DNA sequence is a PCR primer which is used
CC   for amplifying fatty acid binding protein (aFABP) encoding cDNA. This
CC   primer is used in the exemplification of the invention for the expression
CC   of adipocytes in differentiated immortalised human preadipose cells
XX
SQ   Sequence 20 BP; 6 A; 6 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             3.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 25;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        471 CGTTGACCTGGACTGAAGTT 490
              ||||||||||||||||||||
Db         20 CGTTGACCTGGACTGAAGTT 1


RESULT 27
AAD55891/c
ID   AAD55891 standard; DNA; 20 BP.
XX
AC   AAD55891;
XX
DT   07-AUG-2003  (first entry)
XX
DE   Human aP2 gene amplifying forward RT-PCR primer.
XX
KW   Adipose-derived stem cell; ADSC; transgene; cell therapy; gene therapy;
KW   primer; reverse transcription; RT; PCR; aP2; human; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003022988-A2.
XX
PD   20-MAR-2003.
XX
PF   31-JUL-2002; 2002WO-US024374.
XX
PR   10-SEP-2001; 2001US-00952522.
XX
PA   (REGC ) UNIV CALIFORNIA.
XX
PI   Hedrick MH,  Katz AJ,  Llull R,  Futrell JW,  Benhaim P,  Lorenz HP;
PI   Zhu M;
XX
DR   WPI; 2003-354531/33.
XX
PT   New isolated adipose-derived stem cell, useful for generating
PT   differentiated tissues and structures both in vivo and in vitro or
PT   providing conditioned culture media to support the growth and expansion
PT   of other cell populations.
XX
PS   Example 11; Page 234; 241pp; English.
XX
CC   The invention relates to adipose-derived stem cells (ADSC) and lattices
CC   which are useful for generating differentiated tissues and structures
CC   both in vivo and in vitro, for producing molecules such as hormones and
CC   for providing a conditioned culture media for supporting the growth and
CC   expansion of other cell populations. Lattices are useful as substrates
CC   for facilitating the growth and differentiation of cells into mature
CC   tissues or structures. The invention is useful for delivering a transgene
CC   to an animal. The invention is also useful in cell therapy and gene
CC   therapy. The present sequence is reverse transcription PCR (RT-PCR)
CC   primer used to amplify human aP2 gene. This sequence is used in the
CC   exemplification of the invention
XX
SQ   Sequence 20 BP; 3 A; 5 C; 3 G; 9 T; 0 U; 0 Other;

  Query Match             3.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 25;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        353 ATGGGATGGAAAATCAACCA 372
              ||||||||||||||||||||
Db         20 ATGGGATGGAAAATCAACCA 1


RESULT 28
AAI66789/c
ID   AAI66789 standard; DNA; 19 BP.
XX
AC   AAI66789;
XX
DT   07-JAN-2002  (first entry)
XX
DE   aP2 mRNA amplifying RT-PCR primer R.
XX
KW   Adipocyte; hedgehog polypeptide; desert hedgehog; indian hedgehog; Dhh;
KW   Ihh; sonic hedgehog; Shh; therapeutic; cytostatic; primer; RT-PCR; ss.
XX
OS   Synthetic.
XX
PN   WO200164238-A2.
XX
PD   07-SEP-2001.
XX
PF   28-FEB-2001; 2001WO-US006450.
XX
PR   29-FEB-2000; 2000US-0186058P.
XX
PA   (CURI-) CURIS INC.
XX
PI   Zehentner B,  Leser-Reiff U,  Burtscher H;
XX
DR   WPI; 2001-607352/69.
XX
PT   Method for regulating formation and/or maintenance of adipocyte tissue by
```

PT contacting pre-adipocyte or adipocyte cells with a hedgehog polypeptide
PT or ptc therapeutic.
XX
PS Example; Page 77; 132pp; English.
XX
CC The invention provides a method for regulating formation and/or
CC maintenance of adipocyte tissue that comprises contacting pre adipocyte
CC or adipocyte cells with a hedgehog polypeptide or ptc therapeutic. The
CC method is used for regulating the growth state of an adipocyte stem/
CC progenitor cell, and treating or preventing disorders of, or surgical or
CC cosmetic repair of, adipocyte tissues, e.g. for treating or preventing
CC hyperplastic or neoplastic conditions affecting adipocyte tissue, such as
CC soft tissue tumors, especially adipose cell tumors, e.g. lipomas,
CC fibrolipomas, lipoblastomas, lipomatosis, hibernomas, hemangiomas and/or
CC liposarcomas. Hedgehog polypeptides can be used in combination with other
CC therapeutic agents. Sequences AAI66784-793 represent primers used in
CC quantitative RT-PCR of PPARgamma, aP2, gli, ptc and actin mRNAs, during
CC the courrse of the invention
XX
SQ Sequence 19 BP; 2 A; 7 C; 1 G; 9 T; 0 U; 0 Other;

Query Match 3.0%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 27;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 347 GCAGAAATGGGATGGAAAA 365
||||||||||||||||||||
Db 19 GCAGAAATGGGATGGAAAA 1

RESULT 29
AAD25483/c
ID AAD25483 standard; DNA; 19 BP.
XX
AC AAD25483;
XX
DT 26-MAR-2002 (first entry)
XX
DE Probe #20 used in aP2 assay for antagonist.
XX
KW Benzoxazinone derivative; glucose metabolism; lipid metabolism; NIDDM;
KW PPAR gamma; peroxisome proliferator activated receptor gamma; therapy;
KW non-insulin dependant diabetes mellitus; nephropathy; neuropathy; PCOS;
KW atherosclerosis; retinopathy; polycystic ovary syndrome; hypertension;
KW ischaemia; obesity; heart disease; irritable bowel disorder; stroke;
KW reduced insulin sensitivity; inflammation; cataract; aP2 mRNA; probe; ss.
XX
OS Unidentified.
XX
PN WO200187860-A2.
XX
PD 22-NOV-2001.
XX
PF 11-MAY-2001; 2001WO-US015320.
XX
PR 12-MAY-2000; 2000US-0203859P.
PR 11-MAY-2001; 2001US-00853798.
XX
PA (ORTH) ORTHO-MCNEIL PHARM INC.
XX
PI Burris TP, Rybczynski PJ;
XX
DR WPI; 2002-082970/11.
XX
PT Use of benzoxazinone derivatives for treating a subject suffering from a
PT disorder in glucose and lipid metabolism such as non-insulin dependant
PT diabetes mellitus or obesity.
XX
PS Example 2; Page 34; 45pp; English.
XX
CC The invention relates to benzoxazinone derivatives useful as peroxisome
CC proliferator activated receptor (PPAR) gamma modulators. The invention
CC also relates to pharmaceutical compositions comprising benzoxazinone
CC derivatives and methods for treating the onset of a disorder in glucose
CC and lipid metabolism, preferably a condition of reduced insulin
CC sensitivity such as non-insulin dependant diabetes mellitus (NIDDM),
CC obesity, nephropathy, neuropathy, retinopathy, atherosclerosis,
CC polycystic ovary syndrome (PCOS), hypertension, ischaemia, stroke, heart
CC diseases, irritable bowel disorder, inflammation and cataract. The
CC present sequence is a probe designed to anneal to the aP2 mRNA and
CC function in the bDNA mRNA detection system. This probe used in the aP2
CC assay for antagonist which is used in the exemplification of the
CC invention
XX
SQ Sequence 19 BP; 5 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 3.0%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 27;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 417 GTCATGAAAGGCGTCACTT 435
||||||||||||||||||||
Db 19 GTCATGAAAGGCGTCACTT 1

RESULT 30
AAI68023/c
ID AAI68023 standard; DNA; 19 BP.
XX
AC AAI68023;
XX
DT 13-MAR-2002 (first entry)
XX
DE ap2 mRNA specific oligonucleotide probe.
XX
KW Peroxisome proliferator activated receptor gamma; benzoxazinone; NIDDM;
KW non-insulin dependant diabetes mellitus; antidiabetic; anorectic;
KW nephrotropic; ophthalmological; antiarteriosclerotic; cytostatic;
KW hypotensive; vasotropic; cerebroprotective; cardiant; antiinflammatory;
KW PPARgamma; probe; ap2; ss.
XX
OS Synthetic.
XX
PN WO200187861-A2.
XX
PD 22-NOV-2001.
XX
PF 11-MAY-2001; 2001WO-US015377.
XX
PR 12-MAY-2000; 2000US-0203861P.
PR 11-MAY-2001; 2001US-00854368.
XX
PA (ORTH) ORTHO-MCNEIL PHARM INC.
XX
PI Burris TP, Demarest KT, Combs DW, Rybczynski PJ, Turchi IJ;
XX
DR WPI; 2002-082971/11.
XX
PT Use of benzoxazinone derivatives for treating a subject suffering from a
PT condition associated with peroxisome proliferator activated receptor
PT gamma activity e.g. non-insulin dependant diabetes mellitus and obesity.
XX
PS Example 7; Page 29; 46pp; English.
XX
CC The invention provides methods of treating a subject suffering from a
CC condition associated with peroxisome proliferator activated receptor
CC gamma (PPARgamma) activity that involves administering a benzoxazinone
CC compound of a specified formula to the subject. The method is useful for
CC treating and inhibiting in a subject the onset of a condition associated
CC with PPARgamma activity such as a condition of reduced insulin
CC sensitivity, non-insulin dependant diabetes mellitus, obesity,
CC nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovary
CC syndrome, hypertension, ischemia, stroke, heart diseases, irritable bowel
CC disorder, inflammation and cataract. Sequences AAI68004-023 represent
CC oligonucleotide probes specific for ap2 used in ap2 mRNA assay for
CC antagonists

```
XX
SQ   Sequence 19 BP; 5 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             3.0%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 27;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        417 GTCATGAAAGGCGTCACTT 435
              |||||||||||||||||||
Db         19 GTCATGAAAGGCGTCACTT 1


RESULT 31
AAD24707/c
ID   AAD24707 standard; DNA; 19 BP.
XX
AC   AAD24707;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Probe #20, used in aP2 assay for antagonist.
XX
KW   4h-Benzo(1,4)oxazin-3-one compound; glucose metabolism; lipid metabolism;
KW   PPAR gamma; peroxisome proliferator activated receptor; therapy; NIDDM;
KW   non-insulin dependant diabetes mellitus; nephropathy; neuropathy; stroke;
KW   atherosclerosis; retinopathy; polycystic ovary syndrome; hypertension;
KW   ischaemia; obesity; heart disease; irritable bowel disorder; cataract;
KW   anorectic; nephrotropic; ophthalmological; cytostatic; hypotensive;
KW   vasotropic; cerebroprotective; cardiant; antiinflammatory; probe;
KW   aP2 mRNA; ss.
XX
OS   Unidentified.
XX
PN   WO200187862-A2.
XX
PD   22-NOV-2001.
XX
PF   11-MAY-2001; 2001WO-US015383.
XX
PR   12-MAY-2000; 2000US-0203860P.
PR   11-MAY-2001; 2001US-00854302.
XX
PA   (ORTH ) ORTHO-MCNEIL PHARM INC.
XX
PI   Burris TP,  Combs DW,  Rybczynski PJ;
XX
DR   WPI; 2002-055671/07.
XX
PT   Use of 4h-benzo(1,4)oxazin-3-one derivatives for treating a subject
PT   suffering from a disorder in glucose and lipid metabolism e.g. non-
PT   insulin dependant diabetes mellitus and obesity.
XX
PS   Example 38; Page 59; 76pp; English.
XX
CC   The patent discloses 4h-Benzo(1,4)oxazin-3-one compounds which are useful
CC   as peroxisome proliferator activated receptor (PPAR) gamma agonists and
CC   antagonists. The invention also relates to compositions comprising such
CC   compounds and methods for treating or inhibiting the onset of a disorder
CC   in glucose and lipid metabolism, preferably a condition of reduced
CC   insulin sensitivity, such as non-insulin dependent diabetes mellitus
CC   (NIDDM), obesity, atherosclerosis, nephropathy, neuropathy, retinopathy,
CC   polycystic ovary syndrome, hypertension, ischaemia, stroke, heart
CC   diseases, irritable bowel disorder, inflammation and cataract. The
CC   present DNA sequence is a probe which is designed to anneal to aP2 mRNA
CC   and function in the bDNA mRNA detection system. This probe is used in aP2
CC   assay for antagonist in the exemplification of the invention
XX
SQ   Sequence 19 BP; 5 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             3.0%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 27;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        417 GTCATGAAAGGCGTCACTT 435
              |||||||||||||||||||
Db         19 GTCATGAAAGGCGTCACTT 1


RESULT 32
AAD55892
ID   AAD55892 standard; DNA; 20 BP.
XX
AC   AAD55892;
XX
DT   07-AUG-2003  (first entry)
XX
DE   Human aP2 gene amplifying reverse RT-PCR primer #1.
XX
KW   Adipose-derived stem cell; ADSC; transgene; cell therapy; gene therapy;
KW   primer; reverse transcription; RT; PCR; aP2; human; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003022988-A2.
XX
PD   20-MAR-2003.
XX
PF   31-JUL-2002; 2002WO-US024374.
XX
PR   10-SEP-2001; 2001US-00952522.
XX
PA   (REGC ) UNIV CALIFORNIA.
XX
PI   Hedrick MH,  Katz AJ,  Llull R,  Futrell JW,  Benhaim P,  Lorenz HP;
PI   Zhu M;
XX
DR   WPI; 2003-354531/33.
XX
PT   New isolated adipose-derived stem cell, useful for generating
PT   differentiated tissues and structures both in vivo and in vitro or
PT   providing conditioned culture media to support the growth and expansion
PT   of other cell populations.
XX
PS   Example 11; Page 234; 241pp; English.
XX
CC   The invention relates to adipose-derived stem cells (ADSC) and lattices
CC   which are useful for generating differentiated tissues and structures
CC   both in vivo and in vitro, for producing molecules such as hormones and
CC   for providing a conditioned culture media for supporting the growth and
CC   expansion of other cell populations. Lattices are useful as substrates
CC   for facilitating the growth and differentiation of cells into mature
CC   tissues or structures. The invention is useful for delivering a transgene
CC   to an animal. The invention is also useful in cell therapy and gene
CC   therapy. The present sequence is reverse transcription PCR (RT-PCR)
CC   primer used to amplify human aP2 gene. This sequence is used in the
CC   exemplification of the invention
XX
SQ   Sequence 20 BP; 5 A; 3 C; 6 G; 6 T; 0 U; 0 Other;

  Query Match             3.0%;  Score 19;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 28;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        259 TACTGGGCCAGGAATTTGA 277
              |||||||||||||||||||
Db          1 TACTGGGCCAGGAATTTGA 19


RESULT 33
AAX32484/c
ID   AAX32484 standard; DNA; 22 BP.
XX
AC   AAX32484;
XX
DT   22-JUN-1999  (first entry)
XX
```

DE Forward primer flanking CA repeat in porcine A-FABP gene.
XX
KW A-FABP; adipocyte fatty acid binding protein; pig; porcine; allele;
KW breeding program; fatty acid transport; fat deposition; primer; ss.
XX
OS Synthetic.
OS Sus scrofa.
XX
PN WO9914365-A1.
XX
PD 25-MAR-1999.
XX
PF 18-SEP-1998; 98WO-NL000541.
XX
PR 18-SEP-1997; 97EP-00202857.
XX
PA (DALL-) DALLAND BV.
PA (PROV-) PROVA BV.
PA (STAM-) STAMBOEK ZUID BV.
PA (NNEV-) NOORD NEDERLANDS VARKENSSTAMBOEK BV.
PA (DIER-) STICHTING INST DIERHOUDERIJ EN DIERGEZON.
XX
PI Gerbens F;
XX
DR WPI; 1999-229550/19.
XX
PT Nucleic acid specific for the pig adipocyte fatty acid binding protein.
XX
PS Disclosure; Fig 4; 36pp; English.
XX
CC The invention relates to a gene encoding pig A-FABP (adipocyte fatty acid
CC binding protein). Nucleic acid specific for the A-FABP gene or its
CC fragments are used (1) to localize, identify or mark alleles in the gene,
CC particularly those associated with production traits in pigs; and (2) for
CC specific amplification of fragments, its alleles or trait loci,
CC particularly for distinguishing between alleles. Pigs carrying particular
CC alleles are selected for use in breeding programs. Since A-FABP is
CC involved in fatty acid transport and fat deposition, and may control
CC insulin dependency, selection of particular alleles may allow regulation
CC of fat deposition in muscle; body weight, weight gain and feed efficiency
CC ; fatty acid content of meat; embryo survival; birth rate and litter
CC size, and milk quality and quantity
XX
SQ Sequence 22 BP; 4 A; 3 C; 6 G; 9 T; 0 U; 0 Other;

Query Match 3.0%; Score 18.8; DB 1; Length 22;
Best Local Similarity 90.9%; Pred. No. 32;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        212 CACCATTAAATCTGAAAGTACC 233
              |||||||| ||| |||||||||
Db         22 CACCATTAGATCAGAAAGTACC 1
```

RESULT 34
AAD48760
ID AAD48760 standard; RNA; 18 BP.
XX
AC AAD48760;
XX
DT 07-MAR-2003 (first entry)
XX
DE Human fatty acid binding protein 2 (FABP-2) RNA fragment #2.
XX
KW Human; RNA binding molecule; fatty acid binding protein 2; FABP-2; ss.
XX
OS Homo sapiens.
XX
PN WO200281748-A1.
XX
PD 17-OCT-2002.
XX
PF 04-APR-2002; 2002WO-SE000677.
XX
PR 05-APR-2001; 2001SE-00001218.
PR 05-APR-2001; 2001US-0281384P.
XX
PA (BIOV-) BIOVITRUM AB.
XX
PI Ekblom J;
XX
DR WPI; 2003-058568/05.
XX
PT Identifying RNA-binding molecule by predicting structure of RNA fragment,
PT synthesizing DNA fragment corresponding to predicted RNA structure,
PT performing reporter gene assay after placing the DNA upstream of reporter
PT gene.
XX
PS Claim 10; Page 28; 35pp; English.
XX
CC The present invention relates to a method of identifying RNA-binding
CC molecule comprising predicting the structure of RNA-fragment, selecting
CC suitable predicted RNA fragment with an individual stem, synthesising a
CC DNA-fragment corresponding to the RNA fragment, inserting the DNA
CC fragment in upstream proximity of reporter assay gene to form reporter
CC construct and performing a reporter gene assay which detects interaction
CC between a molecule to be tested for RNA-binding and RNA fragment of the
CC reporter construct. The method is useful for identifying an RNA binding
CC molecule. The present sequence is human fatty acid binding protein 2
CC (FABP-2) RNA fragment. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 18 BP; 3 A; 4 C; 7 G; 0 T; 4 U; 0 Other;

Query Match 2.8%; Score 18; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 30;
Matches 14; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

```
Qy          9 AGGAGGGTGCAGCTTCCT 26
              |||||||:|||||:::||:
Db          1 AGGAGGGUGCAGCUUCCU 18
```

RESULT 35
ABZ85335
ID ABZ85335 standard; DNA; 20 BP.
XX
AC ABZ85335;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.

XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Claim 15; SEQ ID NO 577; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 7 A; 4 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 2.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 38;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 279 GAAGTCACTGCAGATGACAG 298
||||||| |||| |||||||
Db 1 GAAGTCATTGCACATGACAG 20

RESULT 36
ABK92082
ID ABK92082 standard; DNA; 21 BP.
XX
AC ABK92082;
XX
DT 14-AUG-2002 (first entry)
XX
DE Novel fatty acid-binding protein-like protein, forward primer.
XX
KW Cancer; metabolic disorder; skin disorder; infectious disease; anorexia;
KW behavioral disorder; valve disease; endocrine disorder; heart disorder;
KW blood disorder; anxiety disorder; brain disorder; inflammatory disorder;
KW neurodegenerative disorder; Alzheimer's disease; Parkinson's disease;
KW immune disorder; haematopoietic disorder; dyslipidaemia;
KW metabolic disturbance; obesity; metabolic syndrome X; wasting disorder;
KW gene therapy; transgenic animal; human; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200229058-A2.
XX
PD 11-APR-2002.
XX
PF 05-OCT-2001; 2001WO-US031248.
XX
PR 05-OCT-2000; 2000US-0238323P.
PR 05-OCT-2000; 2000US-0238325P.
PR 06-OCT-2000; 2000US-0238372P.
PR 06-OCT-2000; 2000US-0238373P.
PR 06-OCT-2000; 2000US-0238379P.
PR 06-OCT-2000; 2000US-0238382P.
PR 06-OCT-2000; 2000US-0238383P.
PR 06-OCT-2000; 2000US-0238384P.
PR 06-OCT-2000; 2000US-0238397P.
PR 06-OCT-2000; 2000US-0238400P.
PR 06-OCT-2000; 2000US-0238401P.
PR 06-OCT-2000; 2000US-0238402P.
PR 14-MAR-2001; 2001US-0275892P.
PR 08-JUN-2001; 2001US-0296860P.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Shimkets RA, Taupier RJ, Burgess CE, Zerhusen BD, Mezes PS;
PI Rastelli L, Malyankar UM, Grosse WM, Alsobrook JP, Lepley DM;
PI Spytek KA, Li L, Edinger S, Gerlach V, Ellerman K, Macdougall J;
PI Gunther E, Millet I, Stone D, Smithson G, Szekeres ES;
XX
DR WPI; 2002-444103/47.
XX
PT Novel isolated polypeptide, designated NOVX, useful for treating or
PT preventing cancer, diabetes, obesity, dyslipidemia, anorexia, and
PT metabolic, neurodegenerative, immune and hematopoietic disorders.
XX
PS Example 3; Page 228; 316pp; English.
XX
CC The invention describes an isolated polypeptide (I), useful in the
CC manufacture of a medicament for treating a syndrome associated with a
CC human disease. (I), the polynucleotide encoding it (II) and an antibody
CC (III) to (I) are useful for treating or preventing cancer, metabolic
CC disorders, skin disorders, infectious disease, anorexia, behavioral
CC disorders, valve diseases, endocrine disorders, heart and blood
CC disorders, anxiety disorders, brain disorders, inflammatory disorders,
CC neurodegenerative disorder, Alzheimer's disease, Parkinson's disorder,
CC immune disorders, haematopoietic disorders, and the various
CC dyslipidaemias, metabolic disturbances associated with obesity, and the
CC metabolic syndrome X and wasting disorders associated with chronic
CC diseases. (I), (II) or (III) are useful in screening assays, detection
CC assays (e.g., chromosomal mapping, tissue typing, forensic biology),
CC predictive medicine (e.g., diagnostic assays and prognostic assays), and
CC in methods of treatment (e.g., therapeutic and prophylactic). (I) is
CC useful as immunogen to produce antibodies immunospecific for (I), to
CC screen for potential agonist and antagonist compounds, and as bait
CC protein in a two-hybrid or three-hybrid assay. (II) is useful in gene
CC therapy, to express (I), to detect (I) mRNA or a genetic lesion in a (I)
CC gene, and to modulate activity of (I). A cell containing a vector
CC exressing (I) is useful for producing non-human transgenic animals. This
CC sequence represents a primer used to study expression of the novel human
CC polypeptides described in the invention
XX
SQ Sequence 21 BP; 5 A; 1 C; 9 G; 6 T; 0 U; 0 Other;

Query Match 2.6%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 39;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 405 GTGGTGGAATGCGTCATGAA 424
|||||||| || ||||||||
Db 2 GTGGTGGAGTGTGTCATGAA 21

RESULT 37
ABZ61709/c
ID ABZ61709 standard; RNA; 17 BP.
XX
AC ABZ61709;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human H-Ras DNAzyme target #500.
XX
KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX
OS Homo sapiens.

XX
PN WO200297114-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US016840.
XX
PR 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J;
XX
DR WPI; 2003-140484/13.
XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS Claim 58; Page 120; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 4 A; 6 C; 4 G; 0 T; 3 U; 0 Other;

Query Match 2.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 40;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 8 CAGGAGGGTGCAGCTTC 24
||||||||| |||||||
Db 17 CAGGAGGGTTCAGCTTC 1

RESULT 38
AAZ77088
ID AAZ77088 standard; DNA; 18 BP.
XX
AC AAZ77088;
XX
DT 10-SEP-2001 (first entry)
XX
DE Human biallelic marker downstream amplification primer SEQ ID NO:11444.
XX
KW Human genome; biallelic marker; high density disequilibrium map;
KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW haplotyping; hybridisation; identification; characterisation;
KW amplification; single nucleotide polymorphism; SNP; PCR primer;
KW diagnosis; ss.
XX
OS Homo sapiens.
XX
PN WO9954500-A2.
XX
PD 28-OCT-1999.
XX
PF 21-APR-1999; 99WO-IB000822.
XX
PR 21-APR-1998; 98US-0082614P.
PR 23-NOV-1998; 98US-0109732P.
XX
PA (GEST) GENSET.
XX
PI Cohen D, Blumenfeld M, Chumakov I;
XX
DR WPI; 2000-013267/01.
XX
PT Novel biallelic markers used to construct a high density disequilibrium
PT map of the human genome.
XX
PS Claim 9; Page 2670; 2745pp; English.
XX
CC AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC invention, which contain a polymorphic base at position 24 of their
CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC primers for the biallelic markers. The biallelic markers of the invention
CC have a variety of uses: they can be used for high density mapping of the
CC human genome, and in complex association studies and haplotyping studies
CC which are useful in determining the genetic basis for disease states.
CC Compositions and methods of the invention can also be useful for the
CC identification of the targets for the development of pharmaceutical
CC agents and diagnostic methods, as well as the characterisation of the
CC differential efficacious responses to and side effects from
CC pharmaceutical agents acting on a disease as well as other treatment.
CC N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC 3367, are not actually given a sequence in the Sequence Listing from the
CC present invention
XX
SQ Sequence 18 BP; 4 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 2.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 42;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 570 ATTTTCTCCCAAGCTGA 586
||||||||||||| |||
Db 1 ATTTTCTCCCAAGGTGA 17

RESULT 39
AAZ73388
ID AAZ73388 standard; DNA; 18 BP.
XX
AC AAZ73388;
XX
DT 10-SEP-2001 (first entry)
XX
DE Human biallelic marker upstream amplification primer SEQ ID NO:7744.
XX
KW Human genome; biallelic marker; high density disequilibrium map;
KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW haplotyping; hybridisation; identification; characterisation;
KW amplification; single nucleotide polymorphism; SNP; PCR primer;
KW diagnosis; ss.
XX
OS Homo sapiens.
XX
PN WO9954500-A2.
XX
PD 28-OCT-1999.
XX
PF 21-APR-1999; 99WO-IB000822.
XX
PR 21-APR-1998; 98US-0082614P.
PR 23-NOV-1998; 98US-0109732P.
XX
PA (GEST) GENSET.
XX
PI Cohen D, Blumenfeld M, Chumakov I;
XX
DR WPI; 2000-013267/01.
XX
PT Novel biallelic markers used to construct a high density disequilibrium

```
PT   map of the human genome.
XX
PS   Claim 9; Page 1882; 2745pp; English.
XX
CC   AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC   invention, which contain a polymorphic base at position 24 of their
CC   nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC   primers for the biallelic markers. The biallelic markers of the invention
CC   have a variety of uses: they can be used for high density mapping of the
CC   human genome, and in complex association studies and haplotyping studies
CC   which are useful in determining the genetic basis for disease states.
CC   Compositions and methods of the invention can also be useful for the
CC   identification of the targets for the development of pharmaceutical
CC   agents and diagnostic methods, as well as the characterisation of the
CC   differential efficacious responses to and side effects from
CC   pharmaceutical agents acting on a disease as well as other treatment.
CC   N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC   3367, are not actually given a sequence in the Sequence Listing from the
CC   present invention
XX
SQ   Sequence 18 BP; 9 A; 4 C; 5 G; 0 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 45;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        450 GAGAGAGCATAAGCCAAG 467
              ||||||||| || |||||
Db          1 GAGAGAGCAAAACCCAAG 18


RESULT 40
AAD33908
ID   AAD33908 standard; DNA; 18 BP.
XX
AC   AAD33908;
XX
DT   16-JUL-2002  (first entry)
XX
DE   Human carboxypeptidase-like enzyme DNA amplifying PCR forward primer.
XX
KW   Human; carboxypeptidase-like enzyme; therapy; cancer; asthma; allergy;
KW   chronic obstructive pulmonary disease; cytostatic; antiasthmatic;
KW   antiallergic; enzyme; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200220805-A2.
XX
PD   14-MAR-2002.
XX
PF   05-SEP-2001; 2001WO-EP010203.
XX
PR   11-SEP-2000; 2000US-0231546P.
XX
PA   (FARB ) BAYER AG.
XX
PI   Liou J;
XX
DR   WPI; 2002-315660/35.
XX
PT   New purified human carboxypeptidase-like enzyme, useful for identifying
PT   modulators of enzyme activity for treating cancer, asthma, allergy or
PT   chronic obstructive pulmonary disease.
XX
PS   Example 6; Page 68; 127pp; English.
XX
CC   The invention relates to a purified human carboxypeptidase-like enzyme.
CC   The enzyme is useful for screening for agents which decrease the activity
CC   of an carboxypeptidase-like enzyme. The invention is also useful for
CC   treating a carboxypeptidase-like enzyme dysfunction related diseases
CC   condition such as chronic obstructive pulmonary disease, cancer, asthma
CC   or allergy. The invention is also useful for modulating carboxypeptidase-
CC   like enzyme activity in a disease condition. The invention is useful in
CC   diagnostic assays for detecting diseases and abnormalities or
CC   susceptibility to diseases and abnormalities related to presence of
CC   mutations in the nucleic acid sequences which encode the enzyme. The
CC   present sequence is a PCR primer used for amplifying human DNA encoding
CC   carboxypeptidase-like enzyme
XX
SQ   Sequence 18 BP; 4 A; 3 C; 8 G; 3 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 45;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        151 CCAGGAAAGTGGCTGGCA 168
              ||||||| |||| |||||
Db          1 CCAGGAAGGTGGTTGGCA 18


RESULT 41
AAQ11390
ID   AAQ11390 standard; DNA; 17 BP.
XX
AC   AAQ11390;
XX
DT   25-MAR-2003  (revised)
DT   02-JUL-1991  (first entry)
XX
DE   Probe COD 957 specific for T. hyo 39kD antigen genes.
XX
KW   Swine dysentery; vaccine.
XX
OS   Synthetic.
XX
PN   WO9104036-A.
XX
PD   04-APR-1991.
XX
PF   13-SEP-1989;   89US-00406535.
XX
PR   13-SEP-1989;   89US-00406535.
XX
PA   (MLTE-) ML TECHN VENTURES.
XX
PI   Gabe J,  Dragon E,  Mccaman M;
XX
DR   WPI; 1991-117317/16.
XX
PT   Treponema hyodysenteriae antigens - having molecular wt. of 39 K daltons
PT   and their DNA codes, and use for preparing vaccine.
XX
PS   Disclosure; Page 38; 84pp; English.
XX
CC   The probe was designed from the sequence of the pTrep106 encoding the T.
CC   hyo 39 kD antigen no. 1. It was used for screening of clones prepd. from
CC   T. hyo genomic DNA following PCR treatment. See also AAQ11377-Q11409.
CC   (Updated on 25-MAR-2003 to correct PA field.)
XX
SQ   Sequence 17 BP; 6 A; 4 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 45;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        223 CTGAAAGTACCTTTAA 238
              | ||||||||||||||
Db          1 CCGAAAGTACCTTTAA 16


RESULT 42
ABV80082
ID   ABV80082 standard; DNA; 17 BP.
XX
AC   ABV80082;
```

```
XX
DT   03-JAN-2003  (first entry)
XX
DE   Human HTPL scanning oligonucleotide SEQ ID 1328.
XX
KW   Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW   human testis expressed Patched like protein; testis; adrenal; liver;
KW   male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW   prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX
OS   Homo sapiens.
XX
PN   EP1229046-A2.
XX
PD   07-AUG-2002.
XX
PF   28-JAN-2002; 2002EP-00001167.
XX
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   23-MAY-2001; 2001US-00864761.
PR   09-OCT-2001; 2001US-0327898P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Zhan J;
XX
DR   WPI; 2002-676582/73.
XX
PT   Novel isolated human testis expressed Patched like protein (HTPL), useful
PT   for identifying agonist and antagonist and specific binding partners, and
PT   for treating subjects having defects in HTPL.
XX
PS   Example 2; Page 237; 718pp; English.
XX
CC   The present invention relates to human testis expressed Patched like
CC   protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
CC   has two isoforms, with a few single base pair differences between the
CC   two. One of the single base pair changes introduces a premature stop
CC   codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
CC   shares an overall structure organisation with the Patched protein. The
CC   shared structural features strongly imply that HTPL plays a role similar
CC   to that of Patched, and is a potential tumour suppressor. HTPL is
CC   important in regulating male germ cell development, and the HTPL gene was
CC   mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC   useful for diagnosing a disorder caused by mutation in HTPL, and in
CC   therapy and manufacture of a medicament for treatment or prevention of
CC   such disorder associated with decreased expression or activity of human
CC   HTPL. Such disorders include disorders of testis, or adrenal, adult and
CC   foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC   skeletal muscle or colon function. HTPL proteins and nucleic acids are
CC   clinically useful diagnostic markers and potenial therapeutic agents for
CC   male infertility and cancer. The present oligonucleotide was used in an
CC   example from the invention
XX
SQ   Sequence 17 BP; 6 A; 2 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 45;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         58 ACAAAATGTGTGATGC 73
              ||||||||||||| |||
Db          2 ACAAAATGTGTGTTGC 17


RESULT 43
ABV80083
ID   ABV80083 standard; DNA; 17 BP.
XX
AC   ABV80083;
XX
DT   03-JAN-2003  (first entry)
XX
DE   Human HTPL scanning oligonucleotide SEQ ID 1329.
XX
KW   Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW   human testis expressed Patched like protein; testis; adrenal; liver;
KW   male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW   prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX
OS   Homo sapiens.
XX
PN   EP1229046-A2.
XX
PD   07-AUG-2002.
XX
PF   28-JAN-2002; 2002EP-00001167.
XX
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   23-MAY-2001; 2001US-00864761.
PR   09-OCT-2001; 2001US-0327898P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Zhan J;
XX
DR   WPI; 2002-676582/73.
XX
PT   Novel isolated human testis expressed Patched like protein (HTPL), useful
PT   for identifying agonist and antagonist and specific binding partners, and
PT   for treating subjects having defects in HTPL.
XX
PS   Example 2; Page 238; 718pp; English.
XX
CC   The present invention relates to human testis expressed Patched like
CC   protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
CC   has two isoforms, with a few single base pair differences between the
CC   two. One of the single base pair changes introduces a premature stop
CC   codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
CC   shares an overall structure organisation with the Patched protein. The
CC   shared structural features strongly imply that HTPL plays a role similar
CC   to that of Patched, and is a potential tumour suppressor. HTPL is
CC   important in regulating male germ cell development, and the HTPL gene was
CC   mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC   useful for diagnosing a disorder caused by mutation in HTPL, and in
CC   therapy and manufacture of a medicament for treatment or prevention of
CC   such disorder associated with decreased expression or activity of human
CC   HTPL. Such disorders include disorders of testis, or adrenal, adult and
CC   foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC   skeletal muscle or colon function. HTPL proteins and nucleic acids are
CC   clinically useful diagnostic markers and potenial therapeutic agents for
CC   male infertility and cancer. The present oligonucleotide was used in an
CC   example from the invention
XX
SQ   Sequence 17 BP; 5 A; 2 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 45;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         58 ACAAAATGTGTGATGC 73
              ||||||||||||| |||
Db          1 ACAAAATGTGTGTTGC 16


RESULT 44
```

```
ABK17807/c
ID   ABK17807 standard; RNA; 17 BP.
XX
AC   ABK17807;
XX
DT   09-APR-2002  (first entry)
XX
DE   Human ERG hammerhead ribozyme target sequence, Seq ID No 454.
XX
KW   Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
KW   ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
KW   vulnerary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
KW   tumour angiogenesis; diabetic retinopathy; macular degeneration;
KW   neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
KW   angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
KW   Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
KW   Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNAzyme; inozyme;
KW   amberzyme.
XX
OS   Homo sapiens.
XX
PN   WO200188124-A2.
XX
PD   22-NOV-2001.
XX
PF   16-MAY-2001; 2001WO-US015866.
XX
PR   16-MAY-2000; 2000US-00572021.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (GLAX ) GLAXO GROUP LTD.
XX
PI   Jarvis T,  Von Carlowitz I,  Mcswiggen JA,  Mclaughlin F,  Randi AM;
XX
DR   WPI; 2002-082995/11.
XX
PT   Novel polynucleotide which down regulates expression of Ets-related gene,
PT   useful for treating cancer, diabetic retinopathy, macular degeneration,
PT   arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
XX
PS   Claim 4; Page 67; 149pp; English.
XX
CC   The invention relates to a nucleic acid molecule (I) which down regulates
CC   expression of an Ets-related gene (ERG). (I) is useful for treating
CC   conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
CC   tumour angiogenesis, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
CC   vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
CC   Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
CC   syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
CC   treating a patient having a condition associated with the level of ERG,
CC   by contacting cells of the patient with (I) under conditions suitable for
CC   the treatment. The method comprises the use of one or more therapies
CC   under conditions suitable for the treatment. Leukaemia or tumour
CC   angiogenesis is treated by administering (I) to the patient in
CC   conjunction with one or more of other therapies such as radiation or
CC   chemotherapy treatment. (I) is useful for reducing ERG activity in a
CC   cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
CC   ERG gene, by contacting (I) with RNA, in the presence of a divalent
CC   cation such as Mg2+. (I) is useful for diagnosis of conditions and
CC   diseases related to the expression of ERG, and as diagnostic tool to
CC   examine genetic drift and mutations within diseased cells or to detect
CC   the presence of ERG RNA in a cell. (I) is useful for specifically
CC   targeting genes that share homology with ERG gene or ERG fusion genes.
CC   ABK17354-ABK22719 represent nucleic acids, including antisense and
CC   enzymatic nucleic acid molecules which regulate expression of ERG, and
CC   related PCR primers of the invention
XX
SQ   Sequence 17 BP; 8 A; 2 C; 3 G; 0 T; 4 U; 0 Other;

  Query Match             2.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 45;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        578 CCAAGCTGATTTTATT 593
              ||||||| ||||||||
Db         16 CCAAGCTTATTTTATT 1


RESULT 45
ADB45486/c
ID   ADB45486 standard; DNA; 17 BP.
XX
AC   ADB45486;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Tumour suppression/reversion associated nucleotide #5809.
XX
KW   cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW   primer; probe; tumour suppression; tumour reversion; apoptosis;
KW   virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW   diagnosis.
XX
OS   Homo sapiens.
XX
PN   WO2003040369-A2.
XX
PD   15-MAY-2003.
XX
PF   17-SEP-2002; 2002WO-IB004219.
XX
PR   17-SEP-2001; 2001FR-00011981.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-441574/41.
XX
PT   New nucleic acid encoding human prostate membrane-specific antigen,
PT   useful e.g. for treatment of tumors and viral infection, also related
PT   polypeptide and antibodies.
XX
PS   Disclosure; Page 711; 771pp; French.
XX
CC   The invention relates to the isolation of 6327 nucleotide sequences,
CC   fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC   sequence having at least 80% identity, after optimal alignment, with the
CC   nucleotides, a sequence that hybridizes under stringent conditions with
CC   the nucleotides, or the complement, or corresponding RNA, of the
CC   nucleotides. The nucleotides are used as probes or primers for detecting,
CC   identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC   sense and antisense sequences, of nucleotides involved in tumour
CC   suppression or reversion, apoptosis and or viral resistance, to produce
CC   recombinant polypeptides, and to prepare transgenic animals, as
CC   experimental models. The nucleotides (also vectors containing them and
CC   cells containing the vectors), the encoded polypeptides and antibodies
CC   (Ab) against the polypeptide are useful for prevention and/or treatment
CC   of viral infections or diseases characterized by development of tumours
CC   or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC   Analysis of the expression of the nucleotides can be used for diagnosis
CC   and/or prognosis of these diseases. The nucleotides and polypeptides can
CC   also be used to screen for their specific interactive molecules,
CC   potentially useful for treating diseases associated with abnormal
CC   expression of the nucleotides.
XX
SQ   Sequence 17 BP; 10 A; 1 C; 1 G; 5 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 45;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        615 ATAACTTTTTTTAGAT 630
              |||| ||||||||||||
Db         17 ATAATTTTTTTTAGAT 2
```

RESULT 46
AAS95047
ID AAS95047 standard; DNA; 18 BP.
XX
AC AAS95047;
XX
DT 13-FEB-2002 (first entry)
XX
DE Human otoferlin exon PCR primer #12.
XX
KW Human; mouse; otoferlin; OTOF; brain; auditory function; PCR primer;
KW autosomal nonsyndromic prelingual deafness; DFNB9; ss.
XX
OS Homo sapiens.
XX
PN WO200170972-A2.
XX
PD 27-SEP-2001.
XX
PF 23-MAR-2001; 2001WO-IB000578.
XX
PR 24-MAR-2000; 2000US-0191738P.
XX
PA (INSP) INST PASTEUR.
PA (CNRS) CNRS CENT NAT RECH SCI.
XX
PI Yasunaga S, Grati M, Cohen-Salmon M, El Amraoui A, Petit C;
PI Weil D;
XX
DR WPI; 2001-611499/70.
XX
PT Novel human gene Otoferlin, underlying an autosomal recessive
PT nonsyndromic prelingual deafness, DFNB9, and proteins encoded by the
PT gene, implicated in deafness.
XX
PS Claim 25; Page 17; 99pp; English.
XX
CC The invention relates to a purified polynucleotide (I) encoding a protein
CC sequence (II) encoded by a novel human gene, otoferlin (OTOF) or the long
CC human otoferlin isoform in brain. (I) was identified as underlying an
CC autosomal nonsyndromic prelingual deafness DFNB9, and is thus useful for
CC detecting deafness disease in humans and for characterising the functions
CC of proteins and genes encoding them in auditory function. AAS95022-
CC AAS95248 represent human and mouse otoferlin coding sequences, PCR
CC primers and related sequences of the invention
XX
SQ Sequence 18 BP; 2 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 2.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 47;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy        333 GTCCTGGTACATGTGC 348
              | ||||||||||||||
Db          1 GGCCTGGTACATGTGC 16
```

RESULT 47
ADB42764/c
ID ADB42764 standard; DNA; 17 BP.
XX
AC ADB42764;
XX
DT 18-DEC-2003 (revised)
DT 04-DEC-2003 (first entry)
XX
DE Tumour suppression/reversion associated nucleotide #3087.
XX
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX
OS Homo sapiens.
XX
PN WO2003040369-A2.
XX
PD 15-MAY-2003.
XX
PF 17-SEP-2002; 2002WO-IB004219.
XX
PR 17-SEP-2001; 2001FR-00011981.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-441574/41.
XX
PT New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX
PS Disclosure; Page 392; 771pp; French.
XX
CC The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.
XX
SQ Sequence 17 BP; 3 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 2.2%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 48;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        346 TGCAGAAATGGGAT 359
              ||||||||||||||
Db         15 TGCAGAAATGGGAT 2
```

RESULT 48
AAA21306
ID AAA21306 standard; RNA; 17 BP.
XX
AC AAA21306;
XX
DT 19-JUN-2000 (first entry)
XX
DE Integrin alpha 6 subunit substrate sequence SEQ ID NO:4532.
XX
KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW age related macular degeneration; inflammation; neovascular glaucoma;
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;

KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
OS Homo sapiens.
XX
PN WO9950403-A2.
XX
PD 07-OCT-1999.
XX
PF 24-MAR-1999; 99WO-US006507.
XX
PR 27-MAR-1998; 98US-0079678P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
XX
DR WPI; 1999-591315/50.
XX
PT Novel ribozymes for modulating the synthesis, expression and/or stability
PT of an mRNA encoding an angiogenic factors.
XX
PS Claim 55; Page 200; 305pp; English.
XX
CC The present invention describes enzymatic nucleic acid molecules with RNA
CC cleaving activity, which specifically cleave RNA encoded by an aryl
CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
CC and AAA19155 to AAA19222 represent their corresponding target sequences;
CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
CC AAA21596 to AAA21688 represent their corresponding target sequences;
CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
CC AAA23422 represent their corresponding target sequences. The ribozymes of
CC the invention are used for modulating the synthesis, expression and/or
CC stability of an mRNA encoding angiogenic factor, especially ARNT,
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC especially used to treat cancer, diabetic retinopathy, age related
CC macular degeneration (ARMD), inflammation, and arthritis, as well as
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC integrin subunit alpha-6, or integrin subunit beta-3
XX
SQ Sequence 17 BP; 4 A; 1 C; 2 G; 0 T; 10 U; 0 Other;

Query Match 2.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 41.2%; Pred. No. 49;
Matches 7; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

Qy 581 AGCTGATTTTATTCAAT 597
||:||:::: :: ||:
Db 1 AGCUGAUUUUUUUAAU 17

RESULT 49
AAA21305
ID AAA21305 standard; RNA; 17 BP.
XX
AC AAA21305;
XX
DT 19-JUN-2000 (first entry)
XX
DE Integrin alpha 6 subunit substrate sequence SEQ ID NO:4531.
XX
KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW age related macular degeneration; inflammation; neovascular glaucoma;
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
OS Homo sapiens.
XX
PN WO9950403-A2.
XX
PD 07-OCT-1999.
XX
PF 24-MAR-1999; 99WO-US006507.
XX
PR 27-MAR-1998; 98US-0079678P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
XX
DR WPI; 1999-591315/50.
XX
PT Novel ribozymes for modulating the synthesis, expression and/or stability
PT of an mRNA encoding an angiogenic factors.
XX
PS Claim 55; Page 200; 305pp; English.
XX
CC The present invention describes enzymatic nucleic acid molecules with RNA
CC cleaving activity, which specifically cleave RNA encoded by an aryl
CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
CC and AAA19155 to AAA19222 represent their corresponding target sequences;
CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
CC AAA21596 to AAA21688 represent their corresponding target sequences;
CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
CC AAA23422 represent their corresponding target sequences. The ribozymes of
CC the invention are used for modulating the synthesis, expression and/or
CC stability of an mRNA encoding angiogenic factor, especially ARNT,
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC especially used to treat cancer, diabetic retinopathy, age related
CC macular degeneration (ARMD), inflammation, and arthritis, as well as
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC integrin subunit alpha-6, or integrin subunit beta-3
XX
SQ Sequence 17 BP; 5 A; 1 C; 2 G; 0 T; 9 U; 0 Other;

Query Match 2.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 49;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

Qy 580 AAGCTGATTTTATTCAA 596
||||:||:::: :: ||
Db 1 AAGCUGAUUUUUUUUAA 17

RESULT 50
AAS05096/c
ID AAS05096 standard; DNA; 17 BP.
XX
AC AAS05096;
XX
DT 07-SEP-2001 (first entry)

XX
DE Neurofibromatosis (NF1) HA PCR primer #16.
XX
KW Neurofibromatosis type 1; NF1; peripheral blood lymphocyte; PBL; EBV; ss;
KW Epstein-Barr virus; B-lymphoblastoid cell; phytohaemagglutinin; PHA;
KW frame shift mutation; mis-sense mutation; silent mutation; PCR primer;
KW sequencing primer.
XX
OS Homo sapiens.
XX
PN WO200129251-A2.
XX
PD 26-APR-2001.
XX
PF 18-OCT-2000; 2000WO-EP010255.
XX
PR 18-OCT-1999; 99EP-00870216.
PR 05-JUN-2000; 2000EP-00870122.
XX
PA (UYGE-) UNIV GENT.
XX
PI Messiaen L, Callens T;
XX
DR WPI; 2001-300341/31.
XX
PT Mutation analysis of NF1 gene by treating EBV transformed lymphoblastoid
PT cell lines formed with lymphocytes of patient with protein synthesis
PT inhibitor, and obtaining peptides by translating amplified RNA from cell
PT line.
XX
PS Claim 9; Page 70; 102pp; English.
XX
CC The sequences represent neurofibromatosis type 1 (NF1) cDNA fragments and
CC PCR primers and sequencing primers for use in mutation analysis of NF1. A
CC method for mutation analysis of the NF1 gene involves isolating
CC peripheral blood lymphocytes (PBL) of a patient, establishing Epstein-
CC Barr virus (EBV) transformed B-lymphoblastoid cell line with isolated
CC PBL, or short-term culturing of PBL by phytohaemagglutinin (PHA)
CC stimulation, treating the cell line or short-term culture with protein
CC synthesis inhibitor and immediately extracting RNA from the cultures. The
CC RNA is then amplified and peptide fragments are obtained by in vitro
CC transcription/translation of amplified fragments. Mutation analysis of
CC NF1 is used for detection of frame shift, mis-sense and silent mutations
CC in various exons of the gene. This is useful in screening for NF1
CC mutations in young children who are often oligosymptomatic. Efficacy of a
CC drug or agent can be identified by a screening process in which
CC modulation is monitored in vitro using cell systems in which the
CC defective NF1 gene is expressed. The sequences can be used to design
CC drugs which modulate NF1 activity, by using knowledge of the structure of
CC the NF1 protein and of specific defects of the various NF1 mutant
CC proteins. The method allows for reliable analysis of mutations that are
CC difficult to detect due to unstable or wrong-spliced transcripts
XX
SQ Sequence 17 BP; 7 A; 3 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 2.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 49;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 97 TCTCCAGTGAAAACTTT 113
|| ||||||||| |||||
Db 17 TTTCCAGTGAAGACTTT 1

RESULT 51
ABV85336/c
ID ABV85336 standard; DNA; 17 BP.
XX
AC ABV85336;
XX
DT 11-DEC-2002 (first entry)
XX
DE Human pp-GaNTase 10 scanning 17-mer SEQ ID NO:329.
XX
KW Human; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 10;
KW pp-GaNTase 10; EC 2.4.1.41; chromosome 7q11.2; gene therapy; scanning;
KW ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN EP1243660-A2.
XX
PD 25-SEP-2002.
XX
PF 25-JAN-2002; 2002EP-00001161.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 30-AUG-2001; 2001US-0315984P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhang J, Gu Y, Nguyen C;
XX
DR WPI; 2002-724954/79.
XX
PT Nucleic acid encoding human UDP-GalNAc:polypeptide N-
PT cetylgalactosaminyltransferase 10 protein is useful to diagnose, prevent
PT and treat disorders associated with reduced or over expression of the
PT encoded protein.
XX
PS Example 2; SEQ ID NO 329; 59pp; English.
XX
CC The present invention describes an isolated nucleic acid (I) encoding a
CC human UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 10 (pp-
CC GaNTase 10, EC 2.4.1.41) protein. Human pp-GaNTase 10 is located to
CC chromosome 7q11.2. (I) can be used in gene therapy. Molecules of the
CC present invention can be used in therapy, particularly to prevent or
CC treat a disorder associated with decreased expression or activity of pp-
CC GaNTase. The sequences given in ABV85011 to ABV86689 and ABP53502 to
CC ABP53504 are given in the exemplification of the present invention. N.B.
CC The sequence data for this patent is not represented in the printed
CC specification but is based on sequence information supplied by the
CC European Patent Office
XX
SQ Sequence 17 BP; 4 A; 1 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 2.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 49;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 311 CACCATAACCTTAGATG 327
|||||||||||| |||
Db 17 CACCATAACCTTCAATG 1

RESULT 52
ABT36459
ID ABT36459 standard; DNA; 17 BP.
XX
AC ABT36459;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 2096.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;

KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 278; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 5 A; 2 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 2.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 49;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 185 GATCATCAGTGTGAATG 201
||||.|||||||.||||
Db 1 GATCTTCAGTGTAAATG 17

RESULT 53
ABZ60950
ID ABZ60950 standard; RNA; 17 BP.
XX
AC ABZ60950;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human K-Ras DNAzyme substrate #1062.
XX
KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX
OS Homo sapiens.
XX
PN WO200297114-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US016840.
XX
PR 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J;
XX
DR WPI; 2003-140484/13.
XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS Claim 58; Page 105; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 7 A; 2 C; 3 G; 0 T; 5 U; 0 Other;

Query Match 2.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 49;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 33 CTTGAAGAATAATCCTA 49
|::|||||:|.:|.:|
Db 1 CUUGAAGAAUAGUCAUA 17

RESULT 54
ADB40481/c
ID ADB40481 standard; DNA; 17 BP.
XX
AC ADB40481;
XX
DT 18-DEC-2003 (revised)
DT 04-DEC-2003 (first entry)
XX
DE Tumour suppression/reversion associated nucleotide #804.
XX
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX
OS Homo sapiens.
XX
PN WO2003040369-A2.
XX
PD 15-MAY-2003.
XX
PF 17-SEP-2002; 2002WO-IB004219.
XX
PR 17-SEP-2001; 2001FR-00011981.

```
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-441574/41.
XX
PT   New nucleic acid encoding human prostate membrane-specific antigen,
PT   useful e.g. for treatment of tumors and viral infection, also related
PT   polypeptide and antibodies.
XX
PS   Disclosure; Page 126; 771pp; French.
XX
CC   The invention relates to the isolation of 6327 nucleotide sequences,
CC   fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC   sequence having at least 80% identity, after optimal alignment, with the
CC   nucleotides, a sequence that hybridizes under stringent conditions with
CC   the nucleotides, or the complement, or corresponding RNA, of the
CC   nucleotides. The nucleotides are used as probes or primers for detecting,
CC   identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC   sense and antisense sequences, of nucleotides involved in tumour
CC   suppression or reversion, apoptosis and or viral resistance, to produce
CC   recombinant polypeptides, and to prepare transgenic animals, as
CC   experimental models. The nucleotides (also vectors containing them and
CC   cells containing the vectors), the encoded polypeptides and antibodies
CC   (Ab) against the polypeptide are useful for prevention and/or treatment
CC   of viral infections or diseases characterized by development of tumours
CC   or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC   Analysis of the expression of the nucleotides can be used for diagnosis
CC   and/or prognosis of these diseases. The nucleotides and polypeptides can
CC   also be used to screen for their specific interactive molecules,
CC   potentially useful for treating diseases associated with abnormal
CC   expression of the nucleotides.
XX
SQ   Sequence 17 BP; 2 A; 1 C; 6 G; 8 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 49;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        172 CCAAACCTAACATGATC 188
              | ||||| |||||||||
Db         17 CAAAACCCAACATGATC 1


RESULT 55
AAV93839/c
ID   AAV93839 standard; RNA; 15 BP.
XX
AC   AAV93839;
XX
DT   18-FEB-1999  (first entry)
XX
DE   Target sequence with sequence homology to c-raf and A-raf position 1754.
XX
KW   Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
KW   target; substrate; catalyst; modulation; expression; Raf gene; delivery;
KW   screening; identification; synthesis; deprotection; purification; cancer;
KW   inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;
KW   restenosis; rheumatoid arthritis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9850530-A2.
XX
PD   12-NOV-1998.
XX
PF   05-MAY-1998;   98WO-US009249.
XX
PR   09-MAY-1997;   97US-0046059P.
PR   09-JUN-1997;   97US-0049002P.
PR   03-JUL-1997;   97US-0051718P.
PR   22-AUG-1997;   97US-0056808P.
PR   02-OCT-1997;   97US-0061321P.
PR   02-OCT-1997;   97US-0061324P.
PR   05-NOV-1997;   97US-0064866P.
PR   19-DEC-1997;   97US-0068212P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Jarvis T,  Matulic-Adamic J,  Reynolds M,  Kisich K,  Bellon L;
PI   Parry T,  Beigelman L,  Mcswiggen JA,  Karpeisky A,  Burgin A;
PI   Thompson J,  Workman CT,  Beaudry A,  Sweedler D;
XX
DR   WPI; 1999-009494/01.
XX
PT   Identifying new catalytic nucleic acid that modulates selected processes
PT   - especially ribozymes that cleave Raf RNA for treating cancer,
PT   restenosis, and also new ribozymes and modified nucleoside triphosphates
PT   used as antiviral agents and synthons.
XX
PS   Claim 180; Page 176; 259pp; English.
XX
CC   A method has been developed for the identification of a nucleic acid
CC   capable of modulating a process in a biological system. The method
CC   comprises: (a) introducing into the system a random library of nucleic
CC   acid catalysts (NAC) having a substrate binding domain (SBD), comprising
CC   a random sequence, and a catalytic domain (CD); and (b) identifying NAC
CC   in systems where modulation has occurred and/or determining the sequence
CC   of at least part of the SBDs in such systems. Nucleic acid molecules with
CC   endonuclease activity and catalytic activity, from the present invention,
CC   are used to modulate gene expression in plant and mammalian cells and to
CC   cleave target nucleic acid, particularly for treating systemic diseases
CC   caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic
CC   ascites and infection. They may also be used to detect genetic drift and
CC   mutations in diseased cells and to determine c-raf RNA. Specifically NACs
CC   with RNA-cleaving activity that modulate expression of the Raf gene, are
CC   used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or
CC   generally any condition associated with the level of c-raf. Introduction
CC   of sugar/phosphate modifications increases stability against nuclease and
CC   activity. AAV90922 to AAV93877 represent NACs that can be used in the
CC   method, specifically for modulating the expression of a Raf gene
XX
SQ   Sequence 15 BP; 2 A; 1 C; 4 G; 0 T; 8 U; 0 Other;

  Query Match             2.1%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 46;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        370 CCACCATAAAGAGAA 384
              ||||||||||||| ||
Db         15 CCACCATAAAGATAA 1


RESULT 56
AAQ28744
ID   AAQ28744 standard; DNA; 16 BP.
XX
AC   AAQ28744;
XX
DT   01-MAR-1993  (first entry)
XX
DE   Probe for anti-CEA specific antibody DNA.
XX
KW   Human; carcinoembryonic antigen; heavy chain; light chain; variable;
KW   region; diagnostic; tumour; markers; targetting; ss.
XX
OS   Synthetic.
XX
PN   JP04234987-A.
XX
PD   24-AUG-1992.
XX
PF   28-DEC-1990;   90JP-00408810.
XX
PR   28-DEC-1990;   90JP-00408810.
```

XX
PA (MITU) MITSUBISHI KASEI CORP.
XX
DR WPI; 1992-327631/40.
XX
PT New DNA fragments encoding variable regions of ABS specific for human CEA
PT - for diagnosing and monitoring tumours, as tumour markers and for
PT treatment of tumours.
XX
PS Disclosure; Page 4; 7pp; Japanese.
XX
CC The probe was used to hybridise to a cDNA library prepd. from mRNA obtd.
CC from hybridomas producing anti-CEA-specific antibodies. The cloned DNA
CC encodes either the heavy chain or light chain variable region of anti-CEA
CC murine monoclonal antibody. The DNA fragments are useful as diagnostic
CC agents, as tumour markers for digestive organs, for diagnosis of
CC malignant tumours; for monitering after cancer operations, to follow up
CC bloodless therapy or as therapeutic agents in passive immune therapy and
CC targetting therapy. See also AAQ28745-7
XX
SQ Sequence 16 BP; 2 A; 1 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 2.1%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 49;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 323 AGATGGGGGTGTCCT 337
||||||||||||| |
Db 1 AGATGGGGGTGTCGT 15

RESULT 57
AAV48633
ID AAV48633 standard; DNA; 16 BP.
XX
AC AAV48633;
XX
DT 15-OCT-1998 (first entry)
XX
DE junB gene antisense oligonucleotide JunB-N-19.
XX
KW junB; junD; antisense oligonucleotide; modulate; gene expression; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN EP856579-A1.
XX
PD 05-AUG-1998.
XX
PF 31-JAN-1997; 97EP-00101531.
XX
PR 31-JAN-1997; 97EP-00101531.
XX
PA (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
XX
PI Schlingensiepen K, Brysch W;
XX
DR WPI; 1998-400910/35.
XX
PT Preparation of antisense oligo:nucleotide(s) which lack long runs of
PT consecutive guanosine or inosine - and have specific ratio of residues
PT able to form two or three hydrogen bonds, have greater activity and
PT reduced toxicity, used therapeutically or to modulate growth of cells in
PT culture.
XX
PS Example 3; Fig 5b; 286pp; English.
XX
CC AAV48564-708 represent antisense oligonucleotides directed against the
CC junB and junD genes. Of these, only oligonucleotides AAV48565-614
CC resulted in effective downregulation of negative growth control by JunB
CC or JunD, while AAV48615-708 had little effect. The oligonucleotides
CC exemplify the invention. The specification describes oligonucleotides
CC that contain 8-30 nucleotides, which contain at most 8 nucleotides that
CC can each form three hydrogen bonds to cytosine; do not contain four
CC consecutive nucleotides able to form three H-bonds each to four
CC consecutive cytosines; do not contain two sequences of three consecutive
CC nucleotides each able to form three H-bonds to three consecutive
CC cytosines, and the ratio between residues able to form two H-bonds each
CC (2R) or three such bonds (3R) is given by 2R/3R = 0.33-0.72. The
CC oligonucleotides are used to modulate expression of genes, particularly
CC the genes for p53, ErbB-2, junB, junD, TGF-beta 1 or beta 2 to control
CC proliferation of primary cell cultures (e.g. bone marrow stem, liver or
CC kidney cells, osteoclasts, osteoblasts and/or keratinocytes). The
CC oligonucleotides can also be used to analyse function of proteins (by
CC altering their expression or activity) and therapeutically, e.g. in cases
CC of cancer or (targeting TGF) for stimulating the immune system
XX
SQ Sequence 16 BP; 6 A; 1 C; 1 G; 8 T; 0 U; 0 Other;

Query Match 2.1%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 49;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 586 ATTTTATTCAATATG 600
||| |||||||||||
Db 2 ATTATATTCAATATG 16

Search completed: September 30, 2004, 16:30:57
Job time : 1 secs

This Page Blank (uspto)

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: October 1, 2004, 07:06:08 ; Search time 0.001 Seconds
(without alignments)
1834.796 Million cell updates/sec

Title: US-09-503-596-2
Perfect score: 634
Sequence: 1 ggaattccaggagggtgcag.....ataacttttttagatttag 634

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 61 seqs, 1447 residues

Total number of hits satisfying chosen parameters: 122

Minimum DB seq length: 10
Maximum DB seq length: 100

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 61 summaries

Database : rnpb2.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	65	10.3	65	1	US-10-116-265-7	Sequence 7, Appli
	2	60	9.5	60	1	US-09-908-975-12576	Sequence 12576, A
c	3	51	8.0	60	1	US-10-431-598-18	Sequence 18, Appl
	4	50	7.9	50	1	US-10-131-827-8002	Sequence 8002, Ap
c	5	33	5.2	33	1	US-10-688-572-17	Sequence 17, Appl
c	6	33	5.2	33	1	US-10-688-379-17	Sequence 17, Appl
c	7	33	5.2	33	1	US-10-688-380-17	Sequence 17, Appl
c	8	29	4.6	29	1	US-10-688-572-16	Sequence 16, Appl
c	9	29	4.6	29	1	US-10-688-379-16	Sequence 16, Appl
c	10	29	4.6	29	1	US-10-688-380-16	Sequence 16, Appl
c	11	27	4.3	27	1	US-10-384-491-281	Sequence 281, App
c	12	26	4.1	26	1	US-09-853-798-15	Sequence 15, Appl
c	13	26	4.1	26	1	US-09-854-302-15	Sequence 15, Appl
c	14	26	4.1	26	1	US-09-990-461B-15	Sequence 15, Appl
c	15	26	4.1	26	1	US-10-688-572-15	Sequence 15, Appl
c	16	26	4.1	26	1	US-10-688-379-15	Sequence 15, Appl
c	17	26	4.1	26	1	US-10-688-380-15	Sequence 15, Appl
	18	24	3.8	24	1	US-10-384-491-282	Sequence 282, App
c	19	24	3.8	24	1	US-10-688-572-19	Sequence 19, Appl
c	20	24	3.8	24	1	US-10-688-379-19	Sequence 19, Appl
c	21	24	3.8	24	1	US-10-688-380-19	Sequence 19, Appl
c	22	23	3.6	23	1	US-10-688-572-18	Sequence 18, Appl
c	23	23	3.6	23	1	US-10-688-379-18	Sequence 18, Appl
c	24	23	3.6	23	1	US-10-688-380-18	Sequence 18, Appl
c	25	21	3.3	21	1	US-10-348-480B-24	Sequence 24, Appl
c	26	20	3.2	20	1	US-09-952-522B-27	Sequence 27, Appl
	27	20	3.2	20	1	US-10-416-090-15	Sequence 15, Appl
c	28	20	3.2	20	1	US-10-416-090-16	Sequence 16, Appl
	29	20	3.2	20	1	US-09-795-917-33	Sequence 33, Appl
	30	20	3.2	20	1	US-10-348-480B-11	Sequence 11, Appl
c	31	20	3.2	20	1	US-10-348-480B-12	Sequence 12, Appl
c	32	19	3.0	19	1	US-09-795-917-34	Sequence 34, Appl
	33	19	3.0	19	1	US-10-348-480B-23	Sequence 23, Appl
c	34	19	3.0	19	1	US-10-688-572-20	Sequence 20, Appl
c	35	19	3.0	19	1	US-10-688-379-20	Sequence 20, Appl
c	36	19	3.0	19	1	US-10-688-380-20	Sequence 20, Appl
	37	19	3.0	20	1	US-09-952-522B-28	Sequence 28, Appl
	38	18	2.8	18	1	US-10-116-265-8	Sequence 8, Appli
c	39	17.4	2.7	19	1	US-10-084-839-3080	Sequence 3080, Ap
c	40	17.4	2.7	19	1	US-10-084-839-3086	Sequence 3086, Ap
c	41	17.4	2.7	20	1	US-10-084-839-3083	Sequence 3083, Ap
	42	16.8	2.6	21	1	US-09-972-211-164	Sequence 164, App
	43	16.8	2.6	21	1	US-10-096-625-164	Sequence 164, App
c	44	16.8	2.6	21	1	US-10-084-839-3075	Sequence 3075, Ap
c	45	15.4	2.4	17	1	US-10-238-700-3142	Sequence 3142, Ap
	46	15.4	2.4	18	1	US-10-349-143-11444	Sequence 11444, A
	47	14.8	2.3	18	1	US-10-349-143-7744	Sequence 7744, Ap
	48	14.4	2.3	17	1	US-10-060-756A-1328	Sequence 1328, Ap
	49	14.4	2.3	17	1	US-10-060-756A-1329	Sequence 1329, Ap
c	50	13.8	2.2	17	1	US-10-060-895A-329	Sequence 329, App
	51	13.8	2.2	17	1	US-10-156-306-351	Sequence 351, App
c	52	13.8	2.2	17	1	US-10-156-306-5116	Sequence 5116, Ap
c	53	13.8	2.2	17	1	US-10-156-306-7073	Sequence 7073, Ap
c	54	13.8	2.2	17	1	US-10-128-560-140	Sequence 140, App
c	55	13.8	2.2	17	1	US-10-128-560-196	Sequence 196, App
	56	13.8	2.2	17	1	US-10-238-700-1062	Sequence 1062, Ap
	57	13.4	2.1	15	1	US-10-287-919-1817	Sequence 1817, Ap
	58	13	2.1	15	1	US-10-043-875-276	Sequence 276, App
	59	13	2.1	15	1	US-10-043-875-278	Sequence 278, App
	60	13	2.1	16	1	US-10-043-875-274	Sequence 274, App
	61	13	2.1	16	1	US-10-043-875-277	Sequence 277, App

ALIGNMENTS

RESULT 1
US-10-116-265-7
; Sequence 7, Application US/10116265
; Publication No. US20030077612A1
; GENERAL INFORMATION:
; APPLICANT: Ekblom, Jonas
; TITLE OF INVENTION: NEW METHOD
; FILE REFERENCE: 13425-105001
; CURRENT APPLICATION NUMBER: US/10/116,265
; CURRENT FILING DATE: 2002-04-04
; PRIOR APPLICATION NUMBER: SE 0101218-6
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 60/281,384
; PRIOR FILING DATE: 2001-04-05
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 65
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-116-265-7

Query Match 10.3%; Score 65; DB 1; Length 65;
Best Local Similarity 76.9%; Pred. No. 0.19;
Matches 50; Conservative 15; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 GGAATTCCAGGAGGGTGCAGCTTCCTTCTCACCTTGAAGAATAATCCTAGAAAACTCACA 60
              ||||::|||||||||:|||||::||::|:||||::|||||:||:||:||||||:||||
Db          1 GGAAUUCCAGGAGGGUGCAGCUUCCUUCUCACCUUGAAGAAUAAUCCUAGAAAACUCACA 60

Qy         61 AAATG 65
              |||:|
Db         61 AAAUG 65
```

RESULT 2
US-09-908-975-12576
; Sequence 12576, Application US/09908975
; Publication No. US20030165843A1
; GENERAL INFORMATION:

; APPLICANT: SHOSHAN, Avi
; APPLICANT: WASSERMAN, Alon
; APPLICANT: MINTZ, Eli
; APPLICANT: MINTZ, Liat
; APPLICANT: FAIGLER, Simchon
; TITLE OF INVENTION: OLIGONUCLEOTIDE LIBRARY FOR DETECTING RNA TRANSCRIPTS AND SPLICE
; TITLE OF INVENTION: THAT POPULATE A TRANSCRIPTOME
; FILE REFERENCE: 36688-0005
; CURRENT APPLICATION NUMBER: US/09/908,975
; CURRENT FILING DATE: 2001-07-20
; PRIOR APPLICATION NUMBER: US 60/287,724
; PRIOR FILING DATE: 2001-05-02
; PRIOR APPLICATION NUMBER: US 60/221,607
; PRIOR FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 32337
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 12576
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-908-975-12576

Query Match 9.5%; Score 60; DB 1; Length 60;
Best Local Similarity 100.0%; Pred. No. 0.35;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 446 TTATGAGAGAGCATAAGCCAAGGGACGTTGACCTGGACTGAAGTTCGCATTGAACTCTAC 505
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 TTATGAGAGAGCATAAGCCAAGGGACGTTGACCTGGACTGAAGTTCGCATTGAACTCTAC 60

RESULT 3
US-10-431-598-18/c
; Sequence 18, Application US/10431598
; Publication No. US20040097454A1
; GENERAL INFORMATION:
; APPLICANT: Reusch, Jane E.
; APPLICANT: Klemm, Dwight J.
; TITLE OF INVENTION: METHOD FOR MODULATION OF CELL PHENOTYPE
; FILE REFERENCE: 2848-34 (now 5111-1)
; CURRENT APPLICATION NUMBER: US/10/431,598
; CURRENT FILING DATE: 2003-05-06
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 18
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:probe
US-10-431-598-18

Query Match 8.0%; Score 51; DB 1; Length 60;
Best Local Similarity 91.5%; Pred. No. 1.3;
Matches 54; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 63 ATGTGTGATGCTTTTGTAGGTACCTGGAAACTTGTCTCCAGTGAAAACTTTGATGATTA 121
|||||||||||| ||||| || |||||||| |||||||||||||||||||| ||||||||
Db 60 ATGTGTGATGCCTTTGTGGGAACCTGGAAGCTTGTCTCCAGTGAAAACTTCGATGATTA 2

RESULT 4
US-10-131-827-8002
; Sequence 8002, Application US/10131827
; Publication No. US20040009479A1
; GENERAL INFORMATION:
; APPLICANT: Wohlgemuth, Jay
; APPLICANT: Fry, Kirk
; APPLICANT: Woodward, Robert
; APPLICANT: Ly, Ngoc
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTOIMMUNE
; TITLE OF INVENTION: CHRONIC INFLAMMATORY DISEASES
; FILE REFERENCE: 506612000120
; CURRENT APPLICATION NUMBER: US/10/131,827
; CURRENT FILING DATE: 2002-09-06
; PRIOR APPLICATION NUMBER: US 10/006,290
; PRIOR FILING DATE: 2001-10-22
; PRIOR APPLICATION NUMBER: US 60/296,764
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 9090
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8002
; LENGTH: 50
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-131-827-8002

Query Match 7.9%; Score 50; DB 1; Length 50;
Best Local Similarity 100.0%; Pred. No. 1.2;
Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 539 TTGTTGTTTTCCCTGATTTAGCAAGCAAGTAATTTTCTCCCAAGCTGATT 588
||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 TTGTTGTTTTCCCTGATTTAGCAAGCAAGTAATTTTCTCCCAAGCTGATT 50

RESULT 5
US-10-688-572-17/c
; Sequence 17, Application US/10688572
; Publication No. US20040162352A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith
; APPLICANT: Lee, Jung
; APPLICANT: Matthews, Jay M
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: Treating Syndrome X with Substituted Tetralins and Indanes
; FILE REFERENCE: PRD-0050
; CURRENT APPLICATION NUMBER: US/10/688,572
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,927
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,758
; PRIOR FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-572-17

Query Match 5.2%; Score 33; DB 1; Length 33;
Best Local Similarity 100.0%; Pred. No. 8.4;
Matches 33; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 237 AAAAATACTGAGATTTCCTTCATACTGGGCCAG 269
|||||||||||||||||||||||||||||||||
Db 33 AAAAATACTGAGATTTCCTTCATACTGGGCCAG 1

RESULT 6
US-10-688-379-17/c
; Sequence 17, Application US/10688379
; Publication No. US20040167211A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith T
; APPLICANT: Ambler, Jung Lee
; APPLICANT: Matthews, Jay M
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: METHODS OF USING SUBSTITUTED TETRALINS AND INDANES
; FILE REFERENCE: PRD-0049 NP
; CURRENT APPLICATION NUMBER: US/10/688,379

```
;  CURRENT FILING DATE:  2003-10-17
;  PRIOR APPLICATION NUMBER: 60/420,026
;  PRIOR FILING DATE: 2002-10-21
;  PRIOR APPLICATION NUMBER: 60/495,788
;  PRIOR FILING DATE: 2003-08-15
;  NUMBER OF SEQ ID NOS: 20
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17
;   LENGTH: 33
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-688-379-17

  Query Match             5.2%;  Score 33;  DB 1;  Length 33;
  Best Local Similarity   100.0%;  Pred. No. 8.4;
  Matches   33;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        237 AAAAATACTGAGATTTCCTTCATACTGGGCCAG 269
              |||||||||||||||||||||||||||||||||
Db         33 AAAAATACTGAGATTTCCTTCATACTGGGCCAG 1


RESULT 7
US-10-688-380-17/c
; Sequence 17, Application US/10688380
; Publication No. US20040171680A1
; GENERAL INFORMATION:
;  APPLICANT: Janssen Pharmaceutica, N.V.
;  APPLICANT:  Chen, Xiaoli
;  APPLICANT:  Demarest, Keith
;  APPLICANT:  Lee, Jung
;  APPLICANT:  Matthews, Jay M.
;  APPLICANT:  Rybczynski, Philip
;  TITLE OF INVENTION: Substituted Tetralins and Indanes
;  FILE REFERENCE: PRD0048 NP
;  CURRENT APPLICATION NUMBER: US/10/688,380
;  CURRENT FILING DATE:  2003-10-17
;  PRIOR APPLICATION NUMBER: 60/419,927
;  PRIOR FILING DATE: 2002-10-21
;  PRIOR APPLICATION NUMBER: 60/495,758
;  PRIOR FILING DATE: 2003-08-15
;  NUMBER OF SEQ ID NOS: 20
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17
;   LENGTH: 33
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-688-380-17

  Query Match             5.2%;  Score 33;  DB 1;  Length 33;
  Best Local Similarity   100.0%;  Pred. No. 8.4;
  Matches   33;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        237 AAAAATACTGAGATTTCCTTCATACTGGGCCAG 269
              |||||||||||||||||||||||||||||||||
Db         33 AAAAATACTGAGATTTCCTTCATACTGGGCCAG 1


RESULT 8
US-10-688-572-16/c
; Sequence 16, Application US/10688572
; Publication No. US20040162352A1
; GENERAL INFORMATION:
;  APPLICANT: Janssen Pharmaceutica, N.V.
;  APPLICANT:  Chen, Xiaoli
;  APPLICANT:  Demarest, Keith
;  APPLICANT:  Lee, Jung
;  APPLICANT:  Matthews, Jay M
;  APPLICANT:  Rybczynski, Philip
;  TITLE OF INVENTION: Treating Syndrome X with Substituted Tetralins and Indanes
;  FILE REFERENCE: PRD-0050
;  CURRENT APPLICATION NUMBER: US/10/688,572
;  CURRENT FILING DATE:  2003-10-17
;  PRIOR APPLICATION NUMBER: 60/419,927
;  PRIOR FILING DATE: 2002-10-21
;  PRIOR APPLICATION NUMBER: 60/495,758
;  PRIOR FILING DATE: 2003-08-15
;  NUMBER OF SEQ ID NOS: 20
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16
;   LENGTH: 29
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-688-572-16

  Query Match             4.6%;  Score 29;  DB 1;  Length 29;
  Best Local Similarity   100.0%;  Pred. No. 13;
  Matches   29;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        208 TGATCACCATTAAATCTGAAAGTACCTTT 236
              |||||||||||||||||||||||||||||
Db         29 TGATCACCATTAAATCTGAAAGTACCTTT 1


RESULT 9
US-10-688-379-16/c
; Sequence 16, Application US/10688379
; Publication No. US20040167211A1
; GENERAL INFORMATION:
;  APPLICANT: Janssen Pharmaceutica, N.V.
;  APPLICANT:  Chen, Xiaoli
;  APPLICANT:  Demarest, Keith T
;  APPLICANT:  Ambler, Jung Lee
;  APPLICANT:  Matthews, Jay M
;  APPLICANT:  Rybczynski, Philip
;  TITLE OF INVENTION: METHODS OF USING SUBSTITUTED TETRALINS AND INDANES
;  FILE REFERENCE: PRD-0049 NP
;  CURRENT APPLICATION NUMBER: US/10/688,379
;  CURRENT FILING DATE:  2003-10-17
;  PRIOR APPLICATION NUMBER: 60/420,026
;  PRIOR FILING DATE: 2002-10-21
;  PRIOR APPLICATION NUMBER: 60/495,788
;  PRIOR FILING DATE: 2003-08-15
;  NUMBER OF SEQ ID NOS: 20
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16
;   LENGTH: 29
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-688-379-16

  Query Match             4.6%;  Score 29;  DB 1;  Length 29;
  Best Local Similarity   100.0%;  Pred. No. 13;
  Matches   29;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        208 TGATCACCATTAAATCTGAAAGTACCTTT 236
              |||||||||||||||||||||||||||||
Db         29 TGATCACCATTAAATCTGAAAGTACCTTT 1


RESULT 10
US-10-688-380-16/c
; Sequence 16, Application US/10688380
; Publication No. US20040171680A1
; GENERAL INFORMATION:
;  APPLICANT: Janssen Pharmaceutica, N.V.
;  APPLICANT:  Chen, Xiaoli
;  APPLICANT:  Demarest, Keith
;  APPLICANT:  Lee, Jung
;  APPLICANT:  Matthews, Jay M.
;  APPLICANT:  Rybczynski, Philip
;  TITLE OF INVENTION: Substituted Tetralins and Indanes
;  FILE REFERENCE: PRD0048 NP
;  CURRENT APPLICATION NUMBER: US/10/688,380
;  CURRENT FILING DATE:  2003-10-17
;  PRIOR APPLICATION NUMBER: 60/419,927
```

```
;  PRIOR FILING DATE: 2002-10-21
;  PRIOR APPLICATION NUMBER: 60/495,758
;  PRIOR FILING DATE: 2003-08-15
;  NUMBER OF SEQ ID NOS: 20
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16
;   LENGTH: 29
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-688-380-16

  Query Match             4.6%;  Score 29;  DB 1;  Length 29;
  Best Local Similarity   100.0%;  Pred. No. 13;
  Matches   29;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        208 TGATCACCATTAAATCTGAAAGTACCTTT 236
              |||||||||||||||||||||||||||||
Db         29 TGATCACCATTAAATCTGAAAGTACCTTT 1


RESULT 11
US-10-384-491-281/c
; Sequence 281, Application US/10384491
; Publication No. US20030224040A1
; GENERAL INFORMATION:
;  APPLICANT: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
;  APPLICANT:  BAYLIN, Stephen B.
;  APPLICANT:  HERMAN, James
;  APPLICANT:  Suzuki, Hiromu
;  TITLE OF INVENTION: GENOMIC SCREEN FOR EPIGENETICALLY SILENCED GENES ASSOCIATED WITH
;  FILE REFERENCE: JHU1850-1
;  CURRENT APPLICATION NUMBER: US/10/384,491
;  CURRENT FILING DATE:  2003-03-07
;  PRIOR APPLICATION NUMBER: US 60/362,422
;  PRIOR FILING DATE: 2002-03-07
;  NUMBER OF SEQ ID NOS: 296
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 281
;   LENGTH: 27
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Amplification primer
US-10-384-491-281

  Query Match             4.3%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   27;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        588 TTTATTCAATATGGTTACGTTGGTTAA 614
              ||||||||||||||||||||||||||||
Db         27 TTTATTCAATATGGTTACGTTGGTTAA 1


RESULT 12
US-09-853-798-15/c
; Sequence 15, Application US/09853798
; Patent No. US20020103193A1
; GENERAL INFORMATION:
;  APPLICANT: Rybczynski, Philip
;  APPLICANT:  et al.
;  TITLE OF INVENTION: BIOLOGICALLY ACTIVE 4H-BENZO[1,4]OXAZIN-3-ONES
;  FILE REFERENCE: pm431, patin2.1
;  CURRENT APPLICATION NUMBER: US/09/853,798
;  CURRENT FILING DATE:  2001-05-11
;  NUMBER OF SEQ ID NOS: 15
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-853-798-15

  Query Match             4.1%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches   26;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         90 AAACTTGTCTCCAGTGAAAACTTTGA 115
              ||||||||||||||||||||||||||
Db         26 AAACTTGTCTCCAGTGAAAACTTTGA 1


RESULT 13
US-09-854-302-15/c
; Sequence 15, Application US/09854302
; Patent No. US20020165228A1
; GENERAL INFORMATION:
;  APPLICANT: Rybczynski, Philip
;  APPLICANT:  et al.
;  TITLE OF INVENTION: BIOLOGICALLY ACTIVE 4H-BENZO[1,4]OXAZIN-3-ONES
;  FILE REFERENCE: pm431, patin2.1
;  CURRENT APPLICATION NUMBER: US/09/854,302
;  CURRENT FILING DATE:  2001-10-15
;  NUMBER OF SEQ ID NOS: 15
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-854-302-15

  Query Match             4.1%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches   26;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         90 AAACTTGTCTCCAGTGAAAACTTTGA 115
              ||||||||||||||||||||||||||
Db         26 AAACTTGTCTCCAGTGAAAACTTTGA 1


RESULT 14
US-09-990-461B-15/c
; Sequence 15, Application US/09990461B
; Publication No. US20030083329A1
; GENERAL INFORMATION:
;  APPLICANT: Rybczynski, Philip
;  APPLICANT:  et al.
;  TITLE OF INVENTION: BIOLOGICALLY ACTIVE 4H-BENZO[1,4]OXAZIN-3-ONES
;  FILE REFERENCE: pm431, patin2.1
;  CURRENT APPLICATION NUMBER: US/09/990,461B
;  CURRENT FILING DATE:  2001-11-21
;  NUMBER OF SEQ ID NOS: 15
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-990-461B-15

  Query Match             4.1%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches   26;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         90 AAACTTGTCTCCAGTGAAAACTTTGA 115
              ||||||||||||||||||||||||||
Db         26 AAACTTGTCTCCAGTGAAAACTTTGA 1


RESULT 15
US-10-688-572-15/c
```

; Sequence 15, Application US/10688572
; Publication No. US20040162352A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith
; APPLICANT: Lee, Jung
; APPLICANT: Matthews, Jay M
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: Treating Syndrome X with Substituted Tetralins and Indanes
; FILE REFERENCE: PRD-0050
; CURRENT APPLICATION NUMBER: US/10/688,572
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,927
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,758
; PRIOR FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 15
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-572-15

Query Match 4.1%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 90 AAACTTGTCTCCAGTGAAAACTTTGA 115
||||||||||||||||||||||||||
Db 26 AAACTTGTCTCCAGTGAAAACTTTGA 1

RESULT 16
US-10-688-379-15/c
; Sequence 15, Application US/10688379
; Publication No. US20040167211A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith T
; APPLICANT: Ambler, Jung Lee
; APPLICANT: Matthews, Jay M
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: METHODS OF USING SUBSTITUTED TETRALINS AND INDANES
; FILE REFERENCE: PRD-0049 NP
; CURRENT APPLICATION NUMBER: US/10/688,379
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/420,026
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,788
; PRIOR FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 15
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-379-15

Query Match 4.1%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 90 AAACTTGTCTCCAGTGAAAACTTTGA 115
||||||||||||||||||||||||||
Db 26 AAACTTGTCTCCAGTGAAAACTTTGA 1

RESULT 17
US-10-688-380-15/c
; Sequence 15, Application US/10688380
; Publication No. US20040171680A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith
; APPLICANT: Lee, Jung
; APPLICANT: Matthews, Jay M.
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: Substituted Tetralins and Indanes
; FILE REFERENCE: PRD0048 NP
; CURRENT APPLICATION NUMBER: US/10/688,380
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,927
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,758
; PRIOR FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 15
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-380-15

Query Match 4.1%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 90 AAACTTGTCTCCAGTGAAAACTTTGA 115
||||||||||||||||||||||||||
Db 26 AAACTTGTCTCCAGTGAAAACTTTGA 1

RESULT 18
US-10-384-491-282
; Sequence 282, Application US/10384491
; Publication No. US20030224040A1
; GENERAL INFORMATION:
; APPLICANT: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
; APPLICANT: BAYLIN, Stephen B.
; APPLICANT: HERMAN, James
; APPLICANT: Suzuki, Hiromu
; TITLE OF INVENTION: GENOMIC SCREEN FOR EPIGENETICALLY SILENCED GENES ASSOCIATED WITH C
; FILE REFERENCE: JHU1850-1
; CURRENT APPLICATION NUMBER: US/10/384,491
; CURRENT FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/362,422
; PRIOR FILING DATE: 2002-03-07
; NUMBER OF SEQ ID NOS: 296
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 282
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Amplification primer
US-10-384-491-282

Query Match 3.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 391 AGGATGATAAACTGGTGGTGGAAT 414
||||||||||||||||||||||||
Db 1 AGGATGATAAACTGGTGGTGGAAT 24

RESULT 19
US-10-688-572-19/c
; Sequence 19, Application US/10688572
; Publication No. US20040162352A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.

; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith
; APPLICANT: Lee, Jung
; APPLICANT: Matthews, Jay M
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: Treating Syndrome X with Substituted Tetralins and Indanes
; FILE REFERENCE: PRD-0050
; CURRENT APPLICATION NUMBER: US/10/688,572
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,927
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,758
; PRIOR FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-572-19

Query Match 3.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 293 TGACAGGAAAGTCAAGAGCACCAT 316
||||||||||||||||||||||||
Db 24 TGACAGGAAAGTCAAGAGCACCAT 1

RESULT 20
US-10-688-379-19/c
; Sequence 19, Application US/10688379
; Publication No. US20040167211A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith T
; APPLICANT: Ambler, Jung Lee
; APPLICANT: Matthews, Jay M
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: METHODS OF USING SUBSTITUTED TETRALINS AND INDANES
; FILE REFERENCE: PRD-0049 NP
; CURRENT APPLICATION NUMBER: US/10/688,379
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/420,026
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,788
; PRIOR FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-379-19

Query Match 3.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 293 TGACAGGAAAGTCAAGAGCACCAT 316
||||||||||||||||||||||||
Db 24 TGACAGGAAAGTCAAGAGCACCAT 1

RESULT 21
US-10-688-380-19/c
; Sequence 19, Application US/10688380
; Publication No. US20040171680A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith
; APPLICANT: Lee, Jung
; APPLICANT: Matthews, Jay M.
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: Substituted Tetralins and Indanes
; FILE REFERENCE: PRD0048 NP
; CURRENT APPLICATION NUMBER: US/10/688,380
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,927
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,758
; PRIOR FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-380-19

Query Match 3.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 293 TGACAGGAAAGTCAAGAGCACCAT 316
||||||||||||||||||||||||
Db 24 TGACAGGAAAGTCAAGAGCACCAT 1

RESULT 22
US-10-688-572-18/c
; Sequence 18, Application US/10688572
; Publication No. US20040162352A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith
; APPLICANT: Lee, Jung
; APPLICANT: Matthews, Jay M
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: Treating Syndrome X with Substituted Tetralins and Indanes
; FILE REFERENCE: PRD-0050
; CURRENT APPLICATION NUMBER: US/10/688,572
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,927
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,758
; PRIOR FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-572-18

Query Match 3.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 270 GAATTTGACGAAGTCACTGCAGA 292
|||||||||||||||||||||||
Db 23 GAATTTGACGAAGTCACTGCAGA 1

RESULT 23
US-10-688-379-18/c
; Sequence 18, Application US/10688379
; Publication No. US20040167211A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith T

; APPLICANT: Ambler, Jung Lee
; APPLICANT: Matthews, Jay M
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: METHODS OF USING SUBSTITUTED TETRALINS AND INDANES
; FILE REFERENCE: PRD-0049 NP
; CURRENT APPLICATION NUMBER: US/10/688,379
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/420,026
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,788
; PRIOR FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-379-18

Query Match 3.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 270 GAATTTGACGAAGTCACTGCAGA 292
||||||||||||||||||||||
Db 23 GAATTTGACGAAGTCACTGCAGA 1

RESULT 24
US-10-688-380-18/c
; Sequence 18, Application US/10688380
; Publication No. US20040171680A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith
; APPLICANT: Lee, Jung
; APPLICANT: Matthews, Jay M.
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: Substituted Tetralins and Indanes
; FILE REFERENCE: PRD0048 NP
; CURRENT APPLICATION NUMBER: US/10/688,380
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,927
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,758
; PRIOR FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-380-18

Query Match 3.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 270 GAATTTGACGAAGTCACTGCAGA 292
||||||||||||||||||||||
Db 23 GAATTTGACGAAGTCACTGCAGA 1

RESULT 25
US-10-348-480B-24/c
; Sequence 24, Application US/10348480B
; Publication No. US20030175957A1
; GENERAL INFORMATION:
; APPLICANT: Nestec A.G.
; TITLE OF INVENTION: Pre-adipose cell lines
; FILE REFERENCE: 88265-6004
; CURRENT APPLICATION NUMBER: US/10/348,480B
; CURRENT FILING DATE: 2003-03-25
; PRIOR APPLICATION NUMBER: EP 00115489.7
; PRIOR FILING DATE: 2000-07-18
; PRIOR APPLICATION NUMBER: PCT/EP01/08165
; PRIOR FILING DATE: 2001-07-13
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 24
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapien
; FEATURE:
; OTHER INFORMATION: DNA
US-10-348-480B-24

Query Match 3.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 27;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 449 TGAGAGAGCATAAGCCAAGGG 469
|||||||||||||||||||||
Db 21 TGAGAGAGCATAAGCCAAGGG 1

RESULT 26
US-09-952-522B-27/c
; Sequence 27, Application US/09952522B
; Publication No. US20030082152A1
; GENERAL INFORMATION:
; APPLICANT: Katz, Adam J.
; APPLICANT: Llull, Ramon
; APPLICANT: Futrell, J. William
; APPLICANT: Hedrick, Marc H.
; APPLICANT: Benhaim, Prosper
; APPLICANT: Lorenz, Hermann Peter
; APPLICANT: Zhu, Min
; TITLE OF INVENTION: ADIPOSE-DERIVED STEM CELLS AND LATTICES
; FILE REFERENCE: 30448.77USI1
; CURRENT APPLICATION NUMBER: US/09/952,522B
; CURRENT FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: PCT/US00/06232
; PRIOR FILING DATE: 2000-03-10
; PRIOR APPLICATION NUMBER: 60/123,711
; PRIOR FILING DATE: 1999-03-10
; PRIOR APPLICATION NUMBER: 60/162,462
; PRIOR FILING DATE: 1999-10-29
; NUMBER OF SEQ ID NOS: 58
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: aP2 forward
; OTHER INFORMATION: primer
US-09-952-522B-27

Query Match 3.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 29;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 353 ATGGGATGGAAAATCAACCA 372
||||||||||||||||||||
Db 20 ATGGGATGGAAAATCAACCA 1

RESULT 27
US-10-416-090-15
; Sequence 15, Application US/10416090
; Publication No. US20040071711A1
; GENERAL INFORMATION:
; APPLICANT: Bicknell , Roy
; APPLICANT: Huminiecki, Lukasz

; TITLE OF INVENTION: IMAGING, DIAGNOSIS AND TREATMENT OF
; TITLE OF INVENTION: DISEASE
; FILE REFERENCE: 12795-015US1
; CURRENT APPLICATION NUMBER: US/10/416,090
; CURRENT FILING DATE: 2003-10-15
; PRIOR APPLICATION NUMBER: PCT/US01/04906
; PRIOR FILING DATE: 2001-11-06
; PRIOR APPLICATION NUMBER: US 60/245,566
; PRIOR FILING DATE: 2000-11-06
; PRIOR APPLICATION NUMBER: US 60/273,662
; PRIOR FILING DATE: 2001-03-07
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-416-090-15

Query Match 3.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 29;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 16 TGCAGCTTCCTTCTCACCTT 35
||||||||||||||||||||
Db 1 TGCAGCTTCCTTCTCACCTT 20

RESULT 28
US-10-416-090-16/c
; Sequence 16, Application US/10416090
; Publication No. US20040071711A1
; GENERAL INFORMATION:
; APPLICANT: Bicknell , Roy
; APPLICANT: Huminiecki, Lukasz
; TITLE OF INVENTION: IMAGING, DIAGNOSIS AND TREATMENT OF
; TITLE OF INVENTION: DISEASE
; FILE REFERENCE: 12795-015US1
; CURRENT APPLICATION NUMBER: US/10/416,090
; CURRENT FILING DATE: 2003-10-15
; PRIOR APPLICATION NUMBER: PCT/US01/04906
; PRIOR FILING DATE: 2001-11-06
; PRIOR APPLICATION NUMBER: US 60/245,566
; PRIOR FILING DATE: 2000-11-06
; PRIOR APPLICATION NUMBER: US 60/273,662
; PRIOR FILING DATE: 2001-03-07
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-416-090-16

Query Match 3.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 29;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 191 CAGTGTGAATGGGGATGTGA 210
||||||||||||||||||||
Db 20 CAGTGTGAATGGGGATGTGA 1

RESULT 29
US-09-795-917-33
; Sequence 33, Application US/09795917
; Publication No. US20040171533A1
; GENERAL INFORMATION:
; APPLICANT: Zehentner et al.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REGULATING ADIPOCYTES
; FILE REFERENCE: CIBT-P01-083
; CURRENT APPLICATION NUMBER: US/09/795,917
; CURRENT FILING DATE: 2001-02-28
; PRIOR APPLICATION NUMBER: 60/186,058
; PRIOR FILING DATE: 2000-02-29
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-09-795-917-33

Query Match 3.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 29;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 63 ATGTGTGATGCTTTTGTAGG 82
||||||||||||||||||||
Db 1 ATGTGTGATGCTTTTGTAGG 20

RESULT 30
US-10-348-480B-11
; Sequence 11, Application US/10348480B
; Publication No. US20030175957A1
; GENERAL INFORMATION:
; APPLICANT: Nestec A.G.
; TITLE OF INVENTION: Pre-adipose cell lines
; FILE REFERENCE: 88265-6004
; CURRENT APPLICATION NUMBER: US/10/348,480B
; CURRENT FILING DATE: 2003-03-25
; PRIOR APPLICATION NUMBER: EP 00115489.7
; PRIOR FILING DATE: 2000-07-18
; PRIOR APPLICATION NUMBER: PCT/EP01/08165
; PRIOR FILING DATE: 2001-07-13
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: homo sapien
; FEATURE:
; OTHER INFORMATION: DNA
US-10-348-480B-11

Query Match 3.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 29;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 81 GGTACCTGGAAACTTGTCTC 100
||||||||||||||||||||
Db 1 GGTACCTGGAAACTTGTCTC 20

RESULT 31
US-10-348-480B-12/c
; Sequence 12, Application US/10348480B
; Publication No. US20030175957A1
; GENERAL INFORMATION:
; APPLICANT: Nestec A.G.
; TITLE OF INVENTION: Pre-adipose cell lines
; FILE REFERENCE: 88265-6004
; CURRENT APPLICATION NUMBER: US/10/348,480B
; CURRENT FILING DATE: 2003-03-25
; PRIOR APPLICATION NUMBER: EP 00115489.7
; PRIOR FILING DATE: 2000-07-18
; PRIOR APPLICATION NUMBER: PCT/EP01/08165
; PRIOR FILING DATE: 2001-07-13
; NUMBER OF SEQ ID NOS: 34

```
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: homo sapien
;   FEATURE:
;   OTHER INFORMATION: DNA
US-10-348-480B-12

  Query Match             3.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 29;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        471 CGTTGACCTGGACTGAAGTT 490
              ||||||||||||||||||||
Db         20 CGTTGACCTGGACTGAAGTT 1


RESULT 32
US-09-795-917-34/c
; Sequence 34, Application US/09795917
; Publication No. US20040171533A1
; GENERAL INFORMATION:
;  APPLICANT: Zehentner et al.
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REGULATING ADIPOCYTES
;  FILE REFERENCE: CIBT-P01-083
;  CURRENT APPLICATION NUMBER: US/09/795,917
;  CURRENT FILING DATE:  2001-02-28
;  PRIOR APPLICATION NUMBER: 60/186,058
;  PRIOR FILING DATE: 2000-02-29
;  NUMBER OF SEQ ID NOS: 38
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 34
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: primer
US-09-795-917-34

  Query Match             3.0%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 32;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        347 GCAGAAATGGGATGGAAAA 365
              |||||||||||||||||||
Db         19 GCAGAAATGGGATGGAAAA 1


RESULT 33
US-10-348-480B-23
; Sequence 23, Application US/10348480B
; Publication No. US20030175957A1
; GENERAL INFORMATION:
;  APPLICANT: Nestec A.G.
;  TITLE OF INVENTION: Pre-adipose cell lines
;  FILE REFERENCE: 88265-6004
;  CURRENT APPLICATION NUMBER: US/10/348,480B
;  CURRENT FILING DATE:  2003-03-25
;  PRIOR APPLICATION NUMBER: EP 00115489.7
;  PRIOR FILING DATE: 2000-07-18
;  PRIOR APPLICATION NUMBER: PCT/EP01/08165
;  PRIOR FILING DATE: 2001-07-13
;  NUMBER OF SEQ ID NOS: 34
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 23
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: homo sapien
;   FEATURE:
;   OTHER INFORMATION: DNA
US-10-348-480B-23

  Query Match             3.0%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 32;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        399 AAACTGGTGGTGGAATGCG 417
              |||||||||||||||||||
Db          1 AAACTGGTGGTGGAATGCG 19


RESULT 34
US-10-688-572-20/c
; Sequence 20, Application US/10688572
; Publication No. US20040162352A1
; GENERAL INFORMATION:
;  APPLICANT: Janssen Pharmaceutica, N.V.
;  APPLICANT:  Chen, Xiaoli
;  APPLICANT:  Demarest, Keith
;  APPLICANT:  Lee, Jung
;  APPLICANT:  Matthews, Jay M
;  APPLICANT:  Rybczynski, Philip
;  TITLE OF INVENTION: Treating Syndrome X with Substituted Tetralins and Indanes
;  FILE REFERENCE: PRD-0050
;  CURRENT APPLICATION NUMBER: US/10/688,572
;  CURRENT FILING DATE:  2003-10-17
;  PRIOR APPLICATION NUMBER: 60/419,927
;  PRIOR FILING DATE: 2002-10-21
;  PRIOR APPLICATION NUMBER: 60/495,758
;  PRIOR FILING DATE: 2003-08-15
;  NUMBER OF SEQ ID NOS: 20
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-688-572-20

  Query Match             3.0%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 32;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        417 GTCATGAAAGGCGTCACTT 435
              |||||||||||||||||||
Db         19 GTCATGAAAGGCGTCACTT 1


RESULT 35
US-10-688-379-20/c
; Sequence 20, Application US/10688379
; Publication No. US20040167211A1
; GENERAL INFORMATION:
;  APPLICANT: Janssen Pharmaceutica, N.V.
;  APPLICANT:  Chen, Xiaoli
;  APPLICANT:  Demarest, Keith T
;  APPLICANT:  Ambler, Jung Lee
;  APPLICANT:  Matthews, Jay M
;  APPLICANT:  Rybczynski, Philip
;  TITLE OF INVENTION: METHODS OF USING SUBSTITUTED TETRALINS AND INDANES
;  FILE REFERENCE: PRD-0049 NP
;  CURRENT APPLICATION NUMBER: US/10/688,379
;  CURRENT FILING DATE:  2003-10-17
;  PRIOR APPLICATION NUMBER: 60/420,026
;  PRIOR FILING DATE: 2002-10-21
;  PRIOR APPLICATION NUMBER: 60/495,788
;  PRIOR FILING DATE: 2003-08-15
;  NUMBER OF SEQ ID NOS: 20
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-688-379-20

  Query Match             3.0%;  Score 19;  DB 1;  Length 19;
```

```
  Best Local Similarity   100.0%;  Pred. No. 32;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        417 GTCATGAAAGGCGTCACTT 435
              |||||||||||||||||||
Db         19 GTCATGAAAGGCGTCACTT 1


RESULT 36
US-10-688-380-20/c
; Sequence 20, Application US/10688380
; Publication No. US20040171680A1
; GENERAL INFORMATION:
;  APPLICANT: Janssen Pharmaceutica, N.V.
;  APPLICANT:  Chen, Xiaoli
;  APPLICANT:  Demarest, Keith
;  APPLICANT:  Lee, Jung
;  APPLICANT:  Matthews, Jay M.
;  APPLICANT:  Rybczynski, Philip
;  TITLE OF INVENTION: Substituted Tetralins and Indanes
;  FILE REFERENCE: PRD0048 NP
;  CURRENT APPLICATION NUMBER: US/10/688,380
;  CURRENT FILING DATE:  2003-10-17
;  PRIOR APPLICATION NUMBER: 60/419,927
;  PRIOR FILING DATE: 2002-10-21
;  PRIOR APPLICATION NUMBER: 60/495,758
;  PRIOR FILING DATE: 2003-08-15
;  NUMBER OF SEQ ID NOS: 20
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-688-380-20

  Query Match             3.0%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 32;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        417 GTCATGAAAGGCGTCACTT 435
              |||||||||||||||||||
Db         19 GTCATGAAAGGCGTCACTT 1


RESULT 37
US-09-952-522B-28
; Sequence 28, Application US/09952522B
; Publication No. US20030082152A1
; GENERAL INFORMATION:
;  APPLICANT: Katz, Adam J.
;  APPLICANT:  Llull, Ramon
;  APPLICANT:  Futrell, J. William
;  APPLICANT:  Hedrick, Marc H.
;  APPLICANT:  Benhaim, Prosper
;  APPLICANT:  Lorenz, Hermann Peter
;  APPLICANT:  Zhu, Min
;  TITLE OF INVENTION: ADIPOSE-DERIVED STEM CELLS AND LATTICES
;  FILE REFERENCE: 30448.77USI1
;  CURRENT APPLICATION NUMBER: US/09/952,522B
;  CURRENT FILING DATE:  2001-09-10
;  PRIOR APPLICATION NUMBER: PCT/US00/06232
;  PRIOR FILING DATE: 2000-03-10
;  PRIOR APPLICATION NUMBER: 60/123,711
;  PRIOR FILING DATE: 1999-03-10
;  PRIOR APPLICATION NUMBER: 60/162,462
;  PRIOR FILING DATE: 1999-10-29
;  NUMBER OF SEQ ID NOS: 58
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 28
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: aP2 reverse
;   OTHER INFORMATION: primer
US-09-952-522B-28

  Query Match             3.0%;  Score 19;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 33;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        259 TACTGGGCCAGGAATTTGA 277
              |||||||||||||||||||
Db          1 TACTGGGCCAGGAATTTGA 19


RESULT 38
US-10-116-265-8
; Sequence 8, Application US/10116265
; Publication No. US20030077612A1
; GENERAL INFORMATION:
;  APPLICANT: Ekblom, Jonas
;  TITLE OF INVENTION: NEW METHOD
;  FILE REFERENCE: 13425-105001
;  CURRENT APPLICATION NUMBER: US/10/116,265
;  CURRENT FILING DATE:  2002-04-04
;  PRIOR APPLICATION NUMBER: SE 0101218-6
;  PRIOR FILING DATE: 2001-04-05
;  PRIOR APPLICATION NUMBER: 60/281,384
;  PRIOR FILING DATE: 2001-04-05
;  NUMBER OF SEQ ID NOS: 19
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 8
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-116-265-8

  Query Match             2.8%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   77.8%;  Pred. No. 35;
  Matches   14;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          9 AGGAGGGTGCAGCTTCCT 26
              |||||||:|||||:.||:
Db          1 AGGAGGGUGCAGCUUCCU 18


RESULT 39
US-10-084-839-3080/c
; Sequence 3080, Application US/10084839
; Publication No. US20030186238A1
; GENERAL INFORMATION:
;  APPLICANT: Third Wave Technologies
;  APPLICANT:  Allawi, Hatim
;  APPLICANT:  Argue, Brad T.
;  APPLICANT:  Bartholomay, Christian T.
;  APPLICANT:  Chehak, LuAnne
;  APPLICANT:  Curtis, Michelle L.
;  APPLICANT:  Eis, Peggy S.
;  APPLICANT:  Hall, Jeff G.
;  APPLICANT:  Ip, Hon S.
;  APPLICANT:  Ji, Lin
;  APPLICANT:  Kaiser, Michael
;  APPLICANT:  Kwiatkowski, Jr., Robert W.
;  APPLICANT:  Lukowiak, Andrew A.
;  APPLICANT:  Lyamichev, Victor
;  APPLICANT:  Lymaicheva, Natalie E.
;  APPLICANT:  Ma, WuPo
;  APPLICANT:  Neri, Bruce P.
;  APPLICANT:  Olson, Sarah M.
;  APPLICANT:  Olson-Munoz, Marilyn C.
;  APPLICANT:  Schaefer, James J.
;  APPLICANT:  Skrzypczynski, Zbigniew
;  APPLICANT:  Takova, Tsetska Y.
;  APPLICANT:  Thompson, Lisa C.
;  APPLICANT:  Vedvik, Kevin L.
```

```
;  TITLE OF INVENTION: RNA Detection Assays
;  FILE REFERENCE: FORS-06666
;  CURRENT APPLICATION NUMBER: US/10/084,839
;  CURRENT FILING DATE:  2002-02-26
;  NUMBER OF SEQ ID NOS: 4004
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3080
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-10-084-839-3080

  Query Match             2.7%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 39;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        247 AGATTTCCTTCATACTGGG 265
              ||||||||||||| ||||||
Db         19 AGATTTCCTTCAAACTGGG 1


RESULT 40
US-10-084-839-3086/c
; Sequence 3086, Application US/10084839
; Publication No. US20030186238A1
; GENERAL INFORMATION:
;  APPLICANT: Third Wave Technologies
;  APPLICANT:  Allawi, Hatim
;  APPLICANT:  Argue, Brad T.
;  APPLICANT:  Bartholomay, Christian T.
;  APPLICANT:  Chehak, LuAnne
;  APPLICANT:  Curtis, Michelle L.
;  APPLICANT:  Eis, Peggy S.
;  APPLICANT:  Hall, Jeff G.
;  APPLICANT:  Ip, Hon S.
;  APPLICANT:  Ji, Lin
;  APPLICANT:  Kaiser, Michael
;  APPLICANT:  Kwiatkowski, Jr., Robert W.
;  APPLICANT:  Lukowiak, Andrew A.
;  APPLICANT:  Lyamichev, Victor
;  APPLICANT:  Lymaicheva, Natalie E.
;  APPLICANT:  Ma, WuPo
;  APPLICANT:  Neri, Bruce P.
;  APPLICANT:  Olson, Sarah M.
;  APPLICANT:  Olson-Munoz, Marilyn C.
;  APPLICANT:  Schaefer, James J.
;  APPLICANT:  Skrzypczynski, Zbigniew
;  APPLICANT:  Takova, Tsetska Y.
;  APPLICANT:  Thompson, Lisa C.
;  APPLICANT:  Vedvik, Kevin L.
;  TITLE OF INVENTION: RNA Detection Assays
;  FILE REFERENCE: FORS-06666
;  CURRENT APPLICATION NUMBER: US/10/084,839
;  CURRENT FILING DATE:  2002-02-26
;  NUMBER OF SEQ ID NOS: 4004
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3086
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-10-084-839-3086

  Query Match             2.7%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 39;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        247 AGATTTCCTTCATACTGGG 265
              ||||||||||||| ||||||
Db         19 AGATTTCCTTCAAACTGGG 1


RESULT 41
US-10-084-839-3083/c
; Sequence 3083, Application US/10084839
; Publication No. US20030186238A1
; GENERAL INFORMATION:
;  APPLICANT: Third Wave Technologies
;  APPLICANT:  Allawi, Hatim
;  APPLICANT:  Argue, Brad T.
;  APPLICANT:  Bartholomay, Christian T.
;  APPLICANT:  Chehak, LuAnne
;  APPLICANT:  Curtis, Michelle L.
;  APPLICANT:  Eis, Peggy S.
;  APPLICANT:  Hall, Jeff G.
;  APPLICANT:  Ip, Hon S.
;  APPLICANT:  Ji, Lin
;  APPLICANT:  Kaiser, Michael
;  APPLICANT:  Kwiatkowski, Jr., Robert W.
;  APPLICANT:  Lukowiak, Andrew A.
;  APPLICANT:  Lyamichev, Victor
;  APPLICANT:  Lymaicheva, Natalie E.
;  APPLICANT:  Ma, WuPo
;  APPLICANT:  Neri, Bruce P.
;  APPLICANT:  Olson, Sarah M.
;  APPLICANT:  Olson-Munoz, Marilyn C.
;  APPLICANT:  Schaefer, James J.
;  APPLICANT:  Skrzypczynski, Zbigniew
;  APPLICANT:  Takova, Tsetska Y.
;  APPLICANT:  Thompson, Lisa C.
;  APPLICANT:  Vedvik, Kevin L.
;  TITLE OF INVENTION: RNA Detection Assays
;  FILE REFERENCE: FORS-06666
;  CURRENT APPLICATION NUMBER: US/10/084,839
;  CURRENT FILING DATE:  2002-02-26
;  NUMBER OF SEQ ID NOS: 4004
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3083
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-10-084-839-3083

  Query Match             2.7%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   94.7%;  Pred. No. 40;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        246 GAGATTTCCTTCATACTGG 264
              ||||||||||||| |||||
Db         19 GAGATTTCCTTCAAACTGG 1


RESULT 42
US-09-972-211-164
; Sequence 164, Application US/09972211
; Publication No. US20040048245A1
; GENERAL INFORMATION:
;  APPLICANT: Shimkets, Richard A
;  APPLICANT:  Taupier Jr, Raymond J
;  APPLICANT:  Burgess, Catherine E
;  APPLICANT:  Zerhusen, Bryan D
;  APPLICANT:  Mezes, Peter S
;  APPLICANT:  Rastelli, Luca
;  APPLICANT:  Malyankar, Uriel M
;  APPLICANT:  Grosse, William M
;  APPLICANT:  Alsobrook II, John P
;  APPLICANT:  Lepley, Denise M
;  APPLICANT:  Spytek, Kimberly Ann
;  APPLICANT:  Li, Li
;  APPLICANT:  Edinger, Shlomit
;  APPLICANT:  Gerlach, Valerie
```

```
;  APPLICANT:  Ellerman, Karen
;  APPLICANT:  MacDougall, John R
;  APPLICANT:  Gunther, Erik
;  APPLICANT:  Millet, Isabelle
;  APPLICANT:  Stone, David J
;  APPLICANT:  Smithson, Glennda
;  APPLICANT:  Szekeres Jr, Edward S
;  TITLE OF INVENTION: No. US20040048245A1el Human Proteins, Polynucleotides Encoding Th
;  TITLE OF INVENTION:  Methods Of Using The Same
;  FILE REFERENCE: 21402-141
;  CURRENT APPLICATION NUMBER: US/09/972,211
;  CURRENT FILING DATE:  2001-10-05
;  PRIOR APPLICATION NUMBER: 60/238,325
;  PRIOR FILING DATE: 2000-10-05
;  PRIOR APPLICATION NUMBER: 60/238,323
;  PRIOR FILING DATE: 2000-10-05
;  PRIOR APPLICATION NUMBER: 60/238,400
;  PRIOR FILING DATE: 2000-10-06
;  PRIOR APPLICATION NUMBER: 60/238,397
;  PRIOR FILING DATE: 2000-10-06
;  PRIOR APPLICATION NUMBER: 60/238,401
;  PRIOR FILING DATE: 2000-10-06
;  PRIOR APPLICATION NUMBER: 60/238,379
;  PRIOR FILING DATE: 2000-10-06
;  PRIOR APPLICATION NUMBER: 60/238,402
;  PRIOR FILING DATE: 2000-10-06
;  PRIOR APPLICATION NUMBER: 30/238,384
;  PRIOR FILING DATE: 2000-10-06
;  PRIOR APPLICATION NUMBER: 60/238,373
;  PRIOR FILING DATE: 2000-10-06
;  PRIOR APPLICATION NUMBER: 60/238,372
;  PRIOR FILING DATE: 2000-10-06
;  PRIOR APPLICATION NUMBER: 60/238,383
;  PRIOR FILING DATE: 2000-10-06
;  PRIOR APPLICATION NUMBER: 60/238,382
;  PRIOR FILING DATE: 2000-10-06
;  PRIOR APPLICATION NUMBER: 60/275,892
;  PRIOR FILING DATE: 2001-03-14
;  PRIOR APPLICATION NUMBER: 60/296,860
;  PRIOR FILING DATE: 2001-06-08
;  NUMBER OF SEQ ID NOS: 198
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 164
;    LENGTH: 21
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence: Ag2456 PCR
;    OTHER INFORMATION: Sequence
US-09-972-211-164

  Query Match              2.6%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 45;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        405 GTGGTGGAATGCGTCATGAA 424
              ||||||||  ||  ||||||||
Db          2 GTGGTGGAGTGTGTCATGAA 21


RESULT 43
US-10-096-625-164
; Sequence 164, Application US/10096625
; Publication No. US20040068095A1
; GENERAL INFORMATION:
;  APPLICANT: Shimkets, Richard A
;  APPLICANT:  Taupier Jr, Raymond J
;  APPLICANT:  Burgess, Catherine E
;  APPLICANT:  Zerhusen, Bryan D
;  APPLICANT:  Mezes, Peter S
;  APPLICANT:  Rastelli, Luca
;  APPLICANT:  Malyankar, Uriel M
;  APPLICANT:  Grosse, William M
;  APPLICANT:  Alsobrook II, John P
;  APPLICANT:  Lepley, Denise M
;  APPLICANT:  Spytek, Kimberly Ann
;  APPLICANT:  Li, Li
;  APPLICANT:  Edinger, Shlomit
;  APPLICANT:  Gerlach, Valerie
;  APPLICANT:  Ellerman, Karen
;  APPLICANT:  MacDougall, John R
;  APPLICANT:  Gunther, Erik
;  APPLICANT:  Millet, Isabelle
;  APPLICANT:  Stone, David J
;  APPLICANT:  Smithson, Glennda
;  APPLICANT:  Szekeres Jr, Edward S
;  APPLICANT:  Ji, Weizhen
;  TITLE OF INVENTION: No. US20040068095A1el Human Proteins, Polynucleotides Encoding The
;  TITLE OF INVENTION:  Methods Of Using The Same
;  FILE REFERENCE: 21402-141 CIP
;  CURRENT APPLICATION NUMBER: US/10/096,625
;  CURRENT FILING DATE:  2002-03-13
;  PRIOR APPLICATION NUMBER: 09/972,211
;  PRIOR FILING DATE: 2001-10-05
;  PRIOR APPLICATION NUMBER: 60/238,325
;  PRIOR FILING DATE: 2000-10-05
;  PRIOR APPLICATION NUMBER: 60/238,323
;  PRIOR FILING DATE: 2000-10-05
;  PRIOR APPLICATION NUMBER: 60/238,400
;  PRIOR FILING DATE: 2000-10-06
;  PRIOR APPLICATION NUMBER: 60/238,397
;  PRIOR FILING DATE: 2000-10-06
;  PRIOR APPLICATION NUMBER: 60/238,401
;  PRIOR FILING DATE: 2000-10-06
;  PRIOR APPLICATION NUMBER: 60/238,379
;  PRIOR FILING DATE: 2000-10-06
;  PRIOR APPLICATION NUMBER: 60/238,402
;  PRIOR FILING DATE: 2000-10-06
;  PRIOR APPLICATION NUMBER: 30/238,384
;  PRIOR FILING DATE: 2000-10-06
;  PRIOR APPLICATION NUMBER: 60/238,373
;  PRIOR FILING DATE: 2000-10-06
;  PRIOR APPLICATION NUMBER: 60/238,372
;  PRIOR FILING DATE: 2000-10-06
;  PRIOR APPLICATION NUMBER: 60/238,383
;  PRIOR FILING DATE: 2000-10-06
;  PRIOR APPLICATION NUMBER: 60/238,382
;  PRIOR FILING DATE: 2000-10-06
;  PRIOR APPLICATION NUMBER: 60/275,892
;  PRIOR FILING DATE: 2001-03-14
;  PRIOR APPLICATION NUMBER: 60/296,860
;  PRIOR FILING DATE: 2001-06-08
;  NUMBER OF SEQ ID NOS: 200
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 164
;    LENGTH: 21
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence: Ag2456 PCR
;    OTHER INFORMATION: Sequence
US-10-096-625-164

  Query Match              2.6%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 45;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        405 GTGGTGGAATGCGTCATGAA 424
              ||||||||  ||  ||||||||
Db          2 GTGGTGGAGTGTGTCATGAA 21


RESULT 44
US-10-084-839-3075/c
; Sequence 3075, Application US/10084839
; Publication No. US20030186238A1
```

; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Allawi, Hatim
; APPLICANT: Argue, Brad T.
; APPLICANT: Bartholomay, Christian T.
; APPLICANT: Chehak, LuAnne
; APPLICANT: Curtis, Michelle L.
; APPLICANT: Eis, Peggy S.
; APPLICANT: Hall, Jeff G.
; APPLICANT: Ip, Hon S.
; APPLICANT: Ji, Lin
; APPLICANT: Kaiser, Michael
; APPLICANT: Kwiatkowski, Jr., Robert W.
; APPLICANT: Lukowiak, Andrew A.
; APPLICANT: Lyamichev, Victor
; APPLICANT: Lymaicheva, Natalie E.
; APPLICANT: Ma, WuPo
; APPLICANT: Neri, Bruce P.
; APPLICANT: Olson, Sarah M.
; APPLICANT: Olson-Munoz, Marilyn C.
; APPLICANT: Schaefer, James J.
; APPLICANT: Skrzypczynski, Zbigniew
; APPLICANT: Takova, Tsetska Y.
; APPLICANT: Thompson, Lisa C.
; APPLICANT: Vedvik, Kevin L.
; TITLE OF INVENTION: RNA Detection Assays
; FILE REFERENCE: FORS-06666
; CURRENT APPLICATION NUMBER: US/10/084,839
; CURRENT FILING DATE: 2002-02-26
; NUMBER OF SEQ ID NOS: 4004
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3075
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-084-839-3075

Query Match 2.6%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 45;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        342 CATGTGCAGAAATGGGATGG 361
              || |||||||| ||||||||
Db         20 CAGGTGCAGAAGTGGGATGG 1
```

RESULT 45
US-10-238-700-3142/c
; Sequence 3142, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBHB01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3142
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-3142

Query Match 2.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 46;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy          8 CAGGAGGGTGCAGCTTC 24
              ||||||||| |||||||
Db         17 CAGGAGGGTTCAGCTTC 1
```

RESULT 46
US-10-349-143-11444
; Sequence 11444, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 11444
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-6549 for SEQ 3579, in complemer
US-10-349-143-11444

Query Match 2.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 48;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy        570 ATTTTCTCCCAAGCTGA 586
              ||||||||||||| |||
Db          1 ATTTTCTCCCAAGGTGA 17
```

RESULT 47
US-10-349-143-7744
; Sequence 7744, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7744
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:

```
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-21773 for SEQ 3810,
US-10-349-143-7744

  Query Match             2.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 51;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        450 GAGAGAGCATAAGCCAAG 467
              ||||||||| || |||||
Db          1 GAGAGAGCAAAACCCAAG 18


RESULT 48
US-10-060-756A-1328
; Sequence 1328, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
;  APPLICANT: Zhang, Jian
;  TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
;  FILE REFERENCE: PB0177
;  CURRENT APPLICATION NUMBER: US/10/060,756A
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/327,898
;  PRIOR FILING DATE: 2001-10-09
;  NUMBER OF SEQ ID NOS: 4804
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1328
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-756A-1328

  Query Match             2.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 51;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         58 ACAAAATGTGTGATGC 73
              ||||||||||||| |||
Db          2 ACAAAATGTGTGTTGC 17


RESULT 49
US-10-060-756A-1329
; Sequence 1329, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
;  APPLICANT: Zhang, Jian
;  TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
;  FILE REFERENCE: PB0177
;  CURRENT APPLICATION NUMBER: US/10/060,756A
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/327,898
;  PRIOR FILING DATE: 2001-10-09
;  NUMBER OF SEQ ID NOS: 4804
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1329
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-756A-1329

  Query Match             2.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 51;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         58 ACAAAATGTGTGATGC 73
              ||||||||||||| |||
Db          1 ACAAAATGTGTGTTGC 16


RESULT 50
US-10-060-895A-329/c
; Sequence 329, Application US/10060895A
; Publication No. US20030104403A1
; GENERAL INFORMATION:
;  APPLICANT: Zhang, Jian
;  APPLICANT:  Gu, Yizhong
;  APPLICANT:  Nguyen, Cung-Tuong
;  TITLE OF INVENTION: HUMAN UDP-GALNAC:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 10
;  FILE REFERENCE: PB0158
;  CURRENT APPLICATION NUMBER: US/10/060,895A
;  CURRENT FILING DATE:  2002-06-10
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/315,984
;  PRIOR FILING DATE: 2001-08-30
;  NUMBER OF SEQ ID NOS: 1682
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 329
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-895A-329

  Query Match             2.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 55;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        311 CACCATAACCTTAGATG 327
              ||||||||||||  |||
```

```
Db         17 CACCATAACCTTCAATG 1


RESULT 51
US-10-156-306-351
; Sequence 351, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 351
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-351

  Query Match             2.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 55;
  Matches   14;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        451 AGAGAGCATAAGCCAAG 467
              ||||| | :||||||||
Db          1 AGAGAUCUUAAGCCAAG 17


RESULT 52
US-10-156-306-5116/c
; Sequence 5116, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5116
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-5116

  Query Match             2.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 55;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        254 CTTCATACTGGGCCAGG 270
              |||||| |||||| |||
Db         17 CTTCATCCTGGGCTAGG 1


RESULT 53
US-10-156-306-7073/c
; Sequence 7073, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7073
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-7073

  Query Match             2.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 55;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        253 CCTTCATACTGGGCCAG 269
              ||||||| |||||| ||
Db         17 CCTTCATCCTGGGCTAG 1


RESULT 54
US-10-128-560-140/c
; Sequence 140, Application US/10128560
; Publication No. US20030134272A1
; GENERAL INFORMATION:
;  APPLICANT: Universiteit Gent
;  TITLE OF INVENTION: Improved mutation analysis of the NF1 Gene
;  FILE REFERENCE: UG-005-PCT
;  CURRENT APPLICATION NUMBER: US/10/128,560
;  CURRENT FILING DATE:  2002-04-18
;  PRIOR APPLICATION NUMBER: EP 99870216.1
;  PRIOR FILING DATE: 1999-10-18
;  PRIOR APPLICATION NUMBER: EP 00870122.9
;  PRIOR FILING DATE: 2000-06-05
;  PRIOR APPLICATION NUMBER: UG 60/211,929
;  PRIOR FILING DATE: 2000-06-16
;  NUMBER OF SEQ ID NOS: 264
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 140
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-128-560-140

  Query Match             2.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 55;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         97 TCTCCAGTGAAAACTTT 113
              | ||||||||| |||||
Db         17 TTTCCAGTGAAGACTTT 1


RESULT 55
US-10-128-560-196/c
; Sequence 196, Application US/10128560
; Publication No. US20030134272A1
; GENERAL INFORMATION:
;  APPLICANT: Universiteit Gent
;  TITLE OF INVENTION: Improved mutation analysis of the NF1 Gene
;  FILE REFERENCE: UG-005-PCT
;  CURRENT APPLICATION NUMBER: US/10/128,560
;  CURRENT FILING DATE:  2002-04-18
;  PRIOR APPLICATION NUMBER: EP 99870216.1
;  PRIOR FILING DATE: 1999-10-18
;  PRIOR APPLICATION NUMBER: EP 00870122.9
;  PRIOR FILING DATE: 2000-06-05
;  PRIOR APPLICATION NUMBER: UG 60/211,929
;  PRIOR FILING DATE: 2000-06-16
;  NUMBER OF SEQ ID NOS: 264
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 196
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-128-560-196
```

```
  Query Match             2.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 55;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         97 TCTCCAGTGAAAACTTT 113
              | |||||||||| |||||
Db         17 TTTCCAGTGAAGACTTT 1


RESULT 56
US-10-238-700-1062
; Sequence 1062, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  FILE REFERENCE: 400/057  (MBHB01-1158-A)
;  CURRENT APPLICATION NUMBER: US/10/238,700
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  NUMBER OF SEQ ID NOS: 4666
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1062
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-238-700-1062

  Query Match             2.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 55;
  Matches   10;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         33 CTTGAAGAATAATCCTA 49
              |::|||||:| :| :|
Db          1 CUUGAAGAAUAGUCAUA 17


RESULT 57
US-10-287-919-1817
; Sequence 1817, Application US/10287919
; Publication No. US20030085830A1
; GENERAL INFORMATION:
;  APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
;  TITLE OF INVENTION: Methanococcus jannaschii complete genome.
;  FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
;  CURRENT APPLICATION NUMBER: US/10/287,919
;  CURRENT FILING DATE:  2002-11-05
;  NUMBER OF SEQ ID NOS: 2706
;  SOFTWARE: Proprietary
; SEQ ID NO 1817
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Methanococcus jannaschii complete genome.
;   FEATURE:
;   LOCATION: (1050269)...(1050283)
;   OTHER INFORMATION: Chromosome = 1  Strand = negative  ConnectronObjectNumber =  2300
US-10-287-919-1817

  Query Match             2.1%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 53;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        583 CTGATTTTATTCAAT 597
              ||||||||| |||||
Db          1 CTGATTTTAATCAAT 15


RESULT 58
US-10-043-875-276
; Sequence 276, Application US/10043875
; Publication No. US20030054339A1
; GENERAL INFORMATION:
;  APPLICANT: De Smet, Koenraad
;  APPLICANT:  Stuyver, Lieven
;  TITLE OF INVENTION: Method for Detection of Drug-Induced Mutations in the HIV Reverse
;  TITLE OF INVENTION:  Transcriptase Gene
;  FILE REFERENCE: 11362-0033-NPUS01 (INNS:033)
;  CURRENT APPLICATION NUMBER: US/10/043,875
;  CURRENT FILING DATE:  2002-04-03
;  PRIOR APPLICATION NUMBER: 60/286,102
;  PRIOR FILING DATE: 2001-04-24
;  PRIOR APPLICATION NUMBER: EP 01870085.6
;  PRIOR FILING DATE: 2001-04-20
;  PRIOR APPLICATION NUMBER: EP 01870005.4
;  PRIOR FILING DATE: 2001-01-11
;  NUMBER OF SEQ ID NOS: 884
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 276
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Human immunodeficiency virus
US-10-043-875-276

  Query Match             2.1%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 55;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        352 AATGGGATGGAAA 364
              |||||||||||||
Db          3 AATGGGATGGAAA 15


RESULT 59
US-10-043-875-278
; Sequence 278, Application US/10043875
; Publication No. US20030054339A1
; GENERAL INFORMATION:
;  APPLICANT: De Smet, Koenraad
;  APPLICANT:  Stuyver, Lieven
;  TITLE OF INVENTION: Method for Detection of Drug-Induced Mutations in the HIV Reverse
;  TITLE OF INVENTION:  Transcriptase Gene
;  FILE REFERENCE: 11362-0033-NPUS01 (INNS:033)
;  CURRENT APPLICATION NUMBER: US/10/043,875
;  CURRENT FILING DATE:  2002-04-03
;  PRIOR APPLICATION NUMBER: 60/286,102
;  PRIOR FILING DATE: 2001-04-24
;  PRIOR APPLICATION NUMBER: EP 01870085.6
;  PRIOR FILING DATE: 2001-04-20
;  PRIOR APPLICATION NUMBER: EP 01870005.4
;  PRIOR FILING DATE: 2001-01-11
;  NUMBER OF SEQ ID NOS: 884
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 278
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Human immunodeficiency virus
US-10-043-875-278

  Query Match             2.1%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 55;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        352 AATGGGATGGAAA 364
              |||||||||||||
Db          2 AATGGGATGGAAA 14


RESULT 60
US-10-043-875-274
; Sequence 274, Application US/10043875
; Publication No. US20030054339A1
```

; GENERAL INFORMATION:
; APPLICANT: De Smet, Koenraad
; APPLICANT: Stuyver, Lieven
; TITLE OF INVENTION: Method for Detection of Drug-Induced Mutations in the HIV Reverse
; TITLE OF INVENTION: Transcriptase Gene
; FILE REFERENCE: 11362-0033-NPUS01 (INNS:033)
; CURRENT APPLICATION NUMBER: US/10/043,875
; CURRENT FILING DATE: 2002-04-03
; PRIOR APPLICATION NUMBER: 60/286,102
; PRIOR FILING DATE: 2001-04-24
; PRIOR APPLICATION NUMBER: EP 01870085.6
; PRIOR FILING DATE: 2001-04-20
; PRIOR APPLICATION NUMBER: EP 01870005.4
; PRIOR FILING DATE: 2001-01-11
; NUMBER OF SEQ ID NOS: 884
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 274
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Human immunodeficiency virus
US-10-043-875-274

Query Match 2.1%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 58;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        352 AATGGGATGGAAA 364
              |||||||||||||
Db          4 AATGGGATGGAAA 16
```

RESULT 61
US-10-043-875-277
; Sequence 277, Application US/10043875
; Publication No. US20030054339A1
; GENERAL INFORMATION:
; APPLICANT: De Smet, Koenraad
; APPLICANT: Stuyver, Lieven
; TITLE OF INVENTION: Method for Detection of Drug-Induced Mutations in the HIV Reverse
; TITLE OF INVENTION: Transcriptase Gene
; FILE REFERENCE: 11362-0033-NPUS01 (INNS:033)
; CURRENT APPLICATION NUMBER: US/10/043,875
; CURRENT FILING DATE: 2002-04-03
; PRIOR APPLICATION NUMBER: 60/286,102
; PRIOR FILING DATE: 2001-04-24
; PRIOR APPLICATION NUMBER: EP 01870085.6
; PRIOR FILING DATE: 2001-04-20
; PRIOR APPLICATION NUMBER: EP 01870005.4
; PRIOR FILING DATE: 2001-01-11
; NUMBER OF SEQ ID NOS: 884
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 277
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Human immunodeficiency virus
US-10-043-875-277

Query Match 2.1%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 58;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        352 AATGGGATGGAAA 364
              |||||||||||||
Db          3 AATGGGATGGAAA 15
```

Search completed: October 1, 2004, 07:06:10
Job time : 1 secs

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: October 1, 2004, 07:03:27 ; Search time 0.001 Seconds
(without alignments)
580.744 Million cell updates/sec

Title: US-09-503-596-2
Perfect score: 634
Sequence: 1 ggaattccaggagggtgcag.....ataacttttttagatttag 634

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 25 seqs, 458 residues

Total number of hits satisfying chosen parameters: 50

Minimum DB seq length: 10
Maximum DB seq length: 100

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 25 summaries

Database : rni2.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.		Score	% Query Match	Length	DB	ID	Description
c	1	33	5.2	33	1	US-09-853-798A-17	Sequence 17, Appl
c	2	29	4.6	29	1	US-09-853-798A-16	Sequence 16, Appl
c	3	26	4.1	26	1	US-09-854-302-15	Sequence 15, Appl
c	4	26	4.1	26	1	US-09-853-798A-15	Sequence 15, Appl
c	5	24	3.8	24	1	US-09-853-798A-19	Sequence 19, Appl
c	6	23	3.6	23	1	US-09-853-798A-18	Sequence 18, Appl
c	7	19	3.0	19	1	US-09-853-798A-20	Sequence 20, Appl
	8	15.4	2.4	18	1	US-09-422-978-11444	Sequence 11444, A
	9	14.8	2.3	18	1	US-09-422-978-7744	Sequence 7744, Ap
	10	13	2.1	15	1	US-08-671-071B-2	Sequence 2, Appli
	11	13	2.1	15	1	US-09-253-977-2	Sequence 2, Appli
	12	12.8	2.0	16	1	US-08-753-147-131	Sequence 131, App
c	13	12.8	2.0	16	1	US-08-861-096A-41	Sequence 41, Appl
	14	12.8	2.0	16	1	US-09-479-005A-414	Sequence 414, App
c	15	12.4	2.0	15	1	US-08-311-760A-235	Sequence 235, App
c	16	12.4	2.0	15	1	US-08-182-968A-484	Sequence 484, App
c	17	12.4	2.0	15	1	US-08-334-847-299	Sequence 299, App
	18	12.4	2.0	15	1	US-08-334-847-492	Sequence 492, App
c	19	12.4	2.0	15	1	US-08-292-620A-691	Sequence 691, App
c	20	12.4	2.0	15	1	US-08-774-306A-484	Sequence 484, App
c	21	12.4	2.0	15	1	US-08-774-310-235	Sequence 235, App
c	22	12.4	2.0	15	1	US-09-064-156A-484	Sequence 484, App
c	23	12.4	2.0	15	1	US-09-071-845-691	Sequence 691, App
	24	12	1.9	14	1	US-09-291-541-25	Sequence 25, Appl
	25	12	1.9	15	1	US-08-311-486C-736	Sequence 736, App

ALIGNMENTS

RESULT 1
US-09-853-798A-17/c
; Sequence 17, Application US/09853798A
; Patent No. 6599899
; GENERAL INFORMATION:
; APPLICANT: Rybczynski, Philip
; APPLICANT: et al.
; TITLE OF INVENTION: BIOLOGICALLY ACTIVE 4H-BENZO[1,4]OXAZIN-3-ONES
; FILE REFERENCE: 431565566, patin2.1
; CURRENT APPLICATION NUMBER: US/09/853,798A
; CURRENT FILING DATE: 2001-05-11
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-853-798A-17

Query Match 5.2%; Score 33; DB 1; Length 33;
Best Local Similarity 100.0%; Pred. No. 0.46;
Matches 33; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        237 AAAAATACTGAGATTTCCTTCATACTGGGCCAG 269
              |||||||||||||||||||||||||||||||||
Db         33 AAAAATACTGAGATTTCCTTCATACTGGGCCAG 1
```

RESULT 2
US-09-853-798A-16/c
; Sequence 16, Application US/09853798A
; Patent No. 6599899
; GENERAL INFORMATION:
; APPLICANT: Rybczynski, Philip
; APPLICANT: et al.
; TITLE OF INVENTION: BIOLOGICALLY ACTIVE 4H-BENZO[1,4]OXAZIN-3-ONES
; FILE REFERENCE: 431565566, patin2.1
; CURRENT APPLICATION NUMBER: US/09/853,798A
; CURRENT FILING DATE: 2001-05-11
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
; LENGTH: 29
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-853-798A-16

Query Match 4.6%; Score 29; DB 1; Length 29;
Best Local Similarity 100.0%; Pred. No. 0.94;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        208 TGATCACCATTAAATCTGAAAGTACCTTT 236
              |||||||||||||||||||||||||||||
Db         29 TGATCACCATTAAATCTGAAAGTACCTTT 1
```

RESULT 3
US-09-854-302-15/c
; Sequence 15, Application US/09854302
; Patent No. 6555536
; GENERAL INFORMATION:
; APPLICANT: Rybczynski, Philip
; APPLICANT: et al.
; TITLE OF INVENTION: BIOLOGICALLY ACTIVE 4H-BENZO[1,4]OXAZIN-3-ONES
; FILE REFERENCE: pm431, patin2.1
; CURRENT APPLICATION NUMBER: US/09/854,302
; CURRENT FILING DATE: 2001-10-15
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
; LENGTH: 26
; TYPE: DNA

```
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-854-302-15

  Query Match             4.1%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   100.0%;  Pred. No. 1.6;
  Matches   26;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         90 AAACTTGTCTCCAGTGAAAACTTTGA 115
              ||||||||||||||||||||||||||
Db         26 AAACTTGTCTCCAGTGAAAACTTTGA 1


RESULT 4
US-09-853-798A-15/c
; Sequence 15, Application US/09853798A
; Patent No. 6599899
; GENERAL INFORMATION:
;  APPLICANT: Rybczynski, Philip
;  APPLICANT:  et al.
;  TITLE OF INVENTION: BIOLOGICALLY ACTIVE 4H-BENZO[1,4]OXAZIN-3-ONES
;  FILE REFERENCE: 431565566, patin2.1
;  CURRENT APPLICATION NUMBER: US/09/853,798A
;  CURRENT FILING DATE:  2001-05-11
;  NUMBER OF SEQ ID NOS: 20
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-853-798A-15

  Query Match             4.1%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   100.0%;  Pred. No. 1.6;
  Matches   26;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         90 AAACTTGTCTCCAGTGAAAACTTTGA 115
              ||||||||||||||||||||||||||
Db         26 AAACTTGTCTCCAGTGAAAACTTTGA 1


RESULT 5
US-09-853-798A-19/c
; Sequence 19, Application US/09853798A
; Patent No. 6599899
; GENERAL INFORMATION:
;  APPLICANT: Rybczynski, Philip
;  APPLICANT:  et al.
;  TITLE OF INVENTION: BIOLOGICALLY ACTIVE 4H-BENZO[1,4]OXAZIN-3-ONES
;  FILE REFERENCE: 431565566, patin2.1
;  CURRENT APPLICATION NUMBER: US/09/853,798A
;  CURRENT FILING DATE:  2001-05-11
;  NUMBER OF SEQ ID NOS: 20
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 19
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-853-798A-19

  Query Match             3.8%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 2.2;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        293 TGACAGGAAAGTCAAGAGCACCAT 316
              ||||||||||||||||||||||||
Db         24 TGACAGGAAAGTCAAGAGCACCAT 1


RESULT 6
US-09-853-798A-18/c
; Sequence 18, Application US/09853798A
; Patent No. 6599899
; GENERAL INFORMATION:
;  APPLICANT: Rybczynski, Philip
;  APPLICANT:  et al.
;  TITLE OF INVENTION: BIOLOGICALLY ACTIVE 4H-BENZO[1,4]OXAZIN-3-ONES
;  FILE REFERENCE: 431565566, patin2.1
;  CURRENT APPLICATION NUMBER: US/09/853,798A
;  CURRENT FILING DATE:  2001-05-11
;  NUMBER OF SEQ ID NOS: 20
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 18
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-853-798A-18

  Query Match             3.6%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 2.5;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        270 GAATTTGACGAAGTCACTGCAGA 292
              |||||||||||||||||||||||
Db         23 GAATTTGACGAAGTCACTGCAGA 1


RESULT 7
US-09-853-798A-20/c
; Sequence 20, Application US/09853798A
; Patent No. 6599899
; GENERAL INFORMATION:
;  APPLICANT: Rybczynski, Philip
;  APPLICANT:  et al.
;  TITLE OF INVENTION: BIOLOGICALLY ACTIVE 4H-BENZO[1,4]OXAZIN-3-ONES
;  FILE REFERENCE: 431565566, patin2.1
;  CURRENT APPLICATION NUMBER: US/09/853,798A
;  CURRENT FILING DATE:  2001-05-11
;  NUMBER OF SEQ ID NOS: 20
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-853-798A-20

  Query Match             3.0%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.5;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        417 GTCATGAAAGGCGTCACTT 435
              |||||||||||||||||||
Db         19 GTCATGAAAGGCGTCACTT 1


RESULT 8
US-09-422-978-11444
; Sequence 11444, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
```

```
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 11444
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: downstream amplification primer 99-6549 for SEQ 3579, in compleme
US-09-422-978-11444

  Query Match             2.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        570 ATTTTCTCCCAAGCTGA 586
              ||||||||||||| |||
Db          1 ATTTTCTCCCAAGGTGA 17


RESULT 9
US-09-422-978-7744
; Sequence 7744, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7744
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-21773 for SEQ 3810,
US-09-422-978-7744

  Query Match             2.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 11;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        450 GAGAGAGCATAAGCCAAG 467
              ||||||||| || |||||
Db          1 GAGAGAGCAAAACCCAAG 18


RESULT 10
US-08-671-071B-2
; Sequence 2, Application US/08671071B
; Patent No. 5811270
;  GENERAL INFORMATION:
;    APPLICANT:  Grandgenett, Duane
;    TITLE OF INVENTION:  An in vitro method for concerted integration of
;    TITLE OF INVENTION:  donor DNA molecules using retroviral integrase proteins.
;    NUMBER OF SEQUENCES:  7
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Grandgenett, Duane
;      STREET:  8610 Henrietta Ave
;      CITY:  Brentwood
;      STATE:  Missouri
;      COUNTRY:  USA
;      ZIP:  63144
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Distette, 3.5 inch;
;      COMPUTER:  Gateway 2000,4DX2-66E(Intel)
;      OPERATING SYSTEM:  IBM clone
;      SOFTWARE:  Microsoft Word
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/671,071B
;      FILING DATE:  06/27/96
;      CLASSIFICATION:  435
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (314) 962-0064
;      TELEFAX:  (314) 577-8406
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 bases
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;    HYPOTHETICAL:  no
;    ANTI-SENSE:  no
;    ORIGINAL SOURCE:  Combination of avian or HIV-1 retrovirus
;    ORIGINAL SOURCE:  DNA, piAN7 plasmid and pGEM plasmid.
;    IMMEDIATE SOURCE:  Same as in 2,vi.
;    FEATURE:
;      OTHER INFORMATION:  The sequence is the bottom strand of
;      OTHER INFORMATION:  M-2 U5 and the pGEM target of the top clone shown in
;      OTHER INFORMATION:  Figure 14 of original application.
US-08-671-071B-2

  Query Match             2.1%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 11;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        254 CTTCATACTGGGC 266
              |||||||||||||
Db          1 CTTCATACTGGGC 13


RESULT 11
US-09-253-977-2
; Sequence 2, Application US/09253977A
; Patent No. 6316261
; GENERAL INFORMATION:
;  APPLICANT: Grandgenett, Duane P.
;  TITLE OF INVENTION: Method for Analyzing Concerted Integration of DNA Donor
;  TITLE OF INVENTION: Molecules into Target DNA and the Enzymes that Perform
;  TITLE OF INVENTION: this Concerted Integration Reaction
;  FILE REFERENCE: 16153-8244
;  CURRENT APPLICATION NUMBER: US/09/253,977A
;  CURRENT FILING DATE: 1998-09-21
;  EARLIER APPLICATION NUMBER: 08/671,071
;  EARLIER FILING DATE: 1996-06-27
;  EARLIER APPLICATION NUMBER: 08/247,089
;  EARLIER FILING DATE: 1994-05-20
;  NUMBER OF SEQ ID NOS: 7
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Combination
;   OTHER INFORMATION: of avian or HIV-1 retrovirus DNA and piAN7 plasmid
US-09-253-977-2
```

```
  Query Match             2.1%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 11;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        254 CTTCATACTGGGC 266
              |||||||||||||
Db          1 CTTCATACTGGGC 13


RESULT 12
US-08-753-147-131
; Sequence 131, Application US/08753147
; Patent No. 5770372
;  GENERAL INFORMATION:
;    APPLICANT:  Concannon, Patrick
;    TITLE OF INVENTION:  Detection of Mutations in the Human ATM Gene
;    NUMBER OF SEQUENCES:  196
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Christensen O'Connor Johnson and Kindness
;      STREET:  1420 5th Avenue
;      CITY:  Seattle
;      STATE:  Washingtion
;      COUNTRY:  USA
;      ZIP:  98101-2347
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/753,147
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sheiness, Diana K.
;      REGISTRATION NUMBER:  35,356
;      REFERENCE/DOCKET NUMBER:  VMRC-1-9714
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (206) 743-4387
;      TELEFAX:  (206) 224 0779
;  INFORMATION FOR SEQ ID NO:  131:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    ORIGINAL SOURCE:
;      ORGANISM:  Homo sapiens
US-08-753-147-131

  Query Match             2.0%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 14;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        561 AAGCAAGTAATTTTCT 576
              || || ||||||||||
Db          1 AAACAGGTAATTTTCT 16


RESULT 13
US-08-861-096A-41/c
; Sequence 41, Application US/08861096A
; Patent No. 5958689
;  GENERAL INFORMATION:
;    APPLICANT:  Scholin, Christopher A.
;    APPLICANT:  Cangelosi, Gerard A.
;    APPLICANT:  Haydock, Paul V.
;    TITLE OF INVENTION:  Detection of Toxigenic Marine Diatoms of
;    TITLE OF INVENTION:  the Genus Pseudo-nitzschia
;    NUMBER OF SEQUENCES:  45
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, Eighth Floor
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94111-3834
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/861,096A
;      FILING DATE:  21-MAY-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 60/018,143
;      FILING DATE:  22-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Weber, Kenneth A.
;      REGISTRATION NUMBER:  31,677
;      REFERENCE/DOCKET NUMBER:  017748-000110US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 576-0200
;      TELEFAX:  (415) 576-0300
;  INFORMATION FOR SEQ ID NO:  41:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-861-096A-41

  Query Match             2.0%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 14;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        406 TGGTGGAATGCGTCAT 421
              ||||||| || |||||
Db         16 TGGTGGAGTGAGTCAT 1


RESULT 14
US-09-479-005A-414
; Sequence 414, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
;  FILE REFERENCE: MBHB00-884-C
;  CURRENT APPLICATION NUMBER: US/09/479,005A
;  CURRENT FILING DATE:  2000-01-07
;  PRIOR APPLICATION NUMBER: US 09/444,209
;  PRIOR FILING DATE: 1999-11-19
;  PRIOR APPLICATION NUMBER: US 09/159,274
;  PRIOR FILING DATE: 1998-09-22
;  PRIOR APPLICATION NUMBER: US 60/059,473
;  PRIOR FILING DATE: 1997-09-22
;  NUMBER OF SEQ ID NOS: 1208
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 414
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-479-005A-414

  Query Match             2.0%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   56.2%;  Pred. No. 14;
  Matches    9;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         33 CTTGAAGAATAATCCT 48
```

```
                  |::||||||:| :| :
Db          1 CUUGAAGAAUAGUCAU 16


RESULT 15
US-08-311-760A-235/c
; Sequence 235, Application US/08311760A
; Patent No. 5599706
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Newton, Roger S.
;    APPLICANT:  Ramharack, Randy
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF DISEASES
;    TITLE OF INVENTION:  OR CONDITIONS RELATED TO LEVELS OF
;    TITLE OF INVENTION:  PLASMA LIPOPROTEIN (a) [LP(a)] BY
;    TITLE OF INVENTION:  INHIBITING APOLIPOPROTEIN
;    TITLE OF INVENTION:
;    NUMBER OF SEQUENCES:  392
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/311,760A
;      FILING DATE:  September 23, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/155
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  235:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-311-760A-235

  Query Match             2.0%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 13;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        263 GGGCCAGGAATTTG 276
              ||||||||||| ||
Db         15 GGGCCAGGAATGTG 2


RESULT 16
US-08-182-968A-484/c
; Sequence 484, Application US/08182968A
; Patent No. 5610054
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING HEPATITIS C
;    TITLE OF INVENTION:  VIRUS REPLICATION
;    NUMBER OF SEQUENCES:  497
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/182,968A
;      FILING DATE:  13-JANUARY-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/882,888
;      FILING DATE:  14-MAY-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  205/277
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  484:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-182-968A-484

  Query Match             2.0%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 13;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        130 AAGTAGGAGTGGGC 143
              |||||||||| |||
Db         14 AAGTAGGAGTAGGC 1


RESULT 17
US-08-334-847-299/c
; Sequence 299, Application US/08334847
; Patent No. 5693532
;  GENERAL INFORMATION:
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  Pavco, Pam
;    APPLICANT:  Woolf, Tod
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING RESPIRATORY
;    TITLE OF INVENTION:  SYNCYTIAL VIRUS
;    NUMBER OF SEQUENCES:  909
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
```

```
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/334,847
;      FILING DATE:  No. 5693532ember 4, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/032
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  299:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-334-847-299

  Query Match             2.0%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 13;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        621 TTTTTTAGATTTAG 634
              ||||||| ||||||
Db         15 TTTTTTATATTTAG 2


RESULT 18
US-08-334-847-492
; Sequence 492, Application US/08334847
; Patent No. 5693532
;  GENERAL INFORMATION:
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  Pavco, Pam
;    APPLICANT:  Woolf, Tod
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING RESPIRATORY
;    TITLE OF INVENTION:  SYNCYTIAL VIRUS
;    NUMBER OF SEQUENCES:  909
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/334,847
;      FILING DATE:  No. 5693532ember 4, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/032
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  492:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-334-847-492

  Query Match             2.0%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   71.4%;  Pred. No. 13;
  Matches   10;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        236 TAAAAATACTGAGA 249
              :|||||:||: |||
Db          1 UAAAAAUACUCAGA 14


RESULT 19
US-08-292-620A-691/c
; Sequence 691, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620A
;      FILING DATE:  August 17, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  691:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-292-620A-691
```

```
  Query Match             2.0%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 13;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        190 TCAGTGTGAATGGG 203
              ||||||||||| ||
Db         15 TCAGTGTGAATTGG 2


RESULT 20
US-08-774-306A-484/c
; Sequence 484, Application US/08774306A
; Patent No. 5869253
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING HEPATITIS C
;    TITLE OF INVENTION:  VIRUS REPLICATION
;    NUMBER OF SEQUENCES:  497
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/774,306A
;      FILING DATE:  December 26, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/182,968
;      FILING DATE:  January 13, 1994
;      APPLICATION NUMBER:  07/882,888
;      FILING DATE:  May 14, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  223/227
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  484:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-774-306A-484

  Query Match             2.0%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 13;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        130 AAGTAGGAGTGGGC 143
              |||||||||| |||
Db         14 AAGTAGGAGTAGGC 1


RESULT 21
US-08-774-310-235/c
; Sequence 235, Application US/08774310
; Patent No. 5877022
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Newton, Roger S.
;    APPLICANT:  Ramharack, Randy
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF DISEASES
;    TITLE OF INVENTION:  OR CONDITIONS RELATED TO LEVELS OF
;    TITLE OF INVENTION:  PLASMA LIPOPROTEIN (a) [LP(a)] BY
;    TITLE OF INVENTION:  INHIBITING APOLIPOPROTEIN
;    TITLE OF INVENTION:
;    NUMBER OF SEQUENCES:  392
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/774,310
;      FILING DATE:  December 23, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/311,760
;      FILING DATE:  September 23, 1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  223/229
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  235:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-774-310-235

  Query Match             2.0%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 13;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        263 GGGCCAGGAATTTG 276
              |||||||||| ||
Db         15 GGGCCAGGAATGTG 2


RESULT 22
US-09-064-156A-484/c
; Sequence 484, Application US/09064156A
; Patent No. 6132966
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING HEPATITIS C
;    TITLE OF INVENTION:  VIRUS REPLICATION
;    NUMBER OF SEQUENCES:  498
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
```

```
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  Word Perfect 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/09/064,156A
;       FILING DATE:  April 21, 1998
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/774,306
;       FILING DATE:  December 26, 1996
;       APPLICATION NUMBER:  08/182,968
;       FILING DATE:  January 13, 1994
;       APPLICATION NUMBER:  07/882,888
;       FILING DATE:  May 14, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  234/083
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  484:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-09-064-156A-484

  Query Match             2.0%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 13;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        130 AAGTAGGAGTGGGC 143
              ||||||||||  |||
Db         14 AAGTAGGAGTAGGC 1


RESULT 23
US-09-071-845-691/c
; Sequence 691, Application US/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/071,845
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620
;      FILING DATE:  August 17, 1994
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  691:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-071-845-691

  Query Match             2.0%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 13;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        190 TCAGTGTGAATGGG 203
              ||||||||||| ||
Db         15 TCAGTGTGAATTGG 2


RESULT 24
US-09-291-541-25
; Sequence 25, Application US/09291541
; Patent No. 6461864
; GENERAL INFORMATION:
;  APPLICANT: Soriano, Philippe
;  APPLICANT: Robertson, Elizabeth J.
;  TITLE OF INVENTION: METHODS AND VECTOR CONSTRUCTS FOR MAKING TRANSGENIC
;  TITLE OF INVENTION: NON-HUMAN ANMIALS WHICH UBIQUITOUSLY EXPRESS A
;  TITLE OF INVENTION: HETEROLOGOUS GENE
;  FILE REFERENCE: 14538A-44-1
;  CURRENT APPLICATION NUMBER: US/09/291,541
;  CURRENT FILING DATE: 1999-04-14
;  EARLIER APPLICATION NUMBER: US 60/081,894
;  EARLIER FILING DATE: 1998-04-15
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 25
;   LENGTH: 14
;   TYPE: DNA
;   ORGANISM: Encephalomyocarditis virus
US-09-291-541-25

  Query Match             1.9%;  Score 12;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 13;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        114 GATGATTATATG 125
              ||||||||||||
Db          2 GATGATTATATG 13


RESULT 25
US-08-311-486C-736
; Sequence 736, Application US/08311486C
; Patent No. 5811300
;  GENERAL INFORMATION:
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth Draper
;    APPLICANT:  Kevin Kisich
;    APPLICANT:  Dan T. Stinchcomb
```

```
;    APPLICANT:  James McSwiggen
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  TNF-
;    NUMBER OF SEQUENCES:  1157
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/311,486C
;      FILING DATE:  September 23, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/166
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  736:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-311-486C-736

  Query Match             1.9%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   75.0%;  Pred. No. 14;
  Matches    9;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        328 GGGGTGTCCTGG 339
              ||||:|:||:||
Db          1 GGGGUGUCCUGG 12


Search completed: October  1, 2004, 07:03:27
Job time : 0.001 secs
```

This Page Blank (uspto)

This Page Blank (uspto)

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: September 30, 2004, 16:29:21 ; Search time 0.001 Seconds
(without alignments)
916.764 Million cell updates/sec

Title: US-09-503-596-2
Perfect score: 634
Sequence: 1 ggaattccaggagggtgcag.....ataacttttttagatttag 634

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 36 seqs, 723 residues

Total number of hits satisfying chosen parameters: 72

Minimum DB seq length: 10
Maximum DB seq length: 100

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 36 summaries

Database : rge2.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB	ID	Description
c 1	33	5.2	33	1	AR361918	ACCESSION:AR361918
c 2	29	4.6	29	1	AR361917	ACCESSION:AR361917
c 3	26	4.1	26	1	AR309143	ACCESSION:AR309143
c 4	26	4.1	26	1	AR361916	ACCESSION:AR361916
c 5	26	4.1	26	1	AX327744	ACCESSION:AX327744
c 6	26	4.1	26	1	AX327819	ACCESSION:AX327819
c 7	26	4.1	26	1	AX338577	ACCESSION:AX338577
c 8	24	3.8	24	1	AR361920	ACCESSION:AR361920
c 9	23	3.6	23	1	AR361919	ACCESSION:AR361919
10	20	3.2	20	1	AX282817	ACCESSION:AX282817
11	20	3.2	20	1	AX357027	ACCESSION:AX357027
c 12	20	3.2	20	1	AX357028	ACCESSION:AX357028
c 13	19	3.0	19	1	AR361921	ACCESSION:AR361921
c 14	19	3.0	19	1	AX282822	ACCESSION:AX282822
c 15	18.8	3.0	22	1	A98024	ACCESSION:A98024
16	17.4	2.7	21	1	AX154043	ACCESSION:AX154043
17	16.8	2.6	21	1	AX497397	ACCESSION:AX497397
18	15.4	2.4	18	1	AR299709	ACCESSION:AR299709
19	14.8	2.3	18	1	AR296009	ACCESSION:AR296009
c 20	14.4	2.3	17	1	AX422118	ACCESSION:AX422118
21	14.4	2.3	17	1	AX500021	ACCESSION:AX500021
22	14.4	2.3	17	1	AX500022	ACCESSION:AX500022
c 23	14.4	2.3	17	1	AX762488	ACCESSION:AX762488
c 24	14	2.2	17	1	AX759766	ACCESSION:AX759766
c 25	13.8	2.2	17	1	AX119483	ACCESSION:AX119483
c 26	13.8	2.2	17	1	AX119539	ACCESSION:AX119539
c 27	13.8	2.2	17	1	AX544816	ACCESSION:AX544816
28	13.8	2.2	17	1	AX730462	ACCESSION:AX730462
c 29	13.8	2.2	17	1	AX757483	ACCESSION:AX757483
c 30	13.8	2.2	17	1	AX781960	ACCESSION:AX781960
c 31	13.8	2.2	17	1	AX781961	ACCESSION:AX781961
32	13.8	2.2	17	1	BD201505	ACCESSION:BD201505
33	13.8	2.2	17	1	BD201506	ACCESSION:BD201506
34	13.4	2.1	16	1	A88074	ACCESSION:A88074
35	13.4	2.1	16	1	A90041	ACCESSION:A90041
36	13.4	2.1	16	1	BD065587	ACCESSION:BD065587

ALIGNMENTS

RESULT 1
AR361918/c
LOCUS AR361918 33 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 17 from patent US 6599899.
ACCESSION AR361918
VERSION AR361918.1 GI:33769929
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 33)
AUTHORS Burris,T.P. and Rybczynski,P.J.
TITLE Benzoxazinones as peroxisome proliferator activated receptor gamma modulators and method of treatment
JOURNAL Patent: US 6599899-A 17 29-JUL-2003;
FEATURES Location/Qualifiers
source 1. .33
/organism="unknown"
/mol_type="genomic DNA"

Query Match 5.2%; Score 33; DB 1; Length 33;
Best Local Similarity 100.0%; Pred. No. 1.2;
Matches 33; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 237 AAAAATACTGAGATTTCCTTCATACTGGGCCAG 269
||||||||||||||||||||||||||||||||
Db 33 AAAAATACTGAGATTTCCTTCATACTGGGCCAG 1

RESULT 2
AR361917/c
LOCUS AR361917 29 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 16 from patent US 6599899.
ACCESSION AR361917
VERSION AR361917.1 GI:33769928
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 29)
AUTHORS Burris,T.P. and Rybczynski,P.J.
TITLE Benzoxazinones as peroxisome proliferator activated receptor gamma modulators and method of treatment
JOURNAL Patent: US 6599899-A 16 29-JUL-2003;
FEATURES Location/Qualifiers
source 1. .29
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.6%; Score 29; DB 1; Length 29;
Best Local Similarity 100.0%; Pred. No. 2.2;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 208 TGATCACCATTAAATCTGAAAGTACCTTT 236
|||||||||||||||||||||||||||||
Db 29 TGATCACCATTAAATCTGAAAGTACCTTT 1

RESULT 3
AR309143/c
LOCUS AR309143 26 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 15 from patent US 6555536.
ACCESSION AR309143
VERSION AR309143.1 GI:31700985
KEYWORDS .

```
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   Burris,T.P., Combs,D.W. and Rybczynski,P.J.
  TITLE     Biologically active 4H-benzo [1,4]oxazin-3-ones
  JOURNAL   Patent: US 6555536-A 15 29-APR-2003;
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             4.1%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   100.0%;  Pred. No. 3.4;
  Matches   26;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         90 AAACTTGTCTCCAGTGAAAACTTTGA 115
              ||||||||||||||||||||||||||
Db         26 AAACTTGTCTCCAGTGAAAACTTTGA 1


RESULT 4
AR361916/c
LOCUS       AR361916                 26 bp    DNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 15 from patent US 6599899.
ACCESSION   AR361916
VERSION     AR361916.1  GI:33769927
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   Burris,T.P. and Rybczynski,P.J.
  TITLE     Benzoxazinones as peroxisome proliferator activated receptor gamma
            modulators and method of treatment
  JOURNAL   Patent: US 6599899-A 15 29-JUL-2003;
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             4.1%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   100.0%;  Pred. No. 3.4;
  Matches   26;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         90 AAACTTGTCTCCAGTGAAAACTTTGA 115
              ||||||||||||||||||||||||||
Db         26 AAACTTGTCTCCAGTGAAAACTTTGA 1


RESULT 5
AX327744/c
LOCUS       AX327744                 26 bp    DNA     linear   PAT 07-JAN-2002
DEFINITION  Sequence 15 from Patent WO0187860.
ACCESSION   AX327744
VERSION     AX327744.1  GI:18098055
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Burris,T.P. and Rybczynski,P.J.
  TITLE     Novel benzoxazinones as peroxisome proliferator activated receptor
            gamma modulators and method of treatment
  JOURNAL   Patent: WO 0187860-A 15 22-NOV-2001;
            Ortho-McNeil Pharmaceutical, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="primer"

  Query Match             4.1%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   100.0%;  Pred. No. 3.4;
  Matches   26;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         90 AAACTTGTCTCCAGTGAAAACTTTGA 115
              ||||||||||||||||||||||||||
Db         26 AAACTTGTCTCCAGTGAAAACTTTGA 1


RESULT 6
AX327819/c
LOCUS       AX327819                 26 bp    DNA     linear   PAT 07-JAN-2002
DEFINITION  Sequence 15 from Patent WO0187861.
ACCESSION   AX327819
VERSION     AX327819.1  GI:18098092
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Burris,T.P., Demarest,K.T., Combs,D.W., Rybczynski,P.J. and
            Turchi,I.J.
  TITLE     Methods of treatment using benzoxazinones as peroxisome
            proliferator activated receptor gamma modulators
  JOURNAL   Patent: WO 0187861-A 15 22-NOV-2001;
            Ortho-McNeil Pharmaceutical, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="primer"

  Query Match             4.1%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   100.0%;  Pred. No. 3.4;
  Matches   26;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         90 AAACTTGTCTCCAGTGAAAACTTTGA 115
              ||||||||||||||||||||||||||
Db         26 AAACTTGTCTCCAGTGAAAACTTTGA 1


RESULT 7
AX338577/c
LOCUS       AX338577                 26 bp    DNA     linear   PAT 09-JAN-2002
DEFINITION  Sequence 15 from Patent WO0187862.
ACCESSION   AX338577
VERSION     AX338577.1  GI:18128972
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Burris,T.P., Combs,D.W. and Rybczynski,P.J.
  TITLE     Biologically active 4h-benzo 1,4uoxazin-3-ones
  JOURNAL   Patent: WO 0187862-A 15 22-NOV-2001;
            Ortho-McNeil Pharmaceutical, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="primer"

  Query Match             4.1%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   100.0%;  Pred. No. 3.4;
  Matches   26;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         90 AAACTTGTCTCCAGTGAAAACTTTGA 115
              ||||||||||||||||||||||||||
Db         26 AAACTTGTCTCCAGTGAAAACTTTGA 1
```

```
RESULT 8
AR361920/c
LOCUS       AR361920                  24 bp    DNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 19 from patent US 6599899.
ACCESSION   AR361920
VERSION     AR361920.1  GI:33769931
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Burris,T.P. and Rybczynski,P.J.
  TITLE     Benzoxazinones as peroxisome proliferator activated receptor gamma
            modulators and method of treatment
  JOURNAL   Patent: US 6599899-A 19 29-JUL-2003;
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             3.8%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 4.5;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        293 TGACAGGAAAGTCAAGAGCACCAT 316
              ||||||||||||||||||||||||
Db         24 TGACAGGAAAGTCAAGAGCACCAT 1


RESULT 9
AR361919/c
LOCUS       AR361919                  23 bp    DNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 18 from patent US 6599899.
ACCESSION   AR361919
VERSION     AR361919.1  GI:33769930
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Burris,T.P. and Rybczynski,P.J.
  TITLE     Benzoxazinones as peroxisome proliferator activated receptor gamma
            modulators and method of treatment
  JOURNAL   Patent: US 6599899-A 18 29-JUL-2003;
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             3.6%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 5.1;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        270 GAATTTGACGAAGTCACTGCAGA 292
              |||||||||||||||||||||||
Db         23 GAATTTGACGAAGTCACTGCAGA 1


RESULT 10
AX282817
LOCUS       AX282817                  20 bp    DNA     linear   PAT 02-NOV-2001
DEFINITION  Sequence 31 from Patent WO0164238.
ACCESSION   AX282817
VERSION     AX282817.1  GI:16609817
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Zehentner,B., Leser-Reiff,U. and Burtscher,H.
  TITLE     Methods and compositions for regulating adipocytes
  JOURNAL   Patent: WO 0164238-A 31 07-SEP-2001;
            Curis, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="primer"

  Query Match             3.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.4;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         63 ATGTGTGATGCTTTTGTAGG 82
              ||||||||||||||||||||
Db          1 ATGTGTGATGCTTTTGTAGG 20


RESULT 11
AX357027
LOCUS       AX357027                  20 bp    DNA     linear   PAT 13-FEB-2002
DEFINITION  Sequence 11 from Patent WO0206450.
ACCESSION   AX357027
VERSION     AX357027.1  GI:18674223
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Darimont,C., Mace,K. and Pfeifer,A.
  TITLE     Pre-adipose cell lines
  JOURNAL   Patent: WO 0206450-A 11 24-JAN-2002;
            Societe des Produits Nestle S.A. (CH)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="DNA"

  Query Match             3.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.4;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         81 GGTACCTGGAAACTTGTCTC 100
              ||||||||||||||||||||
Db          1 GGTACCTGGAAACTTGTCTC 20


RESULT 12
AX357028/c
LOCUS       AX357028                  20 bp    DNA     linear   PAT 13-FEB-2002
DEFINITION  Sequence 12 from Patent WO0206450.
ACCESSION   AX357028
VERSION     AX357028.1  GI:18674224
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Darimont,C., Mace,K. and Pfeifer,A.
  TITLE     Pre-adipose cell lines
  JOURNAL   Patent: WO 0206450-A 12 24-JAN-2002;
            Societe des Produits Nestle S.A. (CH)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="DNA"

  Query Match             3.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.4;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy        471 CGTTGACCTGGACTGAAGTT 490
              ||||||||||||||||||||
Db         20 CGTTGACCTGGACTGAAGTT 1


RESULT 13
AR361921/c
LOCUS       AR361921                19 bp    DNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 20 from patent US 6599899.
ACCESSION   AR361921
VERSION     AR361921.1  GI:33769932
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Burris,T.P. and Rybczynski,P.J.
  TITLE     Benzoxazinones as peroxisome proliferator activated receptor gamma
            modulators and method of treatment
  JOURNAL   Patent: US 6599899-A 20 29-JUL-2003;
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             3.0%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 8.3;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        417 GTCATGAAAGGCGTCACTT 435
              ||||||||||||||||||||
Db         19 GTCATGAAAGGCGTCACTT 1


RESULT 14
AX282822/c
LOCUS       AX282822                19 bp    DNA     linear   PAT 02-NOV-2001
DEFINITION  Sequence 36 from Patent WO0164238.
ACCESSION   AX282822
VERSION     AX282822.1  GI:16609822
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Zehentner,B., Leser-Reiff,U. and Burtscher,H.
  TITLE     Methods and compositions for regulating adipocytes
  JOURNAL   Patent: WO 0164238-A 36 07-SEP-2001;
            Curis, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="primer"

  Query Match             3.0%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 8.3;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        347 GCAGAAATGGGATGGAAAA 365
              ||||||||||||||||||||
Db         19 GCAGAAATGGGATGGAAAA 1


RESULT 15
A98024/c
LOCUS       A98024                  22 bp    DNA     linear   PAT 26-JAN-2000
DEFINITION  Sequence 3 from Patent WO9914365.
ACCESSION   A98024
VERSION     A98024.1  GI:6781262
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Gerbens,F.
  TITLE     THE PORCINE ADIPOCYTE FATTY ACID-BINDING PROTEIN ENCODING GENE AND
            METHODS TO LOCALISE, IDENTIFY OR MARK GENES OR ALLELES OR
            QUANTITATIVE TRAIT LOCI OF FARM ANIMALS
  JOURNAL   Patent: WO 9914365-A 3 25-MAR-1999;
            STAMBOEK ZUID B V (NL); DALLAND B V (NL)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             3.0%;  Score 18.8;  DB 1;  Length 22;
  Best Local Similarity   90.9%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        212 CACCATTAAATCTGAAAGTACC 233
              |||||||| ||| |||||||||
Db         22 CACCATTAGATCAGAAAGTACC 1


RESULT 16
AX154043
LOCUS       AX154043                21 bp    DNA     linear   PAT 22-JUN-2001
DEFINITION  Sequence 141 from Patent WO0138576.
ACCESSION   AX154043
VERSION     AX154043.1  GI:14535657
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Cargill,M., Ireland,J.S. and Lander,E.S.
  TITLE     Human single nucleotide polymorphisms
  JOURNAL   Patent: WO 0138576-A 141 31-MAY-2001;
            WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 17.4;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 15;
  Matches   18;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        238 AAAATACTGAGATTTCCTTCA 258
              ||||||| ||:|| |||||||
Db          1 AAAATACAGARATCTCCTTCA 21


RESULT 17
AX497397
LOCUS       AX497397                21 bp    DNA     linear   PAT 26-SEP-2002
DEFINITION  Sequence 164 from Patent WO0229058.
ACCESSION   AX497397
VERSION     AX497397.1  GI:23342687
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Shimkets,R.A., Taupier,R.J., Burgess,C.E., Zerhusen,B.D.,
            Mezes,P.S., Rastelli,L., Malyankar,U.M., Grosse,W.M.,
            Alsobrook,J.P., Lepley,D.M., Spytek,K.A., Li,L., Edinger,S.,
            Gerlach,V., Ellerman,K., Macdougall,J., Gunther,E., Millet,I.,
            Stone,D., Smithson,G. and Szekeres,E.S.
  TITLE     Human proteins, polynucleotides encoding them and methods of using
            the same
```

```
  JOURNAL   Patent: WO 0229058-A 164 11-APR-2002;
            Curagen Corporation (US)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Ag2456 PCR Sequence"

  Query Match             2.6%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 17;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        405 GTGGTGGAATGCGTCATGAA 424
              ||||||||  ||  ||||||||
Db          2 GTGGTGGAGTGTGTCATGAA 21


RESULT 18
AR299709
LOCUS       AR299709                  18 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 11444 from patent US 6537751.
ACCESSION   AR299709
VERSION     AR299709.1  GI:31686993
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 11444 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 16;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        570 ATTTTCTCCCAAGCTGA 586
              |||||||||||||| |||
Db          1 ATTTTCTCCCAAGGTGA 17


RESULT 19
AR296009
LOCUS       AR296009                  18 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 7744 from patent US 6537751.
ACCESSION   AR296009
VERSION     AR296009.1  GI:31683293
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 7744 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 19;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        450 GAGAGAGCATAAGCCAAG 467
              |||||||||  ||  |||||
Db          1 GAGAGAGCAAAACCCAAG 18


RESULT 20
AX422118/c
LOCUS       AX422118                  17 bp    RNA     linear   PAT 18-JUN-2002
DEFINITION  Sequence 454 from Patent WO0188124.
ACCESSION   AX422118
VERSION     AX422118.1  GI:21525500
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Mclaughlin,F.G. and
            Randi,A.M.
  TITLE     Method and reagent for the inhibition of erg
  JOURNAL   Patent: WO 0188124-A 454 22-NOV-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 18;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        578 CCAAGCTGATTTTATT 593
              |||||||  ||||||||
Db         16 CCAAGCTTATTTTATT 1


RESULT 21
AX500021
LOCUS       AX500021                  17 bp    DNA     linear   PAT 27-SEP-2002
DEFINITION  Sequence 1328 from Patent EP1229046.
ACCESSION   AX500021
VERSION     AX500021.1  GI:23382314
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhan,J.
  TITLE     Human testis expressed patched like protein
  JOURNAL   Patent: EP 1229046-A 1328 07-AUG-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 18;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         58 ACAAAATGTGTGATGC 73
              |||||||||||| |||
Db          2 ACAAAATGTGTGTTGC 17


RESULT 22
AX500022
LOCUS       AX500022                  17 bp    DNA     linear   PAT 27-SEP-2002
DEFINITION  Sequence 1329 from Patent EP1229046.
ACCESSION   AX500022
VERSION     AX500022.1  GI:23382315
KEYWORDS    .
```

```
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhan,J.
  TITLE     Human testis expressed patched like protein
  JOURNAL   Patent: EP 1229046-A 1329 07-AUG-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 18;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         58 ACAAAATGTGTGATGC 73
              ||||||||||||  |||
Db          1 ACAAAATGTGTGTTGC 16


RESULT 23
AX762488/c
LOCUS       AX762488                17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 5809 from Patent WO03040369.
ACCESSION   AX762488
VERSION     AX762488.1  GI:32257104
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 5809 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 18;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        615 ATAACTTTTTTTAGAT 630
              ||||  ||||||||||
Db         17 ATAATTTTTTTTAGAT 2


RESULT 24
AX759766/c
LOCUS       AX759766                17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 3087 from Patent WO03040369.
ACCESSION   AX759766
VERSION     AX759766.1  GI:32254382
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 3087 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        346 TGCAGAAATGGGAT 359
              ||||||||||||||
Db         15 TGCAGAAATGGGAT 2


RESULT 25
AX119483/c
LOCUS       AX119483                17 bp    DNA     linear   PAT 11-MAY-2001
DEFINITION  Sequence 140 from Patent WO0129251.
ACCESSION   AX119483
VERSION     AX119483.1  GI:14036402
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Messiaen,L. and Callens,T.
  TITLE     Improved mutation analysis of the nf1 gene
  JOURNAL   Patent: WO 0129251-A 140 26-APR-2001;
            UNIVERSITEIT GENT (BE)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 20;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         97 TCTCCAGTGAAAACTTT 113
              | |||||||||  |||||
Db         17 TTTCCAGTGAAGACTTT 1


RESULT 26
AX119539/c
LOCUS       AX119539                17 bp    DNA     linear   PAT 11-MAY-2001
DEFINITION  Sequence 196 from Patent WO0129251.
ACCESSION   AX119539
VERSION     AX119539.1  GI:14036458
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Messiaen,L. and Callens,T.
  TITLE     Improved mutation analysis of the nf1 gene
  JOURNAL   Patent: WO 0129251-A 196 26-APR-2001;
            UNIVERSITEIT GENT (BE)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 20;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy          97 TCTCCAGTGAAAACTTT 113
               | |||||||||| |||||
Db          17 TTTCCAGTGAAGACTTT 1
```

RESULT 27
AX544816/c
LOCUS AX544816 17 bp DNA linear PAT 26-NOV-2002
DEFINITION Sequence 329 from Patent EP1243660.
ACCESSION AX544816
VERSION AX544816.1 GI:25810027
KEYWORDS .
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Zhang,J., Gu,Y. and Nguyen,C.T.
TITLE Human udp-galnac:polypeptide n-acetylgalatosaminyltransferase 10
JOURNAL Patent: EP 1243660-A 329 25-SEP-2002;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 2.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 20;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy         311 CACCATAACCTTAGATG 327
               |||||||||||  |||
Db          17 CACCATAACCTTCAATG 1
```

RESULT 28
AX730462
LOCUS AX730462 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2096 from Patent WO03025175.
ACCESSION AX730462
VERSION AX730462.1 GI:30509805
KEYWORDS .
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025175-A 2096 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 2.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 20;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy         185 GATCATCAGTGTGAATG 201
               |||| ||||||| ||||
Db           1 GATCTTCAGTGTAAATG 17
```

RESULT 29
AX757483/c
LOCUS AX757483 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 804 from Patent WO03040369.
ACCESSION AX757483
VERSION AX757483.1 GI:32252099
KEYWORDS .
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines
JOURNAL Patent: WO 03040369-A 804 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 2.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 20;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy         172 CCAAACCTAACATGATC 188
               | ||||| |||||||||
Db          17 CAAAACCCAACATGATC 1
```

RESULT 30
AX781960/c
LOCUS AX781960 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 291 from Patent WO03050284.
ACCESSION AX781960
VERSION AX781960.1 GI:32949809
KEYWORDS .
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 291 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES Location/Qualifiers
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 2.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 20;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy         333 GTCCTGGTACATGTGCA 349
               ||||| | |||||||||
Db          17 GTCCTTGGACATGTGCA 1
```

RESULT 31
AX781961/c
LOCUS AX781961 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 292 from Patent WO03050284.
ACCESSION AX781961
VERSION AX781961.1 GI:32949810
KEYWORDS .
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1

```
  AUTHORS   Guo,J.
  TITLE     Human prostate cancer candidate protein 1
  JOURNAL   Patent: WO 03050284-A 292 19-JUN-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 20;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        332 TGTCCTGGTACATGTGC 348
              ||||||  | ||||||||
Db         17 TGTCCTTGGACATGTGC 1


RESULT 32
BD201505
LOCUS       BD201505                  17 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response.
ACCESSION   BD201505
VERSION     BD201505.1  GI:33011275
KEYWORDS    JP 2002509721-A/4531.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  TITLE     Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
  JOURNAL   Patent: JP 2002509721-A 4531 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002509721-A/4531
            PD   02-APR-2002
            PF   24-MAR-1999 JP 2000541291
            PR   27-MAR-1998 US    60/079678
            PI   PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
            PI   JAMES A MCSWIGGEN
            PC
            C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
             A61P29/00,
            PC   A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
              C12N5/00
            CC   Method and reagent for treating diseases or conditions  CC
                   concerning molecule
            CC   participating in vasculogenic response
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 20;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        580 AAGCTGATTTTATTCAA 596
              ||||||||||| || ||
Db          1 AAGCTGATTTTTTTTAA 17


RESULT 33
BD201506
LOCUS       BD201506                  17 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response.
ACCESSION   BD201506
VERSION     BD201506.1  GI:33011276
KEYWORDS    JP 2002509721-A/4532.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  TITLE     Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
  JOURNAL   Patent: JP 2002509721-A 4532 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002509721-A/4532
            PD   02-APR-2002
            PF   24-MAR-1999 JP 2000541291
            PR   27-MAR-1998 US    60/079678
            PI   PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
            PI   JAMES A MCSWIGGEN
            PC
            C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
             A61P29/00,
            PC   A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
              C12N5/00
            CC   Method and reagent for treating diseases or conditions  CC
                   concerning molecule
            CC   participating in vasculogenic response
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 20;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        581 AGCTGATTTTATTCAAT 597
              |||||||||| || |||
Db          1 AGCTGATTTTTTTTAAT 17


RESULT 34
A88074
LOCUS       A88074                    16 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 222 from Patent WO9833904.
ACCESSION   A88074
VERSION     A88074.1  GI:6736644
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Brysch,W. and Schlingensiepen,K.
  TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
  JOURNAL   Patent: WO 9833904-A 222 06-AUG-1998;
            BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 20;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy        586 ATTTTATTCAATATG 600
              ||| ||||||||||||
Db          2 ATTATATTCAATATG 16
```

RESULT 35
A90041
LOCUS A90041 16 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 222 from Patent EP0856579.
ACCESSION A90041
VERSION A90041.1 GI:6738555
KEYWORDS .
SOURCE unidentified
ORGANISM unidentified
unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Brysch,W.D. and Schlingensiepen,K.D.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: EP 0856579-A 222 05-AUG-1998;
BIOGNOSTIK GES (DE)
FEATURES Location/Qualifiers
source 1. .16
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 2.1%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 20;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy        586 ATTTTATTCAATATG 600
              ||| ||||||||||||
Db          2 ATTATATTCAATATG 16
```

RESULT 36
BD065587
LOCUS BD065587 16 bp DNA linear PAT 27-AUG-2002
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD065587
VERSION BD065587.1 GI:22611190
KEYWORDS JP 2001511000-A/222.
SOURCE unidentified
ORGANISM unidentified
unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Schlingensiepen,K.H. and Brysch,W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 222 07-AUG-2001;
BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT OS Unknown
PN JP 2001511000-A/222
PD 07-AUG-2001
PF 30-JAN-1998 JP 1998532533
PR 31-JAN-1997 EP 97101531.8
PI KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
PC C12N15/11,C07H21/04,A61K31/70
CC An antisense oligonucleotide preparation method FH Key
Location/Qualifiers
FT source 1. .16
FT /organism='Unknown'.
FEATURES Location/Qualifiers
source 1. .16
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 2.1%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 20;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy        586 ATTTTATTCAATATG 600
              ||| ||||||||||||
Db          2 ATTATATTCAATATG 16
```

Search completed: September 30, 2004, 16:29:21
Job time : 0.001 secs